International Flavors & Fragrances (IFF) 10-K 27 Feb 23 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2022	Feb. 21, 2023	Jun. 30, 2022
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-4858
Entity Registrant Name	INTERNATIONAL FLAVORS & FRAGRANCES INC
Entity Central Index Key	0000051253
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	NY
Entity Tax Identification Number	13-1432060
Entity Address, Address Line One	521 West 57th Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019-2960
City Area Code	212
Local Phone Number	765-5500
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 30,369,016,357
Entity Common Stock, Shares Outstanding		255,061,711
Documents Incorporated by Reference	Portions of the registrant’s proxy statement for the 2023 Annual Meeting of Shareholders (the “IFF 2023 Proxy Statement”) are incorporated by reference in Part III of this Form 10-K.
Other Address
Entity Information [Line Items]
Entity Address, Address Line One	200 Powder Mill Road
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19803-2907
Common stock
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value 12 1/2¢ per share
Trading Symbol	IFF
Security Exchange Name	NYSE
1.750% Senior Notes Due 2024 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.750% Senior Notes due 2024
Trading Symbol	IFF 24
Security Exchange Name	NYSE
1.800% Senior Notes Due 2026 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.800% Senior Notes due 2026
Trading Symbol	IFF 26
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	New York, New York
Auditor Firm ID	238

CONSOLIDATED STATEMENT OF INCOM

CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales	$ 12,440	$ 11,656	$ 5,084
Cost of goods sold	8,289	7,921	2,998
Gross profit	4,151	3,735	2,086
Research and development expenses	603	629	357
Selling and administrative expenses	1,768	1,749	949
Restructuring and other charges	12	41	17
Amortization of acquisition-related intangibles	727	732	193
Impairment of goodwill	2,250	0	0
Impairment of long-lived assets	120	0	0
(Gains) losses on sale of fixed assets	(3)	(1)	4
Operating (loss) profit	(1,326)	585	566
Interest expense	336	289	132
Other income, net	(37)	(58)	(7)
(Loss) income before taxes	(1,625)	354	441
Provision for income taxes	239	75	74
Net (loss) income	(1,864)	279	367
Net income attributable to non-controlling interest	7	9	4
Net income available to IFF common shareholders	(1,871)	270	363
Other comprehensive (loss) income , after tax:
Foreign currency translation adjustments	(904)	(848)	88
Gains (losses) on derivatives qualifying as hedges	0	8	(9)
Pension and postretirement liability adjustment	158	115	(60)
Other comprehensive (loss) income	(746)	(725)	19
Comprehensive (loss) income	(2,610)	(446)	386
Comprehensive (loss) income attributable to IFF shareholders	$ (2,617)	$ (455)	$ 382
Net income per share - basic (in dollars per share)	$ (7.32)	$ 1.11	$ 3.25
Net income per share - diluted (in dollars per share)	$ (7.32)	$ 1.10	$ 3.21
Average number of shares outstanding - basic (in shares)	255	243	112
Average number of shares outstanding - diluted (in shares)	255	243	114

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 483	$ 711
Restricted cash	10	4
Receivables:
Trade	1,871	1,952
Allowance for doubtful accounts	(53)	(46)
Inventories	3,151	2,516
Assets held for sale	1,200	1,122
Prepaid expenses and other current assets	770	728
Total Current Assets	7,432	6,987
Property, plant and equipment, net	4,203	4,368
Goodwill	13,355	16,414
Other intangible assets, net	9,082	10,506
Operating lease right-of-use assets	636	767
Other assets	699	616
Total Assets	35,407	39,658
Current Liabilities:
Bank borrowings, overdrafts and current portion of long-term debt	410	308
Commercial paper	187	324
Accounts payable	1,418	1,532
Accrued payroll and bonus	267	335
Dividends payable	206	201
Liabilities held for sale	212	101
Other current liabilities	1,028	832
Total Current Liabilities	3,728	3,633
Other Liabilities:
Long-term debt	10,373	10,768
Retirement liabilities	231	385
Deferred income taxes	2,265	2,518
Operating lease liabilities	565	670
Other liabilities	472	462
Total Other Liabilities	13,906	14,803
Commitments and Contingencies (Note 19)
Redeemable non-controlling interests	59	105
Shareholders’ Equity:
Common stock, value, issued	35	35
Capital in excess of par value	19,841	19,826
Retained earnings	955	3,641
Accumulated other comprehensive loss	(2,169)	(1,423)
Treasury stock, value	(978)	(997)
Total Shareholders’ Equity	17,684	21,082
Non-controlling interest	30	35
Total Shareholders’ Equity including non-controlling interest	17,714	21,117
Total Liabilities and Shareholders’ Equity	$ 35,407	$ 39,658

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.125	$ 0.125
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	275,726,629	275,726,629
Common stock, shares outstanding (in shares)	254,968,463	254,573,984
Treasury stock (in shares)	20,758,166	21,152,645

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net (loss) income	$ (1,864)	$ 279	$ 367
Adjustments to reconcile to net cash provided by operating activities:
Depreciation and amortization	1,179	1,156	325
Deferred income taxes	(237)	(236)	(68)
(Gains) losses on sale of fixed assets	(3)	(1)	4
Gains on business divestiture	(11)	0	0
Stock-based compensation	49	54	36
Pension contributions	(36)	(37)	(24)
Amortization Of Inventory Step-Up	0	368	0
Impairment of goodwill	2,250	0	0
Impairment of long-lived assets	120	0	0
Changes in assets and liabilities, net of acquisitions:
Trade receivables	(117)	(169)	(61)
Inventories	(893)	(363)	18
Accounts payable	(57)	419	28
Accruals for incentive compensation	(34)	96	44
Other current payables and accrued expenses	92	4	57
Other assets/liabilities, net	(41)	(133)	(12)
Net cash provided by operating activities	397	1,437	714
Cash flows from investing activities:
Cash paid for acquisitions, net of cash received	(110)	0	0
Additions to property, plant and equipment	(504)	(393)	(192)
Additions to intangible assets	(2)	(4)	0
Proceeds from disposal of assets	8	18	17
Proceeds from unwinding of derivative instruments	173	0	0
Cash acquired from acquisition	11	246	0
Net proceeds received from business divestiture	1,169	115	0
Maturity of net investment hedges	0	0	(14)
Proceeds from life insurance contracts	0	0	2
Net cash provided by (used in) investing activities	745	(18)	(187)
Cash flows from financing activities:
Cash dividends paid to shareholders	(810)	(667)	(323)
Payments of Ordinary Dividends, Noncontrolling Interest	0	(2)	0
Increase (decrease) in revolving credit facility and short term borrowings	104	(105)	0
Proceeds from issuance of commercial paper (maturities after three months)	225	0	0
Repayments of commercial paper (maturities after three months)	(421)	0	0
Net borrowings of commercial paper (maturities less than three months)	48	324	0
Deferred financing costs	0	(3)	(3)
Repayments of long-term debt	(300)	(828)	(347)
Purchases of redeemable non-controlling interest	(47)	0	(22)
Proceeds from issuance of long-term debt	0	(3)	(200)
Contingent consideration paid	0	(14)	(9)
Proceeds from issuance of stock in connection with stock options	0	9	0
Employee withholding taxes paid	(21)	(21)	(8)
Other, net	(7)	0	0
Net cash used in financing activities	(1,229)	(1,304)	(512)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(77)	(59)	21
Net change in cash, cash equivalents and restricted cash	(164)	56	36
Cash, cash equivalents and restricted cash at beginning of year	716	660	624
Cash, cash equivalents and restricted cash at end of year	552	716	660
Supplemental Disclosures:
Interest paid, net of amounts capitalized	310	310	128
Income taxes paid	329	289	133
Accrued capital expenditures	$ 150	$ 117	$ 41

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY - USD ($) $ in Millions	Total	Common stock	Capital in excess of par value	Retained earnings	Accumulated other comprehensive (loss) income	Treasury stock	Non-controlling interest
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury stock (in shares)						(21,738,838)
Beginning balance , common stock (in shares) at Dec. 31, 2019		(128,526,137)
Beginning balance at Dec. 31, 2019	$ 6,229	$ 16	$ 3,823	$ 4,118	$ (717)	$ (1,023)	$ 12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	364			363			1
Cumulative translation adjustment	88				88
Gains (losses) on derivatives qualifying as hedges, net of tax	(9)				(9)
Pension liability and postretirement adjustment; net of tax	(60)				(60)
Cash dividends declared	(325)			(325)
Stock options/SSARs (in shares)						57,652
Stock options/SSARs	3					$ 3
Vested restricted stock units and awards	(5)		(8)			$ 3
Vested restricted stock units and awards (in shares)						93,039
Stock-based compensation	36		36
Redeemable NCI	2		2
Dividends on non-controlling interest and other	(1)						(1)
Ending balance (in shares) at Dec. 31, 2020		(128,526,137)
Ending balance at Dec. 31, 2020	6,322	$ 16	3,853	4,156	(698)	$ (1,017)	12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury stock (in shares)						(21,588,147)
Net loss	273			270			3
Cumulative translation adjustment	(848)				(848)
Gains (losses) on derivatives qualifying as hedges, net of tax	8				8
Pension liability and postretirement adjustment; net of tax	115				115
Cash dividends declared	(785)			(785)
Stock options/SSARs (in shares)						159,222
Stock options/SSARs	11		4			$ 7
Impact of N&B Merger (in shares)		141,740,461
Impact of N&B Merger	15,976	$ 18	15,936				22
Conversion of tangible equity units (in shares)		5,460,031
Conversion of tangible equity units	0	$ 1	(1)
Vested restricted stock units and awards	(5)		(18)			$ 13
Vested restricted stock units and awards (in shares)						276,280
Stock-based compensation	54		54
Redeemable NCI	(2)		(2)
Dividends on non-controlling interest and other	(2)						(2)
Ending balance (in shares) at Dec. 31, 2021		(275,726,629)
Ending balance at Dec. 31, 2021	$ 21,117	$ 35	19,826	3,641	(1,423)	$ (997)	35
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury stock (in shares)	(21,152,645)					(21,152,645)
Net loss	$ (1,868)			(1,871)			3
Cumulative translation adjustment	(904)				(904)
Gains (losses) on derivatives qualifying as hedges, net of tax	0
Pension liability and postretirement adjustment; net of tax	158				158
Cash dividends declared	(815)			(815)
Stock options/SSARs (in shares)						85,728
Stock options/SSARs	15		11			$ 4
Vested restricted stock units and awards	(26)		(41)			$ 15
Vested restricted stock units and awards (in shares)						308,751
Stock-based compensation	49		49
Purchase of NCI	(5)		1				(6)
Redeemable NCI	(5)		(5)
Dividends on non-controlling interest and other	(2)						(2)
Ending balance (in shares) at Dec. 31, 2022		(275,726,629)
Ending balance at Dec. 31, 2022	$ 17,714	$ 35	$ 19,841	$ 955	$ (2,169)	$ (978)	$ 30
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, treasury stock (in shares)	(20,758,166)					(20,758,166)

CONSOLIDATED STATEMENT OF SHA_2

CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax		$ (1)	$ 1
Tax effect of pension liability and postretirement adjustment	$ (4)	$ (4)	$ (9)
Dividends declared per share (in dollars per share)	$ 3.20	$ 3.12	$ 3.04

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations International Flavors & Fragrances Inc. and its subsidiaries (the “Registrant,” “IFF,” “the Company,” “we,” “us” and “our”) is a leading creator and manufacturer of food, beverage, health & biosciences, scent and pharma solutions and complementary adjacent products, including cosmetic active and natural health ingredients, which are used in a wide variety of consumer products. Our products are sold principally to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, sweeteners, dietary supplements, food protection, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. Basis of Presentation On February 1, 2021 (the “Closing Date”), the Company completed the combination (the “Merger”) of IFF and DuPont de Nemours, Inc (“DuPont”) nutrition and biosciences business (the “N&B Business”), which had been transferred to Nutrition and Biosciences, Inc., a Delaware corporation and wholly owned subsidiary of DuPont (“N&B”) in a Reverse Morris Trust transaction. See Note 3 for additional information. As a result, the Company’s Consolidated Financial Statements for the period ended December 31, 2022 reflect the results of N&B for the full twelve months of 2022, whereas the period ended December 31, 2021 reflect the results of N&B from the Closing Date and the period ended December 31, 2020 do not reflect any results of N&B. Certain reclassifications have been made to the prior periods’ financial information in order to conform to the current period’s presentation. Fiscal Year End Effective 2021, the Company changed its fiscal year end from a 52/53-week fiscal year ending on the Friday closest to the last day of the quarter, to a calendar year of the twelve-month period from January 1 to December 31. The Company elected to change its fiscal year end in connection with the Merger with N&B to align the Company’s fiscal year with N&B’s. The 2022, 2021 and 2020 fiscal years were 52 week periods. For ease of presentation, December 31 is used consistently throughout the financial statements and notes to represent the period-end date. For the 2022 and 2021 fiscal years, the actual closing dates were December 31 and for the 2020 fiscal year, the actual closing date was January 1. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and judgments that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The inputs into our judgments and estimates take into account the current economic implications of the novel coronavirus (“COVID-19”), the events in Russia and Ukraine, and the ongoing adverse macroeconomic environment on our critical and significant accounting estimates, including estimates associated with future cash flows that are used in assessing the risk of impairment of certain assets. Actual results could differ from those estimates. Principles of Consolidation The consolidated financial statements include the accounts of International Flavors & Fragrances Inc. and those of its subsidiaries. Significant intercompany balances and transactions have been eliminated. To the extent a subsidiary is not wholly owned, any related non-controlling interests are included as a separate component of Shareholders’ Equity. Revenue Recognition The Company recognizes revenue from contracts with customers when the contract or purchase order has received approval and commitment from both parties, has the rights of the parties and payment terms (which can vary by customer) identified, has commercial substance, collectability of consideration is probable, and control has transferred. The revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those goods. Sales, value added, and other taxes the Company collects are excluded from revenues. The Company receives payment in accordance with standard customer terms. Sales are reduced, at the time revenue is recognized, for applicable discounts, rebates and sales allowances based on historical experience. Related accruals are included in Other current liabilities in the accompanying Consolidated Balance Sheets. The Company considers shipping and handling activities undertaken after the customer has obtained control of the related goods as a fulfillment activity. Net sales include shipping and handling charges billed to customers. Cost of goods sold includes all costs incurred in connection with shipping and handling. Contract Assets and Liabilities With respect to a small number of contracts for the sale of compounds, the Company has an “enforceable right to payment for performance to date” and as the products do not have an alternative use, the Company recognizes revenue for these contracts over time and records a contract asset using the output method. The output method recognizes revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract. As of December 31, 2022 and 2021, the Company’s gross accounts receivable was $1.871 billion and $1.952 billion, respectively. The Company’s contract assets and contract liabilities as of December 31, 2022 and 2021 were not material. Foreign Currency Translation The Company translates the assets and liabilities of non-U.S. subsidiaries into U.S. dollars at year-end exchange rates. Income and expense items are translated at average exchange rates during the year. Cumulative translation adjustments are shown as a separate component of Shareholders’ Equity. Research and Development Research and development (“R&D”) expenses relate to the development of new and improved products, technical product support and compliance with governmental regulation. All research and development costs are expensed as incurred. Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with maturities of three months or less at date of purchase. Restricted Cash Restricted cash is comprised of cash or cash equivalents which has been placed into an account that is restricted for a specific use and from which the Company cannot withdraw the cash on demand. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Company’s statement of cash flows periods ended December 31, 2022, 2021 and 2020 to the amounts reported in the Company’s balance sheets as of December 31, 2022, 2021 and 2020. (DOLLARS IN MILLIONS) December 31, 2022 December 31, 2021 December 31, 2020 Current assets Cash and cash equivalents $ 483 $ 711 $ 650 Cash and cash equivalents included in Assets held for sale 52 — — Restricted cash 10 4 7 Non-current assets Restricted cash included in Other assets 7 1 3 Cash, cash equivalents and restricted cash $ 552 $ 716 $ 660 Accounts Receivable The Company has certain factoring agreements in the U.S. and The Netherlands under which it can factor up to €250 million of its trade receivables. The factoring agreements supplement the Company's existing factoring programs that are sponsored by certain customers. Under all of the arrangements, the Company sells the trade receivables on a non-recourse basis to unrelated financial institutions and accounts for the transactions as sales of receivables. The applicable receivables are removed from the Company’s Consolidated Balance Sheets when the cash proceeds are received by the Company. The Company sold approximately $1.030 billion, $668 million and $351 million of receivables in 2022, 2021 and 2020, respectively. The outstanding principal amounts of receivables under these arrangements amounted to approximately $212 million, $153 million and $57 million, respectively, as of December 31, 2022, 2021 and 2020. The proceeds from the sales of receivables are included in net cash from operating activities in the Consolidated Statements of Cash Flows. The cost of participating in these programs was approximately $12 million, $6 million and $4 million in 2022, 2021 and 2020, respectively, and is included as a component of interest expense. Expected Credit Losses The Company is exposed to credit losses primarily through its sales of products. To determine the appropriate allowance for expected credit losses, the Company considers certain credit quality indicators, such as aging, collection history, and creditworthiness of debtors. Regional and Global Credit committees review and approve specific customer allowance reserves. The allowance for expected credit losses is primarily based on two primary factors: i) the aging of the different categories of trade receivables, and ii) a specific reserve for accounts identified as uncollectible. The Company also considers current and future economic conditions in the determination of the allowance. At December 31, 2022, the Company reported $1.818 billion of trade receivables, net of allowances of $53 million. Based on the aging analysis as of December 31, 2022, approximately 1% of the Company’s accounts receivable were past due by over 365 days based on the payment terms of the invoice. The following is a roll forward of the Company’s allowances for bad debts for the years ended December 31, 2021 and 2022: (DOLLARS IN MILLIONS) Allowance for Bad Debts Balance at December 31, 2020 $ 21 Bad debt expense 6 Write-offs (1) Other adjustments (1) 20 Balance at December 31, 2021 46 Bad debt expense (2) 19 Foreign exchange (12) Balance at December 31, 2022 $ 53 _______________________ (1) The adjustment to allowances for bad debts was a result of purchase price allocation related to the Merger with N&B. (2) The bad debt expense included approximately $11 million related to expected credit losses on receivables from customers located in Russia and Ukraine (for export and domestic sales) due to recent events in those countries. The Company will continue to evaluate its credit exposure related to Russia and Ukraine. Inventories Inventories are stated at the lower of cost (on a weighted-average basis) or net realizable value. The Company's inventories consisted of the following: December 31, (DOLLARS IN MILLIONS) 2022 2021 Raw materials $ 1,073 $ 854 Work in process 442 287 Finished goods 1,636 1,375 Total $ 3,151 $ 2,516 Leases The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset. When the Company determines the arrangement is a lease, or contains a lease, at inception, it then determines whether the lease is an operating lease or a finance lease at the commencement date. The Company leases property and equipment, principally under operating leases. The Company records a right of use asset and related obligation at the present value of lease payments and, over the term of the lease, depreciates the right of use asset and accretes the obligation to future value. Some of the leases include rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. The Company has elected not to separate non-lease components from lease components for all classes of leased assets. When available, the Company uses the rate implicit in the lease to discount lease payments to present value, however, most of the Company's leases do not provide a readily determinable implicit rate and the Company calculates the applicable incremental borrowing rate to discount the lease payments based on the term of the lease at lease commencement. The incremental borrowing rate is determined based on the Company's credit rating, currency and lease terms. Long-Lived Assets Property, Plant and Equipment Property, plant and equipment are recorded at cost. Depreciation is calculated on a straight-line basis, principally over the following estimated useful lives: buildings and improvements, 1 to 50 years; machinery and equipment, 1 to 40 years; information technology hardware and software, 1 to 23 years; and leasehold improvements which are included in buildings and improvements, the estimated life of the improvements or the remaining term of the lease, whichever is shorter. Finite-Lived Intangible Assets Finite-lived intangible assets include customer relationships, patents, trade names, technological know-how and other intellectual property valued at acquisition and amortized on a straight-line basis over the following estimated useful lives: customer relationships, 10 to 27 years; patents, 11 to 15 years; trade names, 4 to 28 years; and technological know-how, 5 to 28 years. The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered. An estimate of undiscounted future cash flows produced by an asset or group of assets is compared to the carrying value to determine whether impairment exists. If assets are determined to be impaired, the loss is measured based on an estimate of fair value using various valuation techniques, including a discounted estimate of future cash flows. Impairment of Long-Lived Assets During the second quarter of 2022, the sales and margins declined for certain entities within Russia due to supply chain issues, reduced product demand and exchange rate volatility. Additionally, future growth is expected to be limited given operating conditions in Russia, which inhibit the required future investment. In connection with uncertainties related to the Company’s operations in Russia and Ukraine, the Company updated its analysis of the undiscounted cash flows of the applicable asset groups to determine if the cash flows exceeded the carrying values of the applicable asset groups. With respect to an asset group in the Nourish segment, that manufactures and sells in Russia and related markets, it was determined that the undiscounted cash flows were insufficient to cover the carrying value and that an impairment charge was required to write-down the long-lived assets to their fair values. The fair value of such asset group was determined based on a discounted cash flow approach which involved estimating the future cash flows for the business discounted to their present values. The discount rate used in the determination of such fair value was based on consideration of the risks inherent in the cash flows and market as of the valuation date. As a result of this assessment, the Company recognized an impairment charge of $120 million in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the year ended December 31, 2022, which was allocated on a pro rata basis to intangible assets and property, plant and equipment within the asset group in the amounts of approximately $92 million and $28 million, respectively. Goodwill Goodwill represents the difference between the total purchase price and the fair value of identifiable assets and liabilities acquired in business acquisitions. The Company tests goodwill for impairment at the reporting unit level as of November 30 every year or more frequently if events or changes in circumstances indicate the asset might be impaired. A reporting unit is an operating segment or one level below an operating segment (referred to as a component) to which goodwill is assigned when initially recorded. The Company identifies their reporting units by assessing whether the components of their reporting units constitute businesses for which discrete financial information is available and management of each reporting unit regularly reviews the operating results of those components. The Company determined that it has six reporting units under the Nourish, Health & Biosciences, Scent and Pharma Solutions segments: (1) Nourish, (2) Fragrance Compounds, (3) Fragrance Ingredients, (4) Cosmetic Actives, (5) Health & Biosciences and (6) Pharma Solutions. These reporting units were determined based on the level at which the performance is measured and reviewed by segment management. In cases where the components of an operating segment have similar economic characteristics, they are aggregated into a single reporting unit. When testing goodwill for impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company elects to bypass the qualitative assessment for any reporting units, or if a qualitative assessment indicates it is more likely than not that the estimated carrying value of a reporting unit exceeds its fair value, the Company performs a quantitative goodwill impairment test. Under the quantitative goodwill impairment test, if a reporting unit’s carrying amount exceeds its fair value, the Company will record an impairment charge based on that difference, and the impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For the third quarter of 2022, the Company determined that the carrying value of the Health & Biosciences reporting unit exceeded its fair value and recorded a goodwill impairment charge of $2.250 billion in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the year ended December 31, 2022 (see Note 6 for additional information). Income Taxes The Company accounts for taxes under the asset and liability method. Under this method, deferred income taxes are recognized for temporary differences between the financial statement and tax return bases of assets and liabilities, based on enacted tax rates and other provisions of the tax law. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized as income in the period in which such change is enacted. Future tax benefits are recognized to the extent that the realization of such benefits is more likely than not, and a valuation allowance is established for any portion of a deferred tax asset that management believes may not be realized. The Company recognizes uncertain tax positions that it has taken or expects to take on a tax return. Pursuant to accounting requirements, the Company first determines whether it is “more likely than not” its tax position will be sustained if the relevant tax authority were to audit the position with full knowledge of all the relevant facts and other information. For those tax positions that meet this threshold, the Company measures the amount of tax benefit based on the largest amount of tax benefit that it has a greater than 50% chance of realizing in a final settlement with the relevant authority. Those tax positions failing to qualify for initial recognition are recognized in the first interim period in which they meet the more likely than not standard. The Company maintains a cumulative risk portfolio relating to all of its uncertainties in income taxes in order to perform this analysis, but the evaluation of its tax positions requires significant judgment and estimation in part because, in certain cases, tax law is subject to varied interpretation, and whether a tax position will ultimately be sustained may be uncertain. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense. Retirement Benefits Current service costs of retirement plans and postretirement health care and life insurance benefits are accrued. Prior service costs resulting from plan improvements are amortized over periods ranging from 10 to 20 years. Financial Instruments Derivative financial instruments are used to manage interest and foreign currency exposures. The gain or loss on the hedging instrument is recorded in earnings at the same time as the transaction being hedged is recorded in earnings. The associated asset or liability related to the open hedge instrument is recorded in Prepaid expenses and Other current assets or Other current liabilities, as applicable. The Company records all derivative financial instruments on the balance sheet at fair value. Changes in a derivative’s fair value are recognized in earnings unless specific hedge criteria are met. If the derivative is designated as a fair value hedge, the changes in the fair value of the derivative and of the hedged item attributable to the hedged risk are recognized in Net (loss) income. If the derivative is designated as a cash flow hedge, the effective portions of changes in the fair value of the derivative are recorded in Accumulated Other Comprehensive Income (Loss) (“AOCI”) in the accompanying Consolidated Balance Sheets and are subsequently recognized in Net income when the hedged item affects earnings. Ineffective portions of changes in the fair value of cash flow hedges, if any, are recognized as a charge or credit to earnings. Software Costs The Company capitalizes direct internal and external development costs for certain significant projects associated with internal-use software and amortizes these costs over seven years. Neither preliminary evaluation costs nor costs associated with the software after implementation are capitalized. Costs related to projects that are not significant are expensed as incurred. Net (Loss) Income Per Share Under the two-class method, earnings are adjusted by accretion of amounts to redeemable non-controlling interests recorded at redemption value. The adjustments represent in-substance dividend distributions to the non-controlling interest holders as the holders have a contractual right to receive a specified amount upon redemption. As a result, earnings are adjusted to reflect this in-substance distribution that is different from other common shareholders. In addition, the Company has unvested share based payment awards with a right to receive nonforfeitable dividends and thus are considered participating securities which are required to be included in the computation of basic and diluted earnings per share. Basic (loss) income per share represents the amount of earnings available to each share of common stock outstanding during the period. Basic (loss) income per share includes the effect of issuing shares of common stock, where (i) for 2021, the prepaid stock purchase contracts (“SPCs”) were converted using the final settlement rate on September 14, 2021 (see Note 11 for additional information) and for 2020, the prepaid SPCs were converted into the minimum number of shares of common stock under the if-converted method, and (ii) an adjustment to (loss) income to reflect adjustments made to record the redeemable value of redeemable non-controlling interests. Diluted (loss) income per share also includes the effect of issuing shares of common stock, assuming (i) stock options and warrants are exercised, (ii) restricted stock units are fully vested under the treasury stock method, and (iii) for 2021, the incremental effect of the prepaid SPCs were converted using the final settlement rate on September 14, 2021 (see Note 11 for additional information) and for 2020, the incremental effect of the prepaid SPCs were converted into the maximum number of shares of common stock under the if-converted method. Stock-Based Compensation Compensation cost of all stock-based awards is measured at fair value on the date of grant and recognized over the service period for which awards are expected to vest. The cost of such stock-based awards is principally recognized on a straight-line attribution basis over their respective vesting periods, net of estimated forfeitures. Financing Costs Costs incurred in the issuance of debt are deferred and amortized as part of interest expense over the stated life of the applicable debt instrument. Unamortized deferred financing costs relating to debt are presented as a reduction in the amount of debt outstanding on the Consolidated Balance Sheets. Unamortized deferred financing costs relating to the revolving credit facility are recorded in Other assets on the Consolidated Balance Sheets. Redeemable Non-controlling Interests Non-controlling interests in subsidiaries that are redeemable for cash or other assets outside of the Company’s control are classified as mezzanine equity, outside of equity and liabilities, at the greater of the carrying value or the redemption value. The increases or decreases in the estimated redemption amount are recorded with corresponding adjustments against Capital in excess of par value and are reflected in the computation of earnings per share using the two-class method. Held for Sale Assets and liabilities to be disposed of by sale (“disposal groups”) are reclassified into assets and liabilities held for sale on the Company’s Consolidated Balance Sheets. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. See Note 21 for additional information. Recent Accounting Pronouncements In December 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848.” The ASU was issued to provide an update on ASU 2020-04 and ASU 2021-01 that were issued in March 2020 and January 2021, respectively, which provided optional accounting guidance for a limited period of time to ease the potential burden in accounting for reference rate reform. The guidance provides optional expedients and exceptions to existing accounting requirements for contract modifications and hedge accounting related to transitioning from discontinued reference rates, such as London Interbank Offered Rate (“LIBOR”), to alternative reference rates, if certain criteria are met. With the issuance of ASU 2022-06, the sunset date of Topic 848 has been deferred from December 31, 2022 to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The Company is currently evaluating the impact of this guidance, but does not expect this guidance to have a material impact on its Consolidated Financial Statements. In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance.” The ASU requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This guidance is effective for all entities for annual periods beginning after December 15, 2021 and early adoption is permitted. This guidance was adopted by the Company as of January 1, 2022 using the prospective method of adoption. The adoption of this guidance did not have a material impact on the Consolidated Financial Statements. In October 2021, the FASB issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The ASU is intended to provide specific guidance on how to recognize and measure acquired contract assets and liabilities from revenue contracts in a business combination. An acquirer needs to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted, including adoption in an interim period. The Company early adopted ASU 2021-08 during the second quarter of 2022. The adoption of this guidance did not have a material impact on the Consolidated Financial Statements.

Restructuring and Other Charges

Restructuring and Other Charges	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	RESTRUCTURING AND OTHER CHARGES Restructuring and other charges primarily consist of separation costs for employees including severance, outplacement and other benefit (“Severance”) costs as well as costs related to plant closures, principally related to fixed asset write-downs (“Fixed asset write-down”) and all other related restructuring (“Other”) costs. All restructuring and other charges are separately stated on the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. Frutarom Integration Initiative In connection with the acquisition of Frutarom, the Company has been executing an integration plan that, among other initiatives, seeks to optimize its manufacturing network (the “Frutarom Integration Initiative”). As part of the Frutarom Integration Initiative, the Company expects to close approximately 30 manufacturing sites with all closures targeted to occur by the end of 2023. Since the inception of the initiative through December 31, 2022, the Company has closed 22 sites and expensed total costs of approximately $39 million. Total costs for the program are expected to be approximately $42 million including cash and non-cash items. 2019 Severance Program During 2019, the Company incurred severance charges related to approximately 190 headcount reductions, excluding those previously mentioned under the Frutarom Integration Initiative. The headcount reductions primarily related to the Scent business unit with additional amounts related to headcount reductions in all business units associated with the establishment of a new shared service center in Europe. Since the program’s inception, the Company has expensed approximately $15 million. As of the third quarter of 2022, the program is complete. 2017 Productivity Program In connection with 2017 Productivity Program, the Company recorded $24 million of charges related to personnel costs and lease termination costs since the program's inception. As of December 31, 2020, the program was completed. Other Restructuring Charges For 2022, 2021 and 2020, the Company incurred total charges of approximately $4 million primarily related to the severance costs in connection with the closure of a facility in Germany. N&B Merger Restructuring Liability For 2022, the Company incurred approximately $15 million of charges related to severance, lease termination costs, and lease impairment charges. Since the inception of the restructuring activities, there have been approximately 240 headcount reductions and the Company has expensed approximately $45 million. Changes in Restructuring Liability Movements in severance-related accruals during 2020, 2021 and 2022 are as follows: (DOLLARS IN MILLIONS) Balance at January 1, 2020 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at December 31, 2020 2017 Productivity Program Severance $ 1 $ (1) $ — $ — $ — Frutarom Integration Initiative Severance 4 2 — (3) 3 Fixed asset write down — 12 (12) — — Other (1) 3 2 — (2) 3 2019 Severance Program Severance 13 (1) — (6) 6 Other Restructuring Charges Severance — 3 — (1) 2 Total restructuring $ 21 $ 17 $ (12) $ (12) $ 14 (DOLLARS IN MILLIONS) Balance at January 1, 2021 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at December 31, 2021 Frutarom Integration Initiative Severance $ 3 $ 5 $ — $ (3) $ 5 Fixed asset write down — 5 (5) — — Other (1) 3 — — — 3 2019 Severance Program Severance 6 — — (1) 5 Other Restructuring Charges Severance 2 — — (1) 1 Other (2) — 1 — (1) — N&B Merger Restructuring Liability Severance — 27 — (12) 15 Other (3) — 3 (3) — — Total restructuring $ 14 $ 41 $ (8) $ (18) $ 29 (DOLLARS IN MILLIONS) Balance at January 1, 2022 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at December 31, 2022 Frutarom Integration Initiative Severance $ 5 $ 1 $ — $ (2) $ 4 Fixed asset write down — 3 (3) — — Other (1) 3 (2) — (1) — 2019 Severance Program Severance 5 (5) — — — Other Restructuring Charges Severance 1 — — — 1 N&B Merger Restructuring Liability Severance 15 8 — (14) 9 Other (3) — 7 (2) (4) 1 Total restructuring $ 29 $ 12 $ (5) $ (21) $ 15 _______________________ (1) Includes supplier contract termination costs, consulting and advisory fees. (2) Includes charges related to legal settlement costs. (3) Includes lease impairment charges and losses incurred from restructuring activities as a result of the Merger with N&B. Charges by Segment The following table summarizes the total amount of costs incurred in connection with these restructuring programs and activities by segment: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Nourish $ 8 $ 32 $ 10 Health & Biosciences 2 5 — Scent 1 3 7 Pharma Solutions 1 1 — Total Restructuring and other charges $ 12 $ 41 $ 17

Acquisitions (Notes)

Acquisitions (Notes)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	ACQUISITIONS Acquisition of Health Wright Products On April 1, 2022 (“Acquisition Date”), the Company completed its acquisition of Health Wright Products, Inc. (“Health Wright”). IFF acquired 100% of the equity of Health Wright pursuant to a purchase agreement entered into on February 16, 2022. Health Wright is known in the consumer Health and Nutrition industries for providing high quality nutritional supplements. The acquisition was made in order to strengthen formulation and finished format capabilities to IFF’s Health & Biosciences probiotics, natural extracts and botanical businesses. The acquisition was accounted for under the purchase method. The fair value of consideration transferred was approximately $157 million, including cash and estimated contingent consideration of $31 million. The preliminary purchase price allocation has been performed and resulted in intangible assets of approximately $75 million, and approximately $45 million of goodwill (which is deductible for income tax purposes). The intangible assets primarily consisted of customer relationships of approximately $74 million that have been fair valued using the Multi-Period Excess Earning Method and which are being amortized over a period of approximately 19 years. The purchase price allocation was finalized as of the end of 2022 when the Company finalized the valuation of the acquired goodwill, intangible assets (trade names and customer relationships) and inventory, in addition to ensuring all other assets and liabilities and contingencies have been identified and recorded. The Company remeasured the fair value of contingent consideration as of December 31, 2022 and recognized a credit of approximately $5 million, within Selling and administrative expenses, for changes in the fair value of contingent consideration obligations. The reduction in the fair value of contingent consideration primarily resulted from changes in the probability assessment of achieving the performance targets. The measurement period adjustments were recorded during the year ended December 31, 2022 and the purchase price allocation is complete as of December 31, 2022. No pro forma information for 2022 was presented as the acquisition was not material to the Consolidated Financial Statements. Transaction with Nutrition & Biosciences, Inc. On February 1, 2021, IFF completed the Merger with N&B. Pursuant to the transaction related agreements, DuPont transferred its N&B Business to N&B, a wholly-owned subsidiary of DuPont, and N&B merged with and into a wholly owned subsidiary of IFF in exchange for 141,740,461 shares of IFF common stock, par value $0.125 per share (“IFF Common Stock”). The Company completed its Merger with N&B in a Reverse Morris Trust transaction (the “Transactions”), pursuant to which the Company acquired the N&B Business of DuPont. In the Transactions, among other steps (i) DuPont transferred the N&B Business to N&B (the “Separation”); (ii) N&B made a cash distribution to DuPont of approximately $7.359 billion, subject to certain adjustments (the “Special Cash Payments”); (iii) DuPont distributed to its stockholders all of the issued and outstanding shares of N&B common stock by way of an exchange offer (the “Distribution”), and; (iv) N&B merged with and into a wholly owned subsidiary of IFF. As a result of the Merger, the existing shares of N&B common stock were automatically converted into the right to receive a number of shares of IFF Common Stock. Immediately after the Merger, holders of DuPont’s common stock that received shares of N&B common stock in the Distribution owned approximately 55.4% of the outstanding shares of IFF Common Stock on a fully diluted basis and existing holders of IFF Common Stock owned approximately 44.6% of the outstanding shares of IFF on a fully diluted basis. The Merger was accounted for using the purchase method of accounting in accordance with ASC Topic 805, Business Combinations, with IFF identified as the acquirer. As a result of the Merger, N&B’s assets, liabilities and the operating results of N&B were included in the Company’s financial statements from the Closing Date. N&B contributed net sales of approximately $6.084 billion and net income of approximately $11 million for the year ended December 31, 2021, which included the effects of purchase accounting adjustments, primarily related to changes in amortization of intangible assets, depreciation of property, plant and equipment and amortization of stepped up inventory. Prior to the Distribution, N&B incurred new indebtedness in the form of term loans and senior notes in an aggregate principal amount of $7.500 billion to pay the Special Cash Payments made to DuPont stockholders. See Note 9 for additional information regarding the new term loans and senior notes incurred by N&B and subsequently assumed by IFF. Purchase Price The following table summarizes the aggregate purchase price consideration paid to acquire N&B (in millions, except share and per share data): (DOLLARS IN MILLIONS) Fair value of common stock issued to DuPont stockholders (1) $ 15,929 Fair value attributable to pre-merger service for replacement equity awards (2) 25 Pension funding adjustment (3) (12) Total purchase consideration $ 15,942 _______________________ (1) The fair value of common stock issued to DuPont stockholders represents 141,740,461 shares of the Company's common stock determined based on the number of fully diluted shares of IFF common stock, immediately prior to the Closing Date, multiplied by the quotient of 55.4%/44.6% and IFF common stock closing share price of $112.38 on the New York Stock Exchange on the Closing Date. (2) At the time of the Transactions, each outstanding stock option, cash-settled stock appreciation right (“SAR”), restricted stock unit (“RSU”) award, and restricted stock award (“RSA”) with respect to DuPont common stock held by employees of N&B were canceled and converted into similar classes of equity awards of IFF’s Class A Common Stock. Further, each outstanding Performance Share Unit (“PSU”) award with respect to DuPont common stock held by employees of N&B were canceled and converted into IFF’s RSU awards. The conversion was based on the ratio of the volume-weighted average per share closing price of DuPont stock on the twenty trading days prior to the Closing Date and IFF’s stock on the twenty trading days following the Closing Date. The fair value of replacement equity-based awards attributable to pre-Merger service was recorded as part of the consideration transferred in the Merger (see Note 13 for additional information). (3) The Merger related agreements provided that if the net pension balance of N&B as of the Closing Date differs from $220 million, such differential amount would be settled in cash. The Company estimated the amount that it would receive and, accordingly, made an adjustment of $12 million to the total purchase consideration. Purchase Price Allocation The Merger with N&B was accounted for under the acquisition method under which the Company allocated the purchase consideration to the tangible net assets and identifiable assets acquired based on estimated fair values at the Closing Date, and recorded the excess of consideration over the fair values of net assets acquired as goodwill. The purchase price allocation was finalized as of the end of 2021 when the Company finalized the valuation of the acquired property, plant and equipment, goodwill, intangible assets (trade names, customer relationships, IPR&D, and technological know-how), inventory and leases, in addition to ensuring all other assets and liabilities and contingencies had been identified and recorded. Further, the assessment of certain contingencies including loss contracts and environmental liabilities, pension and postretirement benefit obligations and taxes was completed. Additionally, in connection with finalizing the purchase price allocation, the Company finalized the projected combined future tax rate applied to the valuation of assets and recorded the applicable adjustments to the values of goodwill and intangible assets. The following table summarizes the fair values of the assets acquired and liabilities assumed as of February 1, 2021, presenting both the preliminary and final purchase price allocations: (DOLLARS IN MILLIONS) Preliminary Estimated Fair Value as Reported in the First Quarter of 2021 Measurement Period Adjustments (1)(2) Final Fair Value as Reported in the Fourth Quarter of 2021 Cash and cash equivalents $ 207 $ (14) $ 193 Receivables 962 (9) 953 Inventory 1,615 (25) 1,590 Prepaid expenses and other current assets 342 32 374 Property, plant and equipment 3,242 (176) 3,066 Deferred income taxes 75 8 83 Intangible assets 9,176 47 9,223 Other assets 702 116 818 Accounts payable and accrued liabilities (1,028) (51) (1,079) Accrued payroll and employee benefits (163) 15 (148) Deferred tax liabilities (3) (2,369) (26) (2,395) Long-term debt (7,636) — (7,636) Other long-term liabilities (907) 12 (895) Total identifiable net assets assumed 4,218 (71) 4,147 Non-controlling interest (26) 4 (22) Goodwill (4) 11,762 55 11,817 Purchase price $ 15,954 $ (12) $ 15,942 _______________________ (1) The preliminary fair value purchase price allocation of the assets and liabilities acquired in the N&B Merger as reported in the first quarter of 2021 were updated during the nine months ended December 31, 2021 to reflect updated fair values for intangible assets, property, plant and equipment, equity method investments and inventory. In addition, the carrying amounts of certain assets and liabilities were updated based on additional analysis of acquired assets and liabilities that existed at the Closing Date. (2) During the fourth quarter of 2021, the Company recorded an adjustment to reflect the receipt of approximately $53 million in cash from DuPont as a result of finalization of adjustments to the Special Cash Payment paid to DuPont by N&B, prior to the close of the Transactions. (3) The change to deferred tax liabilities was primarily a result of the finalization of the jurisdictional allocation of the tangible and intangible assets. All measurement period adjustments were offset against goodwill. (4) The cumulative impact of the adjustments during the nine months ended December 31, 2021 resulted in a $55 million increase to goodwill. Acquired inventory is comprised of finished goods, work in process and raw materials. The fair value of finished goods was calculated as the estimated selling price, adjusted for costs of the selling effort and a reasonable profit allowance relating to the selling effort. The fair value of work in process inventory was primarily calculated as the estimated selling price, adjusted for estimated costs to complete the manufacturing, estimated costs of the selling effort, as well as a reasonable profit margin on the remaining manufacturing and selling effort. The fair value of raw materials and supplies was determined based on replacement cost which approximates historical carrying value. The fair value step-up has been amortized to “Cost of goods sold” in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income, for the year ended December 31, 2021, as the inventory was sold. The fair value of property, plant and equipment was primarily calculated using the cost approach, which determined the replacement costs for the assets and adjusted them for their age and condition. The fair value of the land assets was determined via the sales comparison approach. The long-term debt assumed was comprised of a Term Loan Facility and Notes. The fair value of the Notes was determined on the basis of unadjusted quoted prices on an over-the-counter market. The fair value of the long-term debt assumed as part of the Term Loan Facility was based on the total indebtedness at the time of closing the Merger. See Note 9 for additional information regarding the new term loans and senior notes incurred by N&B and subsequently assumed by IFF. The Company recognized $11.817 billion of goodwill in connection with the N&B Merger, which was in part attributable to expected synergies generated by the integration of N&B including cross-selling benefits as well as cost synergies. Substantially all of the goodwill was not deductible for income tax purposes. Goodwill of $2.900 billion, $6.712 billion, $876 million and $1.329 billion was allocated to the Nourish, Health & Biosciences, Scent and Pharma Solutions segments, respectively. The fair value and useful lives of the identifiable intangible assets assumed as of February 1, 2021 were as follows: (DOLLARS IN MILLIONS) Amounts Useful Lives Indefinite-lived intangible assets In-process research and development $ 13 Indefinite Finite-lived intangible assets Trade names 261 4 to 22 years Customer relationships 6,734 11 to 27 years Technological know-how 2,194 5 to 18 years Other 21 2 years Total finite-lived intangible assets 9,210 Total $ 9,223 The fair value of intangible assets was generally determined using an income method (specifically, for customer relationships, the multi-period excess earnings method), which was based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflected a consideration of other market participants, and included the amount and timing of future cash flows (including revenue growth rates, gross margins and operating expenses), royalty rates used in the relief from royalty method, customer attrition rates, product obsolescence factors, a brand’s relative market position and the discount rates applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also required significant judgment. Trade names, customer relationships and technological know-hows are expected to have finite lives. The costs of finite lived intangible assets are amortized through expense over their estimated lives. Lease liabilities, included in “Other current liabilities” and “Operating lease liabilities” in the Consolidated Balance Sheets, at the Closing Date, were remeasured at the present value of the future minimum lease payments over the remaining lease term and the incremental borrowing rate of the Company as if the acquired leases were new leases as of the Closing Date. Right-of-use assets included in “Operating lease right-of-use assets” in the Consolidated Balance Sheets as of the Closing Date, were principally equal to the amount of the lease liability at the Closing Date, adjusted for any fair value adjustments for off-market leases. The Company reviewed the acquired leases and applied a $15 million adjustment to reflect off-market leases. The remaining lease term was based on the remaining term at the Closing Date plus any renewal or extension options that the Company was reasonably certain would be exercised. Net defined benefit plan liabilities were recognized based on appropriate actuarial assumptions and asset valuations as of the Closing Date and, accordingly, liabilities of approximately $221 million were recorded. The Company accrued approximately $75 million related to certain product liability and legal contingencies for which it was determined that a liability existed at the Closing Date. Of this amount, approximately $61 million was related to the finding of certain grades of microcrystalline cellulose (Avicel® PH 101, 102, and 200 NF and Avicel® RC-591 NF) being out-of-specification. See Note 19 for additional information. The deferred income tax assets and liabilities included the expected future federal, state and foreign tax consequences associated with temporary differences between the fair values of the assets acquired and liabilities assumed and the respective tax bases. Tax rates utilized in calculating deferred income taxes generally represented the enacted statutory tax rates at the effective date of the Merger in the jurisdictions in which legal title of the underlying asset or liability resides. See Note 10 for additional information related to income taxes. The Company incurred transaction-related costs of approximately $91 million and $29 million in 2021 and 2020, respectively. The transaction-related costs primarily consisted of merger and acquisition advisory, legal and professional fees in 2021 and legal and professional fees in 2020. Pro Forma Financial Information The following unaudited pro forma financial information presents the combined results of operations of IFF and N&B as if the Merger had been completed as of January 1, 2020. The unaudited pro forma financial information is presented for informational purposes and is not indicative of the results of operations that would have been achieved if the Merger and related borrowings had taken place on January 1, 2020, nor are they indicative of future results. The unaudited pro forma financial information for the year ended December 31, 2021 includes IFF results, including the post-Merger results of N&B, since February 1, 2021, and pre-Merger results of N&B for the period January 1, 2021 through January 31, 2021. The unaudited pro forma results for the year ended December 31, 2021 and 2020 were as follows: Year Ended December 31, (DOLLARS IN MILLIONS) 2021 2020 Unaudited pro forma net sales $ 12,163 $ 11,143 Unaudited pro forma net income attributable to the Company 687 192 The unaudited pro forma results for all periods include adjustments made to account for certain costs and transactions that would have been incurred had the Merger been completed as of January 1, 2020, including amortization charges for acquired intangibles assets, adjustments for transaction costs, adjustments for depreciation expense for property, plant and equipment, inventory step-up and adjustments to interest expense. These adjustments are net of any applicable tax impact and were included to arrive at the pro forma results above.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment, Net	PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment, net consisted of the following amounts: (DOLLARS IN MILLIONS) December 31, 2022 2021 Asset Type Land $ 199 $ 223 Buildings and improvements 1,697 1,764 Machinery and equipment 3,344 3,442 Information technology 291 271 Construction in process 649 461 Total Property, Plant and Equipment 6,180 6,161 Accumulated depreciation (1,977) (1,793) Total Property, Plant and Equipment, Net $ 4,203 $ 4,368 Impairment of Property, Plant and Equipment As discussed in Note 1, for the year ended December 31, 2022 an impairment charge of approximately $28 million was recorded in connection with property, plant and equipment, primarily buildings and improvements, of an asset group that operates primarily in Russia. Depreciation Depreciation expense was $452 million, $424 million and $132 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill In the first quarter of 2021, in connection to the Merger, the Company reorganized its reporting structure. In connection with this reorganization, goodwill was reassigned among reporting units using a relative fair value approach based on the fair value of the elements transferred and the fair value of the elements remaining within the original reporting units. The Company tested goodwill for impairment on a pre-reorganization basis and determined there was no impairment for the affected reporting units. In connection with the reorganization, $985 million of goodwill previously included in the legacy Taste segment, now the Nourish segment, was moved to the Scent and Health & Biosciences segments amounting to $257 million and $728 million, respectively. Movements in goodwill attributable to each reportable segment during the years ended December 31, 2021 and 2022 were as follows: (DOLLARS IN MILLIONS) Nourish Health & Biosciences Scent Pharma Solutions Total Balance at December 31, 2020 $ 4,859 $ — $ 734 $ — $ 5,593 Acquisitions (1) 2,900 6,712 876 1,329 11,817 Transferred to assets held for sale (2) — (536) — — (536) Reduction from business divestiture (27) — — — (27) Foreign exchange (192) (155) (39) (47) (433) Reallocation (985) 728 257 — — Balance at December 31, 2021 6,555 6,749 1,828 1,282 16,414 Acquisitions (3) — 45 — — 45 Impairment — (2,250) — — (2,250) Transferred to assets held for sale (4) (306) — (42) — (348) Foreign exchange (199) (223) (41) (43) (506) Balance at December 31, 2022 $ 6,050 $ 4,321 $ 1,745 $ 1,239 $ 13,355 _______________________ (1) Acquisitions relate to the Merger with N&B. See Note 3 for additional information. (2) Transferred to assets held for sale relate to the Microbial Control business unit that was classified as “held for sale” as of December 31, 2021. (3) Acquisitions relate to the acquisition of Health Wright. See Note 3 for additional information. (4) Transferred to assets held for sale relate to the portion of the Savory Solutions business and Flavor Specialty Ingredients business that were classified as “held for sale” as of December 31, 2022. See Note 21 for additional information. Goodwill Impairment Test For the annual impairment test as of November 30, 2022, the Company elected to bypass the qualitative assessment for all reporting units, Step 0 of the guidance in ASC Topic 350, Intangibles – Goodwill and Other, which allows for the assessment of qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. For all six reporting units, the Company performed a Step 1 test. The Company assessed the fair value of the reporting units using an income approach. Under the income approach, the Company determined the fair value by using a discounted cash flow method at a rate of return that reflects the relative risk of the projected future cash flows of each reporting unit, as well as a terminal value. The Company used the most current actual and forecasted operating data available. Key estimates and assumptions used in these valuations include revenue growth rates, gross margins, EBITDA margins, terminal growth rates and discount rates. In performing the quantitative impairment test, the Company determined that the fair value of the six reporting units exceeded their carrying values and determined that there was no further impairment of goodwill at any of the Company’s six reporting units as of November 30, 2022. Based on the quantitative impairment test performed, the Company determined that all reporting units except the Health & Biosciences reporting unit had excess fair value over carrying value of more than 25%. As of November 30, 2022, the Health & Biosciences reporting unit had excess fair value over carrying value of approximately 3% and goodwill of approximately $4.321 billion. While management believes that the assumptions used in the impairment test were reasonable, changes in key assumptions, including lower revenue growth, operating margin, terminal growth rates or increase in discount rates could result in a future impairment. If current long-term projections for these reporting units are not realized or materially decrease, the Company may be required to write-off all or a portion of the goodwill. Such charge could have a material effect on the Consolidated Statements of Operations and Balance Sheets. For the third quarter of 2022, the Company determined that goodwill impairment triggering events occurred for its Nourish, Health & Biosciences and Pharma Solutions reporting units, which required it to complete an interim impairment assessment. The primary indicators that were deemed to be triggering events in the quarter for the reporting units were declines in the Company’s projections across various reporting units and ongoing adverse macroeconomic impacts such as inflation, increases in interest rates and unfavorable effects from exchange rates. As a result of the triggering events, the Company assessed the fair value of the reporting units using the income approach. In performing the quantitative impairment test, the Company determined that the fair value of the Nourish and Pharma Solutions reporting units exceeded their carrying value, and determined that there was no impairment of goodwill relating to these reporting units. The Company determined that the carrying value of the Health & Biosciences reporting unit exceeded its fair value and recorded a goodwill impairment charge of $2.250 billion in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the year ended December 31, 2022. Other Intangible Assets Other intangible assets, net consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Asset Type Customer relationships $ 8,318 $ 8,935 Technological know-how 2,339 2,494 Trade names & patents 358 411 Other 47 50 Total carrying value 11,062 11,890 Accumulated Amortization Customer relationships (1,252) (887) Technological know-how (589) (388) Trade names & patents (97) (68) Other (42) (41) Total accumulated amortization (1,980) (1,384) Other intangible assets, net $ 9,082 $ 10,506 Impairment of Intangible Assets As discussed in Note 1, for the year ended December 31, 2022, an impairment charge of approximately $92 million was recorded in connection with intangible assets, primarily customer relationships and technological know-how, of an asset group that operates primarily in Russia, which was included within accumulated amortization. Amortization Amortization expense was $727 million for the year ended December 31, 2022, $732 million for the year ended December 31, 2021 and $193 million for the year ended December 31, 2020. Amortization expense for the next five years and thereafter, based on valuations and determinations of useful lives, is expected to be as follows: December 31, (DOLLARS IN MILLIONS) 2023 2024 2025 2026 2027 Estimated future intangible amortization expense $ 703 $ 702 $ 699 $ 697 $ 598

Other Assets And Liabilities, C

Other Assets And Liabilities, Current and Noncurrent	12 Months Ended
	Dec. 31, 2022
Other Assets [Abstract]
Other Current Assets and Liabilities, and Other Assets	OTHER CURRENT ASSETS AND LIABILITIES, AND OTHER ASSETS Prepaid expenses and other current assets consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Value-added tax receivable $ 212 $ 178 Income tax receivable 129 131 Packaging materials 148 128 Prepaid expenses 144 160 Other 137 131 Total $ 770 $ 728 Other assets consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Finance lease right-of-use assets $ 22 $ 21 Deferred income taxes 158 82 Overfunded pension plans 180 136 Cash surrender value of life insurance contracts 45 52 Equity method investments 10 86 Other (1) 284 239 Total $ 699 $ 616 _______________________ (1) Includes land usage rights in China, long term deposits and receivables on certain derivative instruments. Other current liabilities consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Rebates and incentives payable $ 99 $ 113 Value-added tax payable 65 50 Interest payable 55 48 Current pension and other postretirement benefit obligation 10 11 Accrued insurance (including workers’ compensation) 9 10 Restructuring and other charges 15 29 Current operating lease obligation 86 109 Accrued freight 18 — Accrued commissions payable 11 13 Accrued income taxes 313 94 Accrued expenses payable 256 270 Other 91 85 Total $ 1,028 $ 832

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	DEBT Debt consisted of the following at December 31: (DOLLARS IN MILLIONS) Effective Interest Rate 2022 2021 2022 Notes (3) 0.69 % $ — $ 300 2023 Notes (1) 3.30 % 300 300 2024 Euro Notes (1) 1.88 % 532 565 2025 Notes (3) 1.22 % 1,000 1,001 2026 Euro Notes (1) 1.93 % 845 900 2027 Notes (3) 1.56 % 1,215 1,218 2028 Notes (1) 4.57 % 398 397 2030 Notes (3) 2.21 % 1,510 1,511 2040 Notes (3) 3.04 % 774 775 2047 Notes (1) 4.44 % 495 494 2048 Notes (1) 5.12 % 787 786 2050 Notes (3) 3.21 % 1,571 1,572 2024 Term Loan Facility (4) 3.65 % 625 625 2026 Term Loan Facility (4) 4.92 % 625 625 Commercial Paper (5) 187 324 Amended Revolving Credit facility (6) 100 — Bank overdrafts and other 6 7 Total debt $ 10,970 $ 11,400 Less: Short term borrowings (2) (597) (632) Total Long-term debt $ 10,373 $ 10,768 _______________________ (1) Amount is net of unamortized discount and debt issuance costs. (2) Includes bank borrowings, overdrafts, current portion of long-term debt and commercial paper. (3) Assumed by the Company as part of the N&B Merger. Amount is net of unamortized premium and debt issuance costs. (4) Assumed by the Company as part of the N&B Merger and recorded at fair value. (5) The effective interest rate of commercial paper issuances fluctuate as short-term interest rates and demand fluctuate, and deferred debt issuance costs are immaterial. Additionally, the effective interest rate of commercial paper is not meaningful as issuances do not materially differ from short-term interest rates. Proceeds from the issuance of commercial paper include $225 million of proceeds with original maturities greater than three months. (6) The interest rate on the Amended Revolving Credit Facility is, at the applicable borrower's option, a per annum rate equal to either (x) an eurocurrency rate plus an applicable margin varying from 1.000% to 1.625% or (y) a base rate plus an applicable margin varying from 0.000% to 0.625%, in each case depending on the public debt ratings for non-credit enhanced long-term senior unsecured debt issued by the Company. Term Loan Facility and Senior Notes assumed as part of the N&B Merger Following the Merger, the Company assumed the indebtedness incurred by N&B in the debt financings completed prior to the Distribution. This indebtedness includes (i) a Term Loan Facility of $1.250 billion pursuant to the term loan credit agreement (the “N&B Term Loan Facility”) and (ii) a series of Senior Notes in the aggregate amount of $6.250 billion with maturities ranging from 2 to 30 years as further described below. N&B’s indebtedness raised prior to the Merger was used to finance the Special Cash Payment to DuPont, which has been paid, and for the satisfaction of the related transaction fees and expenses. See Note 3 for additional information. N&B Term Loan Facility The N&B Term Loan Facility was funded on February 1, 2021, and provides for a senior unsecured term loan credit facility in an aggregate principal amount of $1.250 billion, comprised of a $625 million three-year tranche (“2024 Term Loan Facility”) and a $625 million five-year tranche (“2026 Term Loan Facility”). Interest for each tranche equals, at the Company’s option, a per annum rate equal to either (x) an adjusted LIBOR rate plus an applicable margin varying from 0.750% to 2.000% for the three-year tranche and from 1.125% to 2.375% for the five-year tranche or (y) a base rate plus an applicable margin varying from 0.000% to 1.000% for the three-year tranche and from 0.125% to 1.375% for the five-year tranche, in each case depending on the class of IFF’s non-credit-enhanced, senior unsecured long-term debt credit rating. The 2024 Term Loan Facility and 2026 Term Loan Facility are subject to customary affirmative and negative covenants and events of default after the Closing Date of the Merger. On and after the Closing Date of the N&B Transaction, the 2024 Term Loan Facility and 2026 Term Loan Facility are also subject to a financial covenant requiring maintenance of a maximum consolidated leverage ratio of 4.75x, with step downs to 3.50x over time, with the first step-down which occurred after the fiscal quarter ended December 31, 2021 and the final step-down occurring after the fiscal quarter ending June 30, 2023, with a step-up if the Company consummates certain qualified acquisitions. On August 4, 2022, the Company and certain of its subsidiaries entered into Amendment No. 2 To Credit Agreement which amended and restated the Company’s Credit Agreement among the Company, certain of its subsidiaries, the banks, financial institutions and other institutional lenders party thereto, and Morgan Stanley Senior Funding, Inc. as administrative agent. Pursuant to the amendment, the 2024 Term Loan Facility and 2026 Term Loan Facility are subject to a financial covenant requiring maintenance of a maximum consolidated leverage ratio of 4.50x until and including the end of the fiscal quarter ending on June 30, 2023, stepping down to 4.25x until and including the end of the fiscal quarter ending on March 31, 2024, stepping down further to 4.00x until and including the end of the fiscal quarter ending on June 30, 2024, stepping down further to 3.75x until and including the end of the fiscal quarter ending on September 30, 2024, stepping down further to 3.50x thereafter, with a step-up in connection with certain qualifying acquisitions. The Company was in compliance with all covenants as of December 31, 2022. N&B Senior Notes On September 16, 2020, N&B issued $6.250 billion in aggregate principal amount of senior unsecured notes consisting of: (i) $300 million senior unsecured notes which matured on September 15, 2022 (the “2022 Notes”), bearing interest at a rate of 0.697% per year, payable semi-annually on March 15 and September 15 of each year, beginning March 15, 2021; (ii) $1.000 billion senior unsecured notes maturing on October 1, 2025 (the “2025 Notes”), bearing interest at a rate of 1.230% per year, payable semi-annually on April 1 and October 1 of each year, beginning April 1, 2021; (iii) $1.200 billion senior unsecured notes maturing on October 15, 2027 (the “2027 Notes”), bearing interest at a rate of 1.832% per year, payable semi-annually on April 15 and October 15 of each year, beginning April 15, 2021; (iv) $1.500 billion senior unsecured notes maturing on November 1, 2030 (the “2030 Notes”), bearing interest at a rate of 2.300% per year, payable semi-annually on May 1 and November 1 of each year, beginning May 1, 2021; (v) $750 million senior unsecured notes maturing on November 15, 2040 (the “2040 Notes”), bearing interest at a rate of 3.268% per year, payable semi-annually on May 15 and November 15 of each year, beginning May 15, 2021, and; (vi) $1.500 billion senior unsecured notes maturing on December 1, 2050 (the “2050 Notes”), bearing interest at a rate of 3.468% per year, payable semi-annually on June 1 and December 1 of each year, beginning June 1, 2021. Interest on each series of notes began accruing from September 16, 2020 payable semi-annually in arrears as described above. Interest is computed on the basis of a 360-day year comprised of twelve 30-day months. On September 15, 2022, the Company repaid the full $300 million outstanding of its 2022 Notes at maturity. Amended Revolving Credit Facility On August 4, 2022, the Company and certain of its subsidiaries entered into the Amendment No. 1 To Credit Agreement which amended and restated the Company’s Revolving Credit Facility (previously and more recently amended and restated as of July 28, 2021) among the Company, certain of its subsidiaries, the banks, financial institutions and other institutional lenders party thereto, and Citibank, N.A. as administrative agent. The interest rate on the Amended Revolving Credit Facility is, at the applicable borrower's option, a per annum rate equal to either (x) an eurocurrency rate plus an applicable margin varying from 1.000% to 1.625% or (y) a base rate plus an applicable margin varying from 0.000% to 0.625%, in each case depending on the public debt ratings for non-credit enhanced long-term senior unsecured debt issued by the Company. The Amended Revolving Credit Facility is available for general corporate purposes of each borrower and its subsidiaries. The obligations under the Amended Revolving Credit Facility are unsecured and the Company has guaranteed the obligations of each other borrower under the Amended Revolving Credit Facility. The Company pays a commitment fee on the aggregate unused commitments; such fee is not material. The Amended Revolving Credit Agreement contains various covenants, limitations and events of default customary for similar facilities for similarly rated borrowers, including a maximum permitted ratio of Net Debt to Consolidated EBITDA of 4.50x as of December 31, 2022, with step-downs to 3.50x over time, with a step-up if the Company consummates certain qualifying acquisitions. In connection with the initial issuance of the Revolving Credit Facility, the Company incurred $1 million of debt issuance costs. As of December 31, 2022, the Company was in compliance with all covenants under the Amended Revolving Credit Facility. As of December 31, 2022, total capacity under the Amended Revolving Credit Facility was $2.000 billion, with $100 million outstanding borrowings. Under the amended terms of the Revolver Credit Agreement, the Amended Revolving Credit Facility increased from $1.000 billion to $2.000 billion, maturing on July 28, 2026. At the option of the Company, the facility may be increased to $2.500 billion subject to certain conditions. As the Amended Revolving Credit Facility is a multi-year revolving credit agreement, the Company classifies as long-term debt the portion that it has the intent and ability to maintain outstanding longer than 12 months. During 2022, the Company had draw downs of $550 million and repayments of $450 million under the Amended Revolving Credit Facility. There were no draw downs or repayments under the Amended Revolving Credit Facility in 2021. 2018 Senior Unsecured Notes On September 25, 2018 the Company issued €300 million aggregate principal amount of senior unsecured notes that matured on September 25, 2021 (the “2021 Euro Notes”). The 2021 Notes bore interest at a rate of 0.5% per year, payable annually on September 25 of each year, beginning September 25, 2019. Total proceeds from the issuance of the 2021 Notes, net of underwriting discounts and offering costs, were €298 million ($350 million in USD). During the third quarter of 2021, the Company repaid the 2021 Euro Notes in a payment of €300 million. The repayment on the 2021 Euro Notes was funded primarily from the Company’s existing cash balances, with the remainder coming from the issuance of commercial paper. On September 25, 2018, the Company issued €800 million aggregate principal amount of senior unsecured notes that mature on September 25, 2026 (the “2026 Euro Notes”). The 2026 Notes bear interest at a rate of 1.8% per year, payable annually on September 25 of each year, beginning September 25, 2019. Total proceeds from the issuance of the 2026 Notes, net of underwriting discounts and offering costs, were €794 million ($932 million in USD). On September 26, 2018, the Company issued $400 million aggregate principal amount of senior unsecured notes that mature on September 26, 2028 (the “2028 Notes”). The 2028 Notes bear interest at a rate of 4.45% per year, payable semi-annually on March 26 and September 26 of each year, beginning March 26, 2019. Total proceeds from the issuance of the 2028 Notes, net of underwriting discounts and offering costs, were $397 million. On September 26, 2018, the Company issued $800 million aggregate principal amount of senior unsecured notes that mature on September 26, 2048 (the “2048 Notes” and collectively with the 2021 Euro Notes, 2026 Euro Notes, 2020 Notes, 2028 Notes, the “2018 Senior Unsecured Notes”). The 2048 Notes bear interest at a rate of 5.0% per year, payable semi-annually on March 26 and September 26 of each year, beginning March 26, 2019. Total proceeds from the issuance of the 2048 Notes, net of underwriting discounts and offering costs, were $787 million. As discussed in Note 16, the 2021 Euro Notes and 2026 Euro Notes have been designated as a hedge of the Company’s net investment in certain subsidiaries. 2023 Notes On April 4, 2013, the Company issued $300 million face amount of 3.20% Senior Notes (“2023 Notes”) due 2023 at a discount of less than $1 million. The Company received proceeds related to the issuance of these 2023 Notes of $298 million which was net of the less than $1 million discount and a $2 million underwriting discount (recorded as deferred financing costs). In addition, the Company incurred $1 million of other deferred financing costs in connection with the debt issuance. The discount and deferred financing costs are being amortized as interest expense over the term of the 2023 Notes. The 2023 Notes bear interest at a rate of 3.20% per year, with interest payable on May 1 and November 1 of each year, commencing on November 1, 2013. The 2023 Notes mature on May 1, 2023. 2024 Euro Notes On March 14, 2016, the Company issued €500 million face amount of 1.75% Senior Notes (“2024 Euro Notes”) due 2024 at a discount of €1 million. The Company received proceeds related to the issuance of these 2024 Euro Notes of €496 million which was net of the €1 million discount and €3 million underwriting discount (recorded as deferred financing costs). In addition, the Company incurred $1 million of other deferred financing costs in connection with the debt issuance. In connection with the debt issuance, the Company entered into pre-issuance hedging transactions that were settled upon issuance of the debt and resulted in a loss of approximately $3 million. The discount, deferred financing costs and pre-issuance hedge loss are being amortized as interest expense over the eight As discussed in Note 16, the 2024 Euro Notes have been designated as a hedge of the Company’s net investment in certain subsidiaries. 2047 Notes On May 18, 2017, the Company issued $500 million face amount of 4.375% Senior Notes (“2047 Notes”) due 2047 at a discount of $2 million. The Company received proceeds related to the issuance of these 2047 Notes of $494 million which was net of the $2 million discount and $4 million in underwriting fees (recorded as deferred financing costs). In addition, the Company incurred $1 million in legal and professional costs associated with the issuance and such costs were recorded as deferred financing costs. In connection with the debt issuance, the Company entered into pre-issuance hedging transactions that were settled upon issuance of the debt and resulted in a loss of approximately $5 million. The discount, deferred financing costs and pre-issuance hedge loss are being amortized as interest expense over the 30 year term of the debt. The 2047 Notes bear interest at a rate of 4.375% per annum, with interest payable semi-annually on June 1 and December 1 of each year, commencing on December 1, 2017. The 2047 Notes will mature on June 1, 2047. 2018 Term Loan Facility On June 6, 2018, the Company entered into a Term Loan Credit Agreement (as amended on July 13, 2018, January 17, 2020 and August 25, 2020, the “2018 Term Loan Credit Agreement”) with Morgan Stanley Senior Funding, Inc., as the administrative agent, and the lenders party thereto, pursuant to which the lenders thereunder committed to provide, a senior unsecured term loan facility in an original aggregate principal amount of up to $350 million (the “2018 Term Loan Facility”), which matured on October 1, 2021. In 2019, the Company made payments of $110 million on the 2018 Term Loan Facility, and during the third quarter of 2021, the Company repaid the remainder of the 2018 Term Loan Facility in two payments of $120 million each. The repayments on the 2018 Term Loan Facility were funded primarily from the Company's existing cash balances, with the remainder coming from the issuance of commercial paper. 2022 Term Loan Facility On May 15, 2020, the Company entered into a Term Loan Agreement (as amended on August 25, 2020, the “2022 Term Loan Agreement”) with China Construction Bank Corporation, New York Branch, as administrative agent, and the lenders party thereto, pursuant to which the lenders thereunder have committed to provide a senior unsecured two year term loan facility in an aggregate principal amount of up to $200 million (the “2022 Term Loan Facility”). The loans under the 2022 Term Loan Agreement bore interest, at the Company's option, at a per annum rate equal to either (x) an adjusted LIBOR rate plus an applicable margin varying from 1.225% to 2.475% or (y) a base rate plus an applicable margin varying from 0.225% to 1.475%, in each case depending on the public debt ratings for non-credit enhanced long-term senior unsecured debt issued by the Company. The Company could voluntarily prepay the term loans without premium or penalty, with the balance payable on the second anniversary of the funding date. There is no required amortization under the 2022 Term Loan Agreement. During the fourth quarter of 2021, the Company elected to voluntarily prepay the outstanding balance of the 2022 Term Loan Facility. Commercial Paper During 2022, the Company had gross issuances of $6.040 billion and repayments of $6.177 billion under the commercial paper program. The commercial paper issued had original maturities of less than 126 days. During 2021, the Company had gross issuances of $800 million and repayments of $476 million under the commercial paper program. The Commercial Paper Program is backed by the borrowing capacity available under the Revolving Credit Facility. The effective interest rate of commercial paper issuances does not materially differ from short-term interest rates, which fluctuate due to market conditions and as a result may impact our interest expense. Redemption Provisions The 2023 Notes, 2024 Euro Notes, 2026 Euro Notes, 2028 Notes, 2047 Notes, and 2048 Notes (collectively, the “Notes”) share the same redemption provisions. Upon 30 days’ notice to holders of the Notes, the Company may redeem the Notes for cash in whole, at any time, or in part, from time to time, prior to maturity, at redemption prices that include accrued and unpaid interest and a make-whole premium, as specified in the indenture governing the Notes. However, no make-whole premium will be paid for redemptions of each note on or after the following date: Note Redemption Date 2023 Notes February 1, 2023 2024 Euro Notes December 14, 2023 2026 Euro Notes June 25, 2026 2028 Notes June 26, 2028 2047 Notes December 1, 2046 2048 Notes March 26, 2048 The indenture of the Notes provides for customary events of default and contains certain negative covenants that limit the ability of the Company and its subsidiaries to grant liens on assets, or to enter into sale-leaseback transactions. In addition, subject to certain limitations, in the event of the occurrence of both (1) a change of control of the Company and (2) a downgrade of the Notes below investment grade rating by both Moody’s Investors Services, Inc., Standard & Poor’s Ratings Services and Fitch Ratings Inc. within a specified time period, the Company will be required to make an offer to repurchase the Notes at a price equal to 101% of the principal amount of the Notes, plus accrued and unpaid interest to the date of repurchase. The 2025 Notes, 2027 Notes, 2030 Notes, 2040 Notes and 2050 Notes (collectively, the “N&B Senior Notes”), assumed as a result of the Merger, may be redeemed by the issuer at any time at the greater of 100% or the discounted present value of the remaining scheduled payments of principal and interest from the redemption date to the maturity date at Treasury Rate (as defined in the applicable indenture) plus (i) 15 basis points in the case of the 2025 Notes, (ii) 25 basis points in the case of the 2027 Notes, (iii) 25 basis points in the case of the 2030 Notes, (iv) 30 basis points in the case of the 2040 Notes and (v) 30 basis points in the case of the 2050 Notes. The redemption dates of each of the N&B Senior Notes are provided in the table below: Notes Redemption Date 2025 Notes September 1, 2025 2027 Notes August 15, 2027 2030 Notes August 1, 2030 2040 Notes May 15, 2040 2050 Notes June 1, 2050 On or after the applicable redemption dates, each series of the N&B Senior Notes may be redeemed by the issuer at a redemption price equal to 100% of the principal amount of the N&B Senior Notes to be redeemed, plus accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date. Outstanding Borrowings The following table shows the contractual maturities of the Company's long-term debt as of December 31, 2022. Payments Due by Period (DOLLARS IN MILLIONS) Total Less than 1 Year 1-3 Years 3-5 Years More than Total Outstanding Borrowings $ 10,580 $ 300 $ 2,156 $ 2,674 $ 5,450

Tangible Equity Units

Tangible Equity Units	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Shareholders' Equity	SHAREHOLDERS’ EQUITY Dividends Cash dividends declared per share were $3.20, $3.12 and $3.04 for the years ended December 31, 2022, 2021 and 2020, respectively. The Consolidated Balance Sheets reflect $206 million of dividends payable at December 31, 2022. This amount relates to a cash dividend of $0.81 per share declared in December 2022 and paid in January 2023. Dividends declared, but not paid as of December 31, 2021 and December 31, 2020 were $201 million ($0.79 per share) and $82 million ($0.77 per share), respectively. Share Repurchases In December 2012, the Board of Directors authorized a $250 million share repurchase program, which commenced in the first quarter of 2013. In August 2015, the Board of Directors approved an additional $250 million share repurchase authorization and extension through December 31, 2017. Based on the total remaining amount of $56 million available under the amended repurchase program as of October 31, 2017, the Board of Directors re-approved on November 1, 2017 a $250 million share repurchase authorization and extension for a total value of $300 million available under the program. As of May 7, 2018, the Company has suspended its share repurchases. On November 1, 2022, the share repurchase program expired.

Leases (Notes)

Leases (Notes)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	LEASESThe Company has leases for corporate offices, manufacturing facilities, research and development facilities, and certain transportation and office equipment, the majority of which are operating leases. The Company's leases have remaining lease terms of up to 50 years, some of which include options to extend the leases for up to 7 years. The components of lease expense were as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Operating lease cost $ 187 $ 168 $ 62 Finance lease cost 8 7 4 Supplemental cash flow information related to leases was as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow for operating leases $ 135 $ 129 $ 52 Financing cash flow for finance leases 7 6 4 Right-of-use assets obtained in exchange for lease obligations Operating leases 60 88 63 Finance leases 7 15 6 Supplemental balance sheet information related to leases was as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 Operating Leases Operating lease right-of-use assets $ 636 $ 767 Current operating lease obligations (2) 86 109 Operating lease liabilities 565 670 Total operating lease liabilities $ 651 $ 779 Finance Leases Finance lease right-of-use assets (1) $ 22 $ 21 Current finance lease obligations (2) 5 5 Finance lease liabilities (3) 12 15 Total finance lease liabilities $ 17 $ 20 _______________________ (1) Presented in Other assets in the Consolidated Balance Sheets. (2) Presented in Other current liabilities in the Consolidated Balance Sheets. (3) Presented in Other liabilities in the Consolidated Balance Sheets. Weighted average remaining lease term and discount rate were as follows: December 31, 2022 2021 Weighted average remaining lease term in years Operating leases 10.1 11.1 Finance leases 4.0 4.3 Weighted average discount rate Operating leases 4.03 % 2.73 % Finance leases 2.59 % 1.85 % Maturities of lease liabilities as of December 31, 2022 were as follows: (DOLLARS IN MILLIONS) Operating Leases Finance Leases Total 2023 $ 111 $ 6 $ 117 2024 103 3 106 2025 89 4 93 2026 78 3 81 2027 66 2 68 Thereafter 363 — 363 Total undiscounted liabilities 810 18 828 Less: Imputed interest (159) (1) (160) Total lease liabilities $ 651 $ 17 $ 668 Right-of-use assets and lease liabilities acquired from N&B were remeasured at the present value of the future minimum lease payments over the remaining lease term utilizing an updated incremental borrowing rate of the Company as if the acquired leases were new leases as of the Closing Date. Right-of-use assets were further adjusted for any off-market terms of the lease. The remaining lease term is based on the remaining term at the Closing Date plus any renewal or extension options that the Company is reasonably certain will be exercised. Additionally, the Company has elected short-term lease treatment for those acquired lease contracts which, at the Closing Date, have a remaining lease term of 12 months or less. For the leases acquired through the Transactions, the Company will retain the previous lease classification. This resulted in an increase in both right-of-use assets and operating lease liabilities of approximately $525 million and $523 million, respectively, as of the Closing Date. As a result of the Company’s acquisition of Health Wright, there was an increase of approximately $22 million in finance lease right-of-use assets and $21 million in finance lease liabilities as of the Acquisition Date. In the fourth quarter of 2022, the Company exercised its option to purchase the asset and, as such, de-recognized the finance lease right-of-use assets and finance lease liabilities.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Earnings before income taxes consisted of the following: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 U.S. loss before taxes $ (1,918) $ (493) $ (142) Foreign income before taxes 293 847 583 Total (loss) income before taxes $ (1,625) $ 354 $ 441 The income tax provision consisted of the following: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Current tax provision Federal $ 102 $ (5) $ (9) State and local 49 13 1 Foreign 325 303 150 Total current tax provision 476 311 142 Deferred tax provision Federal (77) (121) (8) State and local (111) (34) (2) Foreign (49) (81) (58) Total deferred tax benefit (237) (236) (68) Total provision for income taxes $ 239 $ 75 $ 74 Effective Tax Rate Reconciliation Reconciliation between the U.S. federal statutory income tax rate to the actual effective tax rate was as follows: December 31, 2022 2021 2020 Statutory tax rate 21.0 % 21.0 % 21.0 % Tax effect of non-deductible goodwill impairment (29.1) — — Difference in effective tax rate on foreign earnings and remittances (1) — 8.0 (6.9) Tax benefit from supply chain optimization 0.8 (5.8) (5.0) Unrecognized tax benefit, net of reversals 0.9 0.7 5.7 Tax impact on gains on business disposal (5.9) 4.0 — Deferred taxes on deemed repatriation (2) (5.6) 2.7 (0.2) Global intangible low-taxed income (0.8) 4.1 5.3 Foreign-derived intangible income 1.1 (1.6) (0.3) U.S. foreign tax credit - general limitation 0.1 (3.1) (1.9) Research and development credit 0.8 (1.4) (1.0) Acquisition costs — 2.4 1.0 Establishment (release) of valuation allowance on state deferred — (3.0) (0.4) State and local taxes including rate changes (3) 4.3 (4.8) (0.6) Other, net (2.3) (2.0) 0.1 Effective tax rate (14.7) % 21.2 % 16.8 % _______________________ (1) For 2021, the rate includes rate change impacts related to the Netherlands and United Kingdom. (2) For 2022, the rate includes establishment of the “held for sale” deferred tax liabilities due to a change in assertion. (3) For 2022, the rate includes rate change impacts related to the remeasurement of the state tax rate on deferred taxes. The effective tax rate reflects the recording of non-tax-deductible impairment charges related to goodwill in the Health & Biosciences operating segment and the tax effects of the divestiture of the Microbial Control business unit. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) that significantly revised the U.S. tax code effective January 1, 2018. The Tax Act created significant international tax provisions, including global intangible low-taxed income (“GILTI”). The Company has elected to treat GILTI as a current period cost if and when incurred. This tax position resulted in approximately a net $112 million income tax expense for the year ended December 31, 2022, offset in part by approximately $99 million in foreign tax credits. The U.S. consolidated group has historically generated taxable income after the inclusion of foreign dividends which has allowed the Company to realize its federal deferred tax assets. Foreign dividends are now subject to a 100% dividends received deduction under the Tax Act and do not serve as a source of federal taxable income. However, as of December 31, 2022, the U.S. consolidated group is in a cumulative income position. It is expected to continue to be in a cumulative income position primarily due to the inclusion of GILTI and expects to realize tax benefits from the reversal of its temporary differences, including capitalized research and experimental expenditures. Further, as of December 31, 2022, the Company has maintained a valuation allowance of approximately $1 million on certain state tax attributes based on a state taxable income forecast. The main inputs into the forecast are the 2022 taxable income projections. Changes in the performance of the North American business, the Company’s transfer pricing policies and adjustments to the Company’s U.S. tax profile could impact the estimate. Deferred Taxes The deferred tax assets and liabilities consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Employee and retiree benefits $ 61 $ 148 Credit and net operating loss carryforwards 315 312 Amortizable research and development expenses 84 42 Interest limitation 3 43 Inventory 19 32 Lease obligations 151 189 Other, net 140 79 Gross deferred tax assets 773 845 Property, plant and equipment, net (229) (265) Intangible assets (1) (2,049) (2,486) Right-of-use assets (151) (187) Loss on foreign currency translation (23) (30) Deferred taxes on deemed repatriation (166) (81) Gross deferred tax liabilities (2,618) (3,049) Valuation allowance (262) (232) Total net deferred tax liabilities $ (2,107) $ (2,436) _______________________ (1) Includes deferred taxes on intangible assets owned by a fully consolidated partnership. Net operating loss carryforwards were approximately $301 million and $272 million at December 31, 2022 and 2021, respectively. If unused, approximately $98 million will expire between 2023 and 2042. The remainder, totaling approximately $203 million, may be carried forward indefinitely. Tax credit carryforwards were approximately $14 million and $40 million at December 31, 2022 and 2021, respectively. If unused, the $14 million will expire between 2023 and 2042. Of the $315 million deferred tax asset for net operating loss carryforwards and credits at December 31, 2022, the Company considers it unlikely that a portion of the tax benefit will be realized. Accordingly, a valuation allowance of approximately $261 million on net operating loss carryforwards and $1 million of tax credits has been established against these deferred tax assets. Uncertain Tax Positions A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Balance of unrecognized tax benefits at beginning of year $ 130 $ 99 $ 75 Gross amount of increases in unrecognized tax benefits as a result of positions taken during a prior year (1) 1 42 11 Gross amount of decreases in unrecognized tax benefits as a result of positions taken during a prior year (18) (3) — Gross amount of increases in unrecognized tax benefits as a result of positions taken during the current year 31 5 24 The amounts of decreases in unrecognized benefits relating to settlements with taxing authorities (27) (1) (2) Reduction in unrecognized tax benefits due to the lapse of applicable statute of limitation (5) (12) (9) Balance of unrecognized tax benefits at end of year $ 112 $ 130 $ 99 _______________________ (1) For 2021, the amount includes positions related to N&B opening balance sheet amounts. At December 31, 2022, 2021 and 2020, there were approximately $98 million, $130 million and $98 million, respectively, of unrecognized tax benefits recorded to Other liabilities. There was approximately $14 million recorded to Other current liabilities for 2022, less than $1 million recorded to Other current liabilities for 2021 and approximately $1 million recorded to Other current liabilities for 2020. If these unrecognized tax benefits were recognized, all the benefits and related interest and penalties would be recorded as a benefit to income tax expense. The Company decreased its liabilities for interest and penalties by approximately $1 million, net, for the year ended December 31, 2022, and increased its liabilities for interest and penalties by approximately $19 million and $3 million, net, for the years ended December 31, 2021 and 2020, respectively. At December 31, 2022, 2021 and 2020, the Company had accrued approximately $31 million, $36 million and $17 million, respectively, of interest and penalties classified as Other liabilities, $4 million classified as Other current liabilities for December 31, 2022 and less than $1 million classified as Other current liabilities for December 31, 2021 and 2020. As of December 31, 2022, the Company’s aggregate provision for unrecognized tax benefits, including interest and penalties, was approximately $147 million associated with various tax positions principally asserted in foreign jurisdictions. The Company’s reversal of uncertain tax positions due to the expiration of related statutes of limitations over the next 12 months was estimated to be approximately $18 million, which has been classified as current. The total changes to the uncertain tax positions over the next 12 months is impracticable to estimate and is dependent on the resolution of new or existing tax disputes. Other Tax benefits credited to Shareholders’ equity were not material for the years ended December 31, 2022, 2021 and 2020 associated with stock option exercises and PRSU dividends. The Company regularly repatriates earnings from non-U.S. subsidiaries. As the Company repatriates these funds to the U.S., they will be required to pay income taxes in certain U.S. states and applicable foreign withholding taxes during the period when such repatriation occurs. Accordingly, as of December 31, 2022, the Company had a deferred tax liability of approximately $166 million for the effect of repatriating the funds to the U.S., attributable to various non-U.S. subsidiaries. There is no deferred tax liability associated with non-U.S. subsidiaries where we intend to indefinitely reinvest the earnings to fund local operations and/or capital projects. The Company has ongoing income tax audits and legal proceedings which are at various stages of administrative or judicial review, of which the material items are discussed below. In addition, the Company has other ongoing tax audits and legal proceedings that relate to indirect taxes, such as value-added taxes, capital tax, sales and use and property taxes, which are discussed in Note 19. The Company also has several other tax audits in process and has open tax years with various taxing jurisdictions that range primarily from 2012 to 2021. Based on currently available information, the Company does not believe the ultimate outcome of any of these tax audits and other tax positions related to open tax years, when finalized, will have a material impact on its results of operations and financial position.

Net Income Per Share

Net Income Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Income Per Share	NET (LOSS) INCOME PER SHARE Basic and diluted net (loss) income per share is based on the weighted average number of shares outstanding. A reconciliation of shares used in the computation of basic and diluted net (loss) income per share is as follows: December 31, (AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS) 2022 2021 2020 Net (Loss) Income Net (loss) income attributable to IFF shareholders $ (1,871) $ 270 $ 363 Adjustment related to (increase) decrease in redemption value of redeemable non-controlling interests in excess of earnings allocated 3 (2) 2 Net (loss) income attributable to IFF shareholders $ (1,868) $ 268 $ 365 Shares Weighted average common shares outstanding (basic) (1) 255 243 112 Adjustment for assumed dilution (2) : Stock options and restricted stock awards — — 1 SPC portion of the TEUs — — 1 Weighted average shares assuming dilution (diluted) 255 243 114 Net (Loss) Income per Share Net (loss) income per share - basic (3) $ (7.32) $ 1.11 $ 3.25 Net (loss) income per share - diluted (4) (7.32) 1.10 3.21 _______________________ (1) On September 15, 2021, additional shares of IFF's common stock were issued in settlement of the SPC portion of the TEUs. For the year ended December 31, 2020, the TEUs were assumed to be outstanding at the minimum settlement amount for basic earnings per share (“EPS”). See below for additional information. (2) Effect of dilutive securities includes dilution under stock plans and incremental impact of TEUs. See below for additional information. (3) For the years ended December 31, 2022, 2021 and 2020, the basic net (loss) income per share cannot be recalculated based on the information presented in the table above due to the effects of rounding. (4) For the years ended December 31, 2022 and 2020, the diluted net (loss) income per share cannot be recalculated based on the information presented in the table above due to the effects of rounding. As of the effective time of the Merger, each issued and outstanding share of common stock of N&B (except for shares of common stock of N&B held by N&B as treasury stock or by DuPont, which were canceled and ceased to exist and no consideration was delivered in exchange therefor) was converted into the right to receive one share of common stock of IFF. The Merger was completed in exchange for 141,740,461 shares of IFF common stock, par value $0.125 per share (or cash payment in lieu of fractional shares), which had been approved in the special shareholder meeting that occurred on August 27, 2020 where IFF shareholders voted to approve the issuance of shares of IFF common stock in connection with the N&B Transaction, pursuant to the Merger Agreement. The shares issued in the Merger represented approximately 55.4% of the common stock of IFF on a fully diluted basis, after giving effect to the Merger, as of February 1, 2021. The Company issued 16,500,000 TEUs, consisting of a prepaid SPC and a senior amortizing note, for net proceeds of approximately $800 million on September 17, 2018. On September 14, 2021, the Company notified holders of the TEUs that the final settlement rate in respect of each SPC was 0.330911 shares of IFF’s common stock. On September 15, 2021, 5,460,031 shares of IFF's common stock were issued in settlement of the SPCs. The SPC conversion factor is based on the VWAP per share of the Company’s common stock. For purposes of calculating basic net income per share, the settlement rate of 0.330911 shares per SPC, the final settlement rate, was used on December 31, 2021 and 0.313400 shares per SPC was used on December 31, 2020. For purposes of calculating diluted earnings per share, the settlement rate of 0.330911 shares per SPC, the final settlement rate, was used on December 31, 2021 and 0.383900 shares per SPC was used on December 31, 2020. The Company has issued shares of Purchased Restricted Stock Units (“PRSUs”) which contain non-forfeitable rights to dividends and thus are considered participating securities which are required to be included in the computation of basic and diluted earnings per share pursuant to the two-class method. The two-class method was not presented since there was no difference between basic net (loss) income per share for both common shareholders and PRSU holders as of December 31, 2022, 2021 and 2020, and there was no difference between diluted net loss per share for both common shareholders and PRSU holders as of December 31, 2022. The difference between diluted net income per share for both common shareholders and PRSU holders was less than $0.01 and $0.04 per share as of December 31, 2021 and 2020. In addition, for each year, the number of PRSUs outstanding as of December 31, 2022, 2021 and 2020 was immaterial. Net loss allocated to such PRSUs during 2022 was not material and net income allocated to such PRSUs during 2021 and 2020 was not material. There were approximately 0.3 million potentially dilutive securities excluded from the computation of diluted net loss per share for the year ended December 31, 2022 because there was a net loss attributable to IFF for the period and, as such, the inclusion of these securities would have been anti-dilutive. For the year ended December 31, 2022, there were approximately 0.3 million share equivalents that had an anti-dilutive effect and therefore were excluded from the computation of diluted net loss per share. There were no share equivalents excluded from the computation of diluted net income per share for the years ended December 31, 2021 and 2020.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Shareholders' Equity	SHAREHOLDERS’ EQUITY Dividends Cash dividends declared per share were $3.20, $3.12 and $3.04 for the years ended December 31, 2022, 2021 and 2020, respectively. The Consolidated Balance Sheets reflect $206 million of dividends payable at December 31, 2022. This amount relates to a cash dividend of $0.81 per share declared in December 2022 and paid in January 2023. Dividends declared, but not paid as of December 31, 2021 and December 31, 2020 were $201 million ($0.79 per share) and $82 million ($0.77 per share), respectively. Share Repurchases In December 2012, the Board of Directors authorized a $250 million share repurchase program, which commenced in the first quarter of 2013. In August 2015, the Board of Directors approved an additional $250 million share repurchase authorization and extension through December 31, 2017. Based on the total remaining amount of $56 million available under the amended repurchase program as of October 31, 2017, the Board of Directors re-approved on November 1, 2017 a $250 million share repurchase authorization and extension for a total value of $300 million available under the program. As of May 7, 2018, the Company has suspended its share repurchases. On November 1, 2022, the share repurchase program expired.

Stock Compensation Plans

Stock Compensation Plans	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock Compensation Plans	STOCK COMPENSATION PLANS The Company has various equity plans under which its officers, senior management, other key employees and Board of Directors may be granted options to purchase IFF common stock or other forms of stock-based awards. The cost of all employee stock-based awards are principally recognized on a straight-line attribution basis over their respective vesting periods, net of estimated forfeitures. Total stock-based compensation expense included in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income was as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Equity-based awards $ 49 $ 54 $ 36 Liability-based awards 2 8 4 Total stock-based compensation 51 62 40 Less tax benefit (8) (13) (8) Total stock-based compensation, net of tax $ 43 $ 49 $ 32 The shareholders of the Company approved the Company’s 2021 Stock Award and Incentive Plan (the “2021 Plan”) on May 5, 2021. The 2021 Plan replaced the Company’s 2015 Stock Award and Incentive Plan (the “2015 Plan”) and the Company's 2010 Stock Award and Incentive Plan (the “2010 Plan”), and provides the source for future deferrals of cash into deferred stock under the Company’s Deferred Compensation Plan (with the Deferred Compensation Plan being deemed a subplan under the 2010 Plan for the sole purpose of funding deferrals under the IFF Share Fund). Under the 2021 Plan, a total of 2,290,000 shares were authorized for issuance. At December 31, 2022, 1,403,092 shares were subject to outstanding awards and 1,777,205 shares remained available for future awards under all of the Company’s equity award plans, including the 2015 Plan and 2010 Plan (excluding shares not yet issued under open cycles of the Company’s Long-Term Incentive Plan). The Company offers a Long-Term Incentive Plan (“LTIP”) for senior management. The targeted payout is principally 50% cash and 50% IFF common stock at the end of the three-year cycle. For the 2020-2022 cycle, the LTIP awards are earned based on the achievement of: (i) an annual Leverage Ratio for 2020 (representing one-sixth of the award value), (ii) a 2-year cumulative Leverage Ratio for 2021-2022 (representing one-third of the award value) and (iii) Relative TSR targets (representing one-half of the award value). For the 2021-2023 cycle, the LTIP awards are earned based on the achievement of: (i) an annual Leverage Ratio for 2021, 2022 and 2023 (representing one-half of the award value) and (ii) Relative TSR targets (representing one-half of the award value). For the 2022-2024 cycle, the LTIP awards are earned based on the achievement of: (i) 3-year cumulative Return on Invested Capital (“ROIC”) (representing one-half of the award value) and (ii) Relative TSR targets (representing one-half of the award value). The Leverage Ratio measures Net debt as compared to a measure profitability. The ROIC measures adjusted net operating profit after tax against average invested capital. When the award is granted, 50% of the target dollar value of the award is converted to a number of “notional” shares based on the closing price at the beginning of the cycle. For those shares whose payout is based on Relative TSR, compensation expense is recognized using a graded-vesting attribution method, while compensation expense for the remainder of the performance shares (Leverage Ratio or ROIC targets for the applicable cycle) is recognized on a straight-line basis over the vesting period based on the probable outcome of the performance condition. The 2018-2020 cycle concluded at the end of 2020 and an aggregate 7,484 shares of common stock were issued in March 2021. The 2019-2021 cycle concluded at the end of 2021 and no shares of common stock were issued in March 2022. The 2020-2022 cycle concluded at the end of 2022 and no shares of common stock will be issued in March 2023. In 2006, the Board of Directors approved the Equity Choice Program (the “Program”) for senior management. This program continues under the 2015 Plan. Eligible employees can choose from among three equity alternatives and will be granted such equity awards up to certain dollar awards depending on the participant’s employment grade level. A participant may choose among (1) Stock-Settled Appreciation Rights (“SSARs”), (2) Restricted Stock Units (“RSUs”) or (3) PRSUs. Transaction with Nutrition and Biosciences, Inc. In connection with the Merger, N&B employees’ outstanding (unvested and/or vested and unexercised) equity awards were converted into equity awards denominated in shares of the Company’s common stock based on a defined exchange ratio. N&B employees’ equity awards were converted into 335,347 IFF stock options, 258,572 IFF RSU awards and 5,816 IFF SAR awards. For converted RSU awards, the fair value of the equity award is based on the Closing Date market price of IFF stock. For converted stock options and SAR awards, the exercise price per share of the converted award is equal to the exercise price per share of the N&B award immediately prior to the Merger divided by the exchange ratio. The fair value of the IFF stock options and SAR awards that the Company issued in connection with the Merger was estimated using the Black Scholes model. The converted awards were generally issued with the same terms and conditions as were applicable prior to the Transaction. At the Closing Date, approximately $25 million of the fair value of the replacement awards granted to N&B employees was attributable to pre-combination service and was included in the purchase price. As of December 31, 2022, post-combination expense of approximately $11 million is expected to be recognized related to the replacement awards over the remaining post-combination service period, approximately up to three years. SSARs and Options SSARs are a contractual right to receive the value, in shares of Company stock, of the appreciation in our stock price from the grant date to the date the SSARs are exercised by the participant. SSARs granted become exercisable on the third anniversary of the grant date and have a maximum term of seven years. SSARs do not require a financial investment by the SSARs grantee. Stock options require the participant to pay the exercise price at the time they exercise their stock options. No stock options were granted in 2022, 2021 or 2020. SSARs and options activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Shares Subject to Weighted SSARs/ December 31, 2021 287 $ 107.48 235 Granted 134 126.91 Exercised (84) 106.66 Canceled (6) 117.04 December 31, 2022 331 $ 115.35 182 Expected to Vest at December 31, 2022 142 $ 122.27 The weighted average exercise price of SSARs and options exercisable at December 31, 2022, 2021 and 2020 were $109.50, $109.77 and $118.10, respectively. SSARs and options outstanding at December 31, 2022 was as follows: Price Range Number Weighted Average Weighted Aggregate Over $65 331 5.65 $ 115.35 $ 2 SSARs and options exercisable as of December 31, 2022 was as follows: Price Range Number Weighted Average Weighted Aggregate Over $65 182 5.05 $ 109.50 $ 2 The total intrinsic value of options/SSARs exercised during 2022 was approximately $2 million, $3 million for 2021 and was not material for 2020. As of December 31, 2022, the total unrecognized compensation cost related to non-vested SSARs granted was approximately $4 million; such cost is expected to be recognized over a weighted average period of approximately 1.91 years. Restricted Stock Units The Company has granted RSUs to eligible employees and members of the Board of Directors. The Company has granted both time-based RSUs, which contain no performance criteria provisions, and performance-based RSUs. Such RSUs are subject to forfeitures or adjustments if certain conditions are not met, including service period or pre-established cumulative performance targets. RSUs principally vest 100% at the end of three years. An RSU’s fair value is calculated based on the market price of the Company's stock at date of grant, with an adjustment to reflect the fact that such awards do not participate in dividend rights. The aggregate fair value is amortized to expense ratably over the vesting period. RSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Number of Shares Weighted Average December 31, 2021 777 $ 126.20 Granted 556 115.13 Vested (322) 124.62 Forfeited (58) 129.36 Change due to performance conditions, net (16) 120.48 December 31, 2022 937 $ 120.81 The total fair value of RSUs that vested during the year ended December 31, 2022 was approximately $40 million. As of December 31, 2022, there was approximately $58 million of total unrecognized compensation cost related to non-vested RSUs granted under the equity incentive plans; such cost is expected to be recognized over a weighted average period of approximately 1.98 years. Purchased Restricted Stock Units The grant of awards under the Program provided for eligible employees to purchase shares of IFF common stock and deposit them into an escrow account. For each share deposited in escrow by the eligible employee, the Company matched with the grant of a restricted stock unit. The shares of restricted stock units generally vest on the third anniversary of the grant date, are subject to continued employment and other specified conditions, and pay dividends if and when paid by the Company. Holders of restricted stock units have, in most instances, all of the rights of shareholders, except that they may not sell, assign, pledge or otherwise encumber such shares. PRSUs pay dividend equivalents and do not have voting rights. The following table summarizes the Company's PRSU activity for the years ended December 31, 2022, 2021 and 2020: (DOLLARS IN MILLIONS) Issued Shares Aggregate Purchase Price Covered Shares 2022 43,690 $ 6 21,845 2021 61,870 $ 9 30,935 2020 66,160 $ 9 33,080 PRSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Number of Weighted Average December 31, 2021 155 $ 138.36 Granted 44 126.49 Vested (95) 138.06 Forfeited (14) 135.50 December 31, 2022 90 $ 133.36 The total fair value of PRSUs that vested during the year ended December 31, 2022 was approximately $13 million. As of December 31, 2022, there was approximately $4 million of total unrecognized compensation cost related to non-vested PRSUs granted under the equity incentive plans; such cost is expected to be recognized over a weighted average period of approximately 1.87 years. Liability Awards The Company has granted cash-settled RSUs (“Cash RSUs”) to eligible employees that are paid out 100% in cash upon vesting. Such RSUs are subject to forfeiture if certain conditions are not met. Cash RSUs principally vest 100% at the end of three years and contain no performance criteria provisions. A Cash RSU's fair value is calculated based on the market price of the Company's stock at the date of the closing period and is accounted for as a liability award. The aggregate fair value is amortized to expense ratably over the vesting period. Cash RSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Cash RSUs Weighted Average December 31, 2021 116 $ 150.65 Granted 43 104.84 Vested (38) 130.67 Forfeited (2) 107.00 December 31, 2022 119 $ 104.84 The total fair value of Cash RSUs that vested during the year ended December 31, 2022 was approximately $5 million. As of December 31, 2022, there was approximately $5 million of total unrecognized compensation cost related to non-vested Cash RSUs granted under the equity incentive plans; such cost is expected to be recognized over a weighted average period of approximately 1.81 years. The aggregate compensation cost will be adjusted based on changes in the Company’s stock price.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATIONThe Company is organized into four reportable operating segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. These segments align with the internal structure to manage these businesses. The Company’s Chief Operating Decision Maker regularly reviews financial information to allocate resources and assess performance utilizing these segments. Nourish is comprised of three business units, Ingredients, Flavors and Food Designs, with a diversified portfolio across natural and plant-based specialty food ingredients, flavor compounds, and savory solutions and inclusions, respectively. Ingredients provide texturizing solutions to the food industry, food protection solutions used in food and beverage products, specialty soy and pea protein with value-added formulations, emulsifiers and sweeteners. Flavors provide a range of flavor compounds and natural taste solutions that are ultimately used by IFF’s customers in savory products, beverages, sweets, and dairy products. Flavors also provide value-added spices and seasoning ingredients for meat, food service, convenience, alternative protein and culinary products. Food Designs provide savory solution products such as spices, sauces, marinades and mixtures. Additionally, Food Designs provide inclusion products that help with taste and texture by, among other things, combining flavorings with fruit, vegetables, and other natural ingredients for a wide range of food products, such as health snacks, baked goods, cereals, pastries, ice cream and other dairy products. Health & Biosciences is comprised of five business units, Health, Cultures & Food Enzymes, Home & Personal Care, Animal Nutrition and Grain Processing, with a biotechnology-driven portfolio of products that serve the health and wellness, food, consumer and industrial markets. Products within this portfolio range from enzymes, food cultures, probiotics and specialty ingredients for non-food applications. Health provides ingredients for dietary supplements, food and beverage, specialized nutrition and pharma. Cultures & Food Enzymes provide products that aim to serve the global demand for healthy, natural, clean label and fermented food for fresh dairy, cheese, bakery and brewing products. This is accomplished by providing IFF’s customers with products that allow for extended shelf life and stability, which help to improve customers’ products and performance. The business unit’s enzyme solution also allows IFF’s customers to provide low sugar, high fiber and lactose-free dairy products. Home & Personal Care produces enzymes for detergents, cleaning and textile processing products in the laundry, dishwashing, textiles and industrials and personal care markets that help to enhance product and process performances. Animal Nutrition produces enzymes that help to improve the product and process performance of animal feed products, which aim to lessen environmental impact by reducing farm waste. Grain Processing produces enzymes for biofuel production and carbohydrate processing. Scent is comprised of (1) Fragrance Compounds, which are ultimately used by IFF’s customers in two broad categories: Fine Fragrances, including perfumes and colognes, and Consumer Fragrances, including fragrance compounds for personal care (e.g., soaps), household products (e.g., detergents and cleaning agents) and beauty care, including toiletries; (2) Fragrance Ingredients, consisting of synthetic and natural ingredients that can be combined with other materials to create unique fine fragrance and consumer fragrance compounds; and (3) Cosmetic Active Ingredients, consisting of active and functional ingredients, botanicals and delivery systems to support our customers’ cosmetic and personal care product lines. Major fragrance customers include the cosmetics industry, including perfume and toiletries manufacturers, and the household products industry, including manufacturers of soaps, detergents, fabric care, household cleaners and air fresheners. Pharma Solutions is comprised of a vast portfolio including cellulosics and seaweed-based pharmaceutical excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling the development of more effective pharmaceutical finished dosage formats. Pharma Solutions excipients are used in prescription and over-the-counter pharmaceuticals and dietary supplements. Pharma Solutions products also serve a variety of other specialty and industrial end-uses including coatings, inks, electronics, agriculture, and consumer products. Beginning the first quarter of 2021, the Company’s Chief Operating Decision Maker evaluates the performance of these reportable operating segments based on Segment Adjusted Operating EBITDA, which is defined as (Loss) Income Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges and certain non-recurring items. Prior period amounts have been recast to reflect any necessary changes in segment profitability measures. Reportable segment information is as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Net sales Nourish $ 6,829 $ 6,264 $ 2,886 Health & Biosciences 2,339 2,329 134 Scent 2,301 2,254 2,064 Pharma Solutions 971 809 — Consolidated $ 12,440 $ 11,656 $ 5,084 December 31, (DOLLARS IN MILLIONS) 2022 2021 Segment assets Nourish $ 17,008 $ 17,449 Health & Biosciences 10,877 14,774 Scent 4,310 4,078 Pharma Solutions 3,212 3,357 Consolidated $ 35,407 $ 39,658 December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Segment Adjusted Operating EBITDA: Nourish $ 1,176 $ 1,172 $ 599 Health & Biosciences 634 625 40 Scent 423 463 416 Pharma Solutions 222 165 — Total 2,455 2,425 1,055 Depreciation & Amortization (1,179) (1,156) (325) Interest Expense (336) (289) (132) Other Income, net 37 58 7 Acquisition Related Costs (a) 4 — — Restructuring and Other Charges (12) (41) (17) Gains (Losses) on Sale of Fixed Assets 3 1 (4) Impairment of Goodwill (b) (2,250) — — Impairment of Long-Lived Assets (c) (120) — — Shareholder Activism Related Costs (d) (3) (7) — Business Divestiture Costs (e) (110) (42) — Employee Separation Costs (f) (11) (29) (3) Strategic Initiative Costs (g) (3) — — Global Shared Services Implementation Costs (h) (5) — — Frutarom Acquisition Related Costs (i) (1) (2) (1) Compliance Review & Legal Defense Costs (j) — — (3) N&B Inventory Step-Up Costs — (368) — N&B Transaction Related Costs (k) — (91) (29) Integration Related Costs (l) (94) (105) (107) (Loss) Income Before Taxes $ (1,625) $ 354 $ 441 _______________________ (a) Represents costs related to the acquisition of Health Wright Products, primarily consulting and legal fees, offset in part by earn out adjustments. (b) Represents costs related to the impairment of goodwill in the Health & Biosciences reporting unit. (c) Represents costs related to the impairment of intangible and fixed assets of an asset group that operates primarily in Russia. (d) Represents shareholder activist related costs, primarily professional fees. (e) Represents costs, including establishment of deferred tax liabilities, related to the Company's sales and planned sales of businesses, primarily legal and professional fees. (f) Represents costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated or will separate from the Company. (g) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts, primarily consulting fees. (h) Represents costs related to the Company's efforts of restructuring the Global Shared Services Centers, primarily consulting fees. (i) Represents transaction-related costs and expenses related to the acquisition of Frutarom, primarily includes earn-out payments, net of adjustments. (j) Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits. (k) Represents transaction costs and expenses related to the transaction with N&B, primarily legal and professional fees. (l) Represents costs related to integration activities since 2018, primarily for Frutarom and N&B. For 2022, represents costs primarily related to external consulting fees and internal integration costs, including salaries of individuals who are fully dedicated to integration efforts. For 2021 and 2020, represents costs primarily related to performance stock awards and consulting fees for advisory services. The Company has not disclosed revenues at a lower level than provided herein, such as revenues from external customers by product, as it is impracticable for it to do so. The Company had no customers that accounted for greater than 10% of consolidated net sales in 2022, 2021 and 2020. Long-lived assets, net, by country, consisted as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 United States $ 1,771 $ 2,041 China 258 259 Denmark 250 251 Finland 212 196 France 187 188 Germany 181 156 Other 1,344 1,277 Consolidated $ 4,203 $ 4,368 Segment capital expenditures and depreciation and amortization consisted as follows: Capital Expenditures Depreciation and Amortization (DOLLARS IN MILLIONS) 2022 2021 2020 2022 2021 2020 Nourish $ 215 $ 183 $ 98 $ 596 $ 594 $ 211 Health & Biosciences 160 139 7 363 353 36 Scent 56 41 87 81 84 78 Pharma Solutions 73 30 — 139 125 — Consolidated $ 504 $ 393 $ 192 $ 1,179 $ 1,156 $ 325 Net sales are attributed to individual regions based upon the destination of product delivery and are as follows: Net Sales by Geographic Area (DOLLARS IN MILLIONS) 2022 2021 2020 Europe, Africa and Middle East $ 4,219 $ 4,093 $ 1,987 Greater Asia 2,876 2,728 1,162 North America 3,853 3,499 1,228 Latin America 1,492 1,336 707 Consolidated $ 12,440 $ 11,656 $ 5,084 Net Sales by Geographic Area (DOLLARS IN MILLIONS) 2022 2021 2020 Net sales related to the U.S. $ 3,611 $ 3,211 $ 1,093 Net sales attributed to all foreign countries 8,829 8,445 3,991 No non-U.S. country had net sales greater than 6% of total consolidated net sales for 2022 and net sales greater than 7% and 6% of total consolidated net sales for 2021 and 2020, respectively.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Employee Benefits	EMPLOYEE BENEFITS The Company has pension and/or other retirement benefit plans covering approximately one-fifth of active employees. In 2007, the Company amended its U.S. qualified and non-qualified pension plans under which accrual of future benefits was suspended for all participants that did not meet the rule of 70 (age plus years of service equal to at least 70 as of December 31, 2007). Pension benefits are generally based on years of service and compensation during the final years of employment. Plan assets consist primarily of equity securities and corporate and government fixed income securities. Substantially all pension benefit costs are funded as accrued; such funding is limited, where applicable, to amounts deductible for income tax purposes. Certain other retirement benefits are provided by general corporate assets. In connection with the Merger with N&B, as of the Closing Date, the Company assumed responsibility for approximately 20 additional defined benefit plans and recognized liabilities in the aggregate amount of $221 million. The Company sponsors a qualified defined contribution plan covering substantially all U.S. employees. Under this plan, the Company matches 100% of participants’ contributions up to 4% of compensation and 75% of participants’ contributions from over 4% to 8%. Employees that are still eligible to accrue benefits under the pension plans are limited to a 50% match of up to 6% of the participants’ compensation. In addition to pension benefits, certain health care and life insurance benefits are provided to qualifying U.S. employees upon retirement from IFF. Such coverage is provided through insurance plans with premiums based on benefits paid. The Company does not generally provide health care or life insurance coverage for retired employees of foreign subsidiaries; such benefits are provided in most foreign countries by government-sponsored plans, and the cost of these programs is not material. The Company offers a non-qualified Deferred Compensation Plan (“DCP”) for certain key employees and non-employee directors. Eligible employees and non-employee directors may elect to defer receipt of salary, incentive payments and Board of Directors’ fees into participant-directed investments which are generally invested by the Company in individual variable life insurance contracts it owns that are designed to informally fund savings plans of this nature. The cash surrender value of life insurance is based on the net asset values of the underlying funds available to plan participants. At December 31, 2022 and December 31, 2021, the Consolidated Balance Sheets reflect liabilities of approximately $53 million and $64 million, respectively, related to the DCP in Other liabilities and approximately $25 million and $26 million, respectively, included in Capital in excess of par value related to the portion of the DCP that will be paid out in IFF shares. The total cash surrender value of life insurance contracts the Company owns in relation to the DCP and post-retirement life insurance benefits amounted to $45 million and $52 million at December 31, 2022 and 2021, respectively, and are recorded in Other assets in the Consolidated Balance Sheets. The plan assets and benefit obligations of the defined benefit pension plans are measured at December 31 of each year. U.S. Plans Non-U.S. Plans (DOLLARS IN MILLIONS) 2022 2021 2020 2022 2021 2020 Components of net periodic benefit cost Service cost for benefits earned (1) $ 1 $ 1 $ 1 $ 34 $ 41 $ 24 Interest cost on projected benefit obligation (2) 15 71 17 17 10 13 Expected return on plan assets (2) (21) (106) (28) (42) (55) (46) Net amortization of deferrals (2) 8 29 8 11 19 15 Settlements and curtailments (2) — — — — (10) 5 Net periodic benefit cost (income) 3 (5) (2) 20 5 11 Defined contribution and other retirement plans 33 36 13 29 33 7 Total expense $ 36 $ 31 $ 11 $ 49 $ 38 $ 18 Changes in plan assets and benefit obligations recognized in OCI Net actuarial (gain) loss $ — $ 12 $ (143) $ (135) Recognized actuarial loss (8) (9) (12) (10) Prior service cost — — — (2) Recognized prior service (cost) credit — — 1 1 Currency translation adjustment — — (27) (16) Total (gain) loss recognized in OCI (before tax effects) $ (8) $ 3 $ (181) $ (162) _______________________ (1) Included as a component of Operating Profit. (2) Included as a component of Other Income (Expense), net. Postretirement Benefits (DOLLARS IN MILLIONS) 2022 2021 2020 Components of net periodic benefit cost Service cost for benefits earned $ 1 $ 1 $ 1 Interest cost on projected benefit obligation 1 7 2 Net amortization and deferrals (5) (20) (5) Total credit $ (3) $ (12) $ (2) Changes in plan assets and benefit obligations recognized in OCI Net actuarial loss $ (16) $ (3) Recognized actuarial loss (1) (2) Recognized prior service credit 6 6 Total recognized in OCI (before tax effects) $ (11) $ 1 The weighted-average actuarial assumptions used to determine expense at December 31 of each year are: U.S. Plans Non-U.S. Plans 2022 2021 2020 2022 2021 2020 Discount rate 2.86 % 2.51 % 3.26 % 1.43 % 0.85 % 1.49 % Expected return on plan assets 3.80 % 3.80 % 5.60 % 3.52 % 4.21 % 4.62 % Rate of compensation increase 3.25 % 3.25 % 3.25 % 2.72 % 2.56 % 2.46 % Changes in the postretirement benefit obligation and plan assets, as applicable, are detailed in the following table: U.S. Plans Non-U.S. Plans Postretirement Benefits (DOLLARS IN MILLIONS) 2022 2021 2022 2021 2022 2021 Benefit obligation at beginning of year $ 662 $ 682 $ 1,501 $ 1,294 $ 66 $ 69 Service cost for benefits earned 1 1 34 42 1 1 Interest cost on projected benefit obligation 15 12 17 10 2 1 Actuarial (gain) loss (139) (5) (468) (146) (16) (4) Plan amendments — — — (2) — — Adjustments for expense/tax contained in service cost — — (2) (2) — — Plan participants’ contributions — — 4 4 — — Benefits paid (38) (37) (32) (34) (2) (4) Curtailments/settlements — — (21) (39) — — Translation adjustments — — (104) (93) — — Acquisitions/Transferred Liabilities — — — 465 — 3 Other (1) 9 1 2 (1) — Benefit obligation at end of year $ 500 $ 662 $ 930 $ 1,501 $ 50 $ 66 Fair value of plan assets at beginning of year $ 649 $ 678 $ 1,320 $ 1,145 Actual return on plan assets (118) 3 (286) 25 Employer contributions 5 5 31 32 Participants’ contributions — — 4 4 Benefits paid (38) (37) (32) (34) Settlements — — (21) (24) Translation adjustments — — (96) (74) Acquisitions/Transferred Assets — — — 247 Other — — — (1) Fair value of plan assets at end of year $ 498 $ 649 $ 920 $ 1,320 Funded status at end of year $ (2) $ (13) $ (10) $ (181) The amounts recognized in the balance sheet are detailed in the following table: U.S. Plans Non-U.S. Plans (DOLLARS IN MILLIONS) 2022 2021 2022 2021 Other assets $ 51 $ 53 $ 129 $ 83 Other current liabilities (6) (5) (1) (2) Retirement liabilities (47) (61) (138) (262) Net amount recognized $ (2) $ (13) $ (10) $ (181) The amounts recognized in AOCI are detailed in the following table: U.S. Plans Non-U.S. Plans Postretirement Benefits (DOLLARS IN MILLIONS) 2022 2021 2022 2021 2022 2021 Net actuarial (gain) loss $ 129 $ 137 $ 110 $ 291 $ (3) $ 14 Prior service cost (credit) — — (3) (3) (9) (15) Total AOCI (before tax effects) $ 129 $ 137 $ 107 $ 288 $ (12) $ (1) U.S. Plans Non-U.S. Plans (DOLLARS IN MILLIONS) 2022 2021 2022 2021 Accumulated Benefit Obligation — end of year $ 495 $ 654 $ 870 $ 1,410 Information for Pension Plans with an ABO in excess of Plan Assets: Projected benefit obligation $ 49 $ 63 $ 169 $ 944 Accumulated benefit obligation 49 62 150 330 Fair value of plan assets — — 86 840 Weighted-average assumptions used to determine obligations at December 31 Discount rate 5.42 % 2.86 % 4.02 % 1.43 % Rate of compensation increase 3.75 % 3.25 % 3.00 % 2.72 % (DOLLARS IN MILLIONS) U.S. Plans Non-U.S. Plans Postretirement Estimated Future Benefit Payments 2023 $ 39 $ 34 $ 3 2024 39 34 3 2025 39 36 4 2026 40 38 4 2027 39 39 4 2028 - 2032 188 223 18 Contributions Required Company Contributions in the Following Year (2023) $ 5 $ 32 $ — The Company considers a number of factors in determining and selecting assumptions for the overall expected long-term rate of return on plan assets. The Company considers the historical long-term return experience of its assets, the current and expected allocation of its plan assets and expected long-term rates of return. The Company derives these expected long-term rates of return with the assistance of its investment advisors. The Company bases its expected allocation of plan assets on a diversified portfolio consisting of domestic and international equity securities, fixed income, property and alternative asset classes. The asset allocation is monitored on an ongoing basis. The Company considers a variety of factors in determining and selecting its assumptions for the discount rate at December 31. For the U.S. plans, the discount rate was based on the internal rate of return for a portfolio of high quality bonds rated Aa or higher by either Moody’s or Standard & Poor’s with maturities that are consistent with the projected future benefit payment obligations of the plan. For the Non-U.S. Plans, the discount rates were determined by region and are based on high quality long-term corporate bonds. Consideration has been given to the duration of the liabilities in each plan when selecting the bonds to be used in determining the discount rate. The rate of compensation increase for all plans and the medical cost trend rate for the applicable U.S. plans are based on plan experience. The percentage of assets in the Company’s pension plans, by type, is as follows: U.S. Plans Non-U.S. Plans 2022 2021 2022 2021 Cash and cash equivalents 2 % 1 % 3 % 6 % Equities 47 % 45 % 18 % 18 % Fixed income 51 % 54 % 37 % 34 % Property — % — % 9 % 6 % Alternative and other investments — % — % 33 % 36 % With respect to the U.S. plans, the expected return on plan assets was determined based on an asset allocation model using the current target allocation, real rates of return by asset class and an anticipated inflation rate. The target investment allocation is 10% equity securities and 90% fixed income securities. The expected annual rate of return for the non-U.S. plans employs a similar set of criteria adapted for local investments, inflation rates and in certain cases specific government requirements. The target asset allocation, for the non-U.S. plans, consists of approximately: 35% in fixed income securities; 35% in alternative investments; 15% in equity securities; and 15% in properties. The following tables present the Company’s plan assets for the U.S. and non-U.S. plans using the fair value hierarchy as of December 31, 2022 and 2021. The plans’ assets were accounted for at fair value and are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and their placement within the fair value hierarchy levels. For more information on a description of the fair value hierarchy, see Note 16. U.S. Plans for the Year Ended December 31, 2022 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash Equivalents $ — $ 9 $ — $ 9 Fixed Income Securities Government & Government Agency Bonds — 6 — 6 Corporate Bonds — 73 — 73 Municipal Bonds — 5 — 5 Assets measured at net asset value (1) 404 Total $ — $ 93 $ — $ 497 Receivables $ 1 Total $ 498 U.S. Plans for the Year Ended December 31, 2021 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash Equivalents $ — $ 5 $ — $ 5 Fixed Income Securities Government & Government Agency Bonds — 15 — 15 Corporate Bonds — 77 — 77 Municipal Bonds — 4 — 4 Assets measured at net asset value (1) 547 Total $ — $ 101 $ — $ 648 Receivables $ 1 Total $ 649 _______________________ (1) Investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets. The total amount measured at net asset value includes approximately $234 million and $294 million in pooled equity funds and $170 million and $253 million in fixed income mutual funds for the years ended December 31, 2022 and 2021, respectively. Non-U.S. Plans for the Year Ended December 31, 2022 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash $ 14 $ 9 $ — $ 23 Equity Securities U.S. Large Cap 73 — — 73 U.S. Mid Cap 6 — — 6 Non-U.S. Large Cap 79 — — 79 Non-U.S. Mid Cap 4 — — 4 Non-U.S. Small Cap 1 — — 1 Emerging Markets 7 — — 7 Fixed Income Securities U.S. Corporate Bonds 35 — — 35 Non-U.S. Treasuries/Government Bonds 144 — — 144 Non-U.S. Corporate Bonds 34 75 — 109 Non-U.S. Asset-Backed Securities — 46 — 46 Non-U.S. Other Fixed Income 2 — — 2 Alternative Types of Investments Insurance Contracts — 177 — 177 Derivative Financial Instruments — 56 — 56 Absolute Return Funds 4 2 — 6 Other — 64 3 67 Property Non-U.S. Property 4 — 81 85 Total $ 407 $ 429 $ 84 $ 920 Non-U.S. Plans for the Year Ended December 31, 2021 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash $ 37 $ 36 $ — $ 73 Equity Securities U.S. Large Cap 100 — — 100 Non-U.S. Large Cap 104 — — 104 Non-U.S. Mid Cap 1 — — 1 Non-U.S. Small Cap 1 — — 1 Emerging Markets 30 — — 30 Fixed Income Securities U.S. Corporate Bonds 42 — — 42 Non-U.S. Treasuries/Government Bonds 162 — — 162 Non-U.S. Corporate Bonds 58 137 — 195 Non-U.S. Asset-Backed Securities — 51 — 51 Non-U.S. Other Fixed Income 2 — — 2 Alternative Types of Investments Insurance Contracts — 265 — 265 Derivative Financial Instruments — 91 — 91 Absolute Return Funds 4 110 — 114 Other — 2 10 12 Property Non-U.S. Property 5 — 72 77 Total $ 546 $ 692 $ 82 $ 1,320 Cash and cash equivalents are primarily held in registered money market funds which are valued using a market approach based on the quoted market prices of identical instruments. Other cash and cash equivalents are valued daily by the fund using a market approach with inputs that include quoted market prices for similar instruments. Equity securities are primarily valued using a market approach based on the quoted market prices of identical instruments. Pooled funds are typically common or collective trusts valued at their net asset values (NAVs). Fixed income securities are primarily valued using a market approach with inputs that include broker quotes and benchmark yields. Derivative instruments are valued by the custodian using closing market swap curves and market derived inputs. Property values are primarily based on valuation of the underlying investments, which include inputs such as cost, discounted future cash flows, independent appraisals and market comparable data. Hedge funds are valued based on valuation of the underlying securities and instruments within the funds. Quoted market prices are used when available and NAVs are used for unquoted securities within the funds. Absolute return funds are actively managed funds mainly invested in debt and equity securities and are valued at their NAVs. The following table presents a reconciliation of Level 3 non-U.S. plan assets held during the year ended December 31, 2022: Non-U.S. Plans (DOLLARS IN MILLIONS) Property Hedge Total Ending balance as of December 31, 2021 $ 72 $ 10 $ 82 Actual return on plan assets (2) (1) (3) Purchases, sales and settlements 11 (6) 5 Ending balance as of December 31, 2022 $ 81 $ 3 $ 84 The following weighted average assumptions were used to determine the postretirement benefit expense and obligation for the years ended December 31: Expense Liability 2022 2021 2022 2021 Discount rate 2.90 % 2.60 % 5.40 % 2.90 % Current medical cost trend rate 6.75 % 7.00 % 6.50 % 6.75 % Ultimate medical cost trend rate 4.75 % 4.75 % 4.75 % 4.75 % Medical cost trend rate decreases to ultimate rate in year 2030 2030 2030 2030 The following table presents the sensitivity of disclosures to changes in selected assumptions for the year ended December 31, 2022: (DOLLARS IN MILLIONS) U.S. Pension Plans Non-U.S. Pension Plans Postretirement Benefit Plan 25 Basis Point Decrease in Discount Rate Change in PBO $ 12 $ 38 N/A Change in ABO 11 37 1 Change in pension expense — 5 — 25 Basis Point Decrease in Long-Term Rate of Return Change in pension expense 1 3 N/A The Company contributed $31 million to its non-U.S. pension plans in 2022. No contributions were made to the Company’s qualified U.S. pension plans in 2022. The Company made $5 million in benefit payments with respect to its non-qualified U.S. pension plan. In addition, $2 million of payments were made with respect to the Company’s other postretirement plans.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	FINANCIAL INSTRUMENTS Fair Value Accounting guidance on fair value measurements specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs create the following fair value hierarchy: • Level 1 — Quoted prices for identical instruments in active markets. • Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. • Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable . This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company determines the fair value of structured liabilities (where performance is linked to structured interest rates, inflation or currency risks) using the LIBOR swap curve and forward interest and exchange rates at period end. Such instruments are classified as Level 2 based on the observability of significant inputs to the model. The Company does not have any instruments classified as Level 3, other than those included in pension asset trusts included in Note 15. These valuations take into consideration the Company's credit risk and its counterparties’ credit risk. The carrying value and the estimated fair values of financial instruments at December 31 consisted of the following: 2022 2021 (DOLLARS IN MILLIONS) Carrying Value Fair Carrying Value Fair LEVEL 1 Cash and cash equivalents (1) $ 483 $ 483 $ 711 $ 711 LEVEL 2 Credit facilities and bank overdrafts (2) 106 106 7 7 Derivatives Derivative assets (3) 20 20 — — Derivative liabilities (3) 56 56 7 7 Commercial paper (2) 187 187 324 324 Long-term debt: 2022 Notes (4) — — 300 300 2023 Notes (4) 300 298 300 308 2024 Euro Notes (4) 532 519 565 585 2025 Notes (4) 1,000 884 1,001 968 2026 Euro Notes (4) 845 774 900 960 2027 Notes (4) 1,215 1,006 1,218 1,180 2028 Notes (4) 398 380 397 452 2030 Notes (4) 1,510 1,188 1,511 1,466 2040 Notes (4) 774 535 775 762 2047 Notes (4) 495 390 494 585 2048 Notes (4) 787 685 786 1,026 2050 Notes (4) 1,571 1,021 1,572 1,556 2024 Term Loan Facility (5) 625 625 625 625 2026 Term Loan Facility (5) 625 625 625 625 _______________________ (1) The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments. (2) The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments. (3) The carrying amount approximates fair value as the instruments are marked-to-market and held at fair value on the Consolidated Balance Sheets. (4) The fair value of the Note is obtained from pricing services engaged by the Company, and the Company receives one price for each security. The fair value provided by the pricing services are estimated using pricing models, where the inputs to those models are based on observable market inputs or recent trades of similar securities. The inputs to the valuation techniques applied by the pricing services are typically benchmark yields, benchmark security prices, credit spreads, reported trades and broker-dealer quotes, all with reasonable levels of transparency. (5) The carrying amount approximates fair value as the Term Loans were assumed at fair value and the interest rate is reset frequently based on current market rates. Derivatives Forward Currency Forward Contracts The Company periodically enters into foreign currency forward contracts with the objective of reducing exposure to cash flow volatility associated with its intercompany loans, foreign currency receivables and payables and anticipated purchases of certain raw materials used in operations. These contracts generally involve the exchange of one currency for a second currency at a future date, have maturities not exceeding twelve months and are with counterparties which are major international financial institutions. Commodity Contracts The Company utilizes options that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans, soybean oil and soybean meal. Cash Flow Hedges Through the third quarter of 2021, the Company maintained several forward currency contracts which qualified as cash flow hedges. The objective of these hedges is to protect against the currency risk associated with forecasted U.S. dollar (“USD”) denominated raw material purchases made by Euro (“EUR”) functional currency entities which result from changes in the EUR/USD exchange rate. The effective portions of cash flow hedges are recorded in other comprehensive income (“OCI”) as a component of Gains (losses) on derivatives qualifying as hedges in the accompanying Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. Realized gains/(losses) in accumulated other comprehensive income (loss) (“AOCI”) related to cash flow hedges of raw material purchases are recognized as a component of Cost of goods sold in the accompanying Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income in the same period as the related costs are recognized. There were no cash flow hedges as of December 31, 2022 and December 31, 2021. Hedges Related to Issuances of Debt Subsequent to the issuance of the 2021 Euro Notes and 2026 Euro Notes during the third quarter of 2018, the Company designated the debt as a hedge of a portion of its net European investments. Accordingly, the change in the value of the debt that is attributable to foreign exchange movements is recorded in OCI as a component of foreign currency translation adjustments in the accompanying Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. Subsequent to the issuance of the 2024 Euro Notes during the first quarter of 2016, the Company designated the debt as a hedge of a portion of its net European investments. Accordingly, the change in the value of the debt that is attributable to foreign exchange movements is recorded in OCI as a component of foreign currency translation adjustments in the accompanying Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. During the first quarter of 2016, the Company entered into and terminated two Euro interest rate swap agreements to hedge the anticipated issuance of fixed-rate debt. These swaps were designated as cash flow hedges. The effective portions of cash flow hedges are recorded in OCI as a component of Losses on derivatives qualifying as hedges in the accompanying Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. The Company incurred a loss of €3 million ($3 million) due to the termination of these swaps. The loss is being amortized as interest expense over the life of the 2024 Euro Notes as discussed in Note 9. During the fourth quarter of 2016 and the first quarter of 2017, the Company entered into interest rate swap agreements to hedge the anticipated issuance of fixed-rate debt, which are designated as cash flow hedges. The various hedge instruments were settled upon issuance of the debt on May 18, 2017 and resulted in a loss of approximately $5 million. As discussed in Note 9, the loss is being amortized as interest expense over the life of the 2047 Notes. Cross Currency Swaps During the third quarter of 2022, the Company entered into a transaction to unwind the fourteen outstanding EUR/USD cross currency swaps designated as net investment hedges issued between the third quarter of 2019 and the first quarter of 2022. The Company received proceeds of approximately $183 million, including $11 million of interest income. The gain arising from the termination of the swaps has been included as a component of Accumulated other comprehensive loss. Following the unwinding of the existing swaps, during the third quarter of 2022, the Company entered into twelve new EUR/USD cross currency swaps, with a notional value of $1.400 billion that mature through November 2030. The swaps all qualified as net investment hedges in order to mitigate a portion of the Company's net European investments from foreign currency risk. As of December 31, 2022, the twelve remaining swaps were in a net liability position with an aggregate fair value of $37 million which were classified as Other assets and Other liabilities on the Consolidated Balance Sheets. Changes in fair value related to cross currency swaps are recorded in OCI. The following table shows the notional amount of the Company’s derivative instruments outstanding as of December 31, 2022 and December 31, 2021: December 31, (DOLLARS IN MILLIONS) 2022 2021 Foreign currency contracts (1) $ 92 $ 46 Commodity contracts (1) (1) 10 Cross currency swaps 1,400 300 ______________________ (1) Foreign currency contracts and commodity contracts are presented net of contracts bought and sold. The following tables show the Company’s derivative instruments measured at fair value (Level 2 of the fair value hierarchy) as reflected in the Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021: December 31, 2022 (DOLLARS IN MILLIONS) Fair Value of Derivatives Fair Value of Derivatives Not Designated as Hedging Instruments Total Fair Value Derivative assets (1) Foreign currency contracts $ — $ 1 $ 1 Cross currency swaps 19 — 19 Total derivative assets $ 19 $ 1 $ 20 Derivative liabilities (2) Cross currency swaps $ 56 $ — $ 56 December 31, 2021 (DOLLARS IN MILLIONS) Fair Value of Derivatives Designated as Hedging Instruments Fair Value of Derivatives Not Designated as Hedging Instruments Total Fair Value Derivative liabilities (2) Foreign currency contracts $ — $ 2 $ 2 Cross currency swaps 5 — 5 Total derivative liabilities $ 5 $ 2 $ 7 _______________________ (1) Derivative assets are recorded to Other assets in the Consolidated Balance Sheets. (2) Derivative liabilities are recorded as Other current liabilities in the Consolidated Balance Sheets. The following table shows the effect of the Company’s derivative instruments which were not designated as hedging instruments in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the years ended December 31, 2022 and December 31, 2021: (DOLLARS IN MILLIONS) Amount of Gain (Loss) Location of Gain (Loss) 2022 2021 Foreign currency contracts $ 7 $ 6 Other (income) expense, net These net gains (losses) mostly offset any recognized gains (losses) arising from the revaluation of the related intercompany loans during the same respective periods. The following table shows the effect of the Company’s derivative instruments designated as cash flow and net investment hedging instruments, net of tax, in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the years ended December 31, 2022 and December 31, 2021: Amount of Gain (Loss) Location of Gain Amount of Gain (Loss) Reclassified from AOCI For the years ended For the years ended (DOLLARS IN MILLIONS) 2022 2021 2022 2021 Derivatives in Cash Flow Hedging Relationships: Foreign currency contracts $ — $ 7 Cost of goods sold $ — $ (6) Interest rate swaps (1) — 1 Interest expense — (1) Derivatives in Net Investment Hedging Relationships: Cross currency swaps (16) 14 N/A — — Non-Derivatives in Net Investment Hedging Relationships: 2024 Euro Notes 27 38 N/A — — 2021 Euro Notes & 2026 Euro Notes 43 72 N/A — — Total $ 54 $ 132 $ — $ (7) _______________________ (1) Interest rate swaps were entered into as pre-issuance hedges for the Company's bond offerings. The ineffective portion of the above noted cash flow hedges and net investment hedges was not material for the years ended December 31, 2022 and 2021. At December 31, 2022, based on current market rates, the Company does not expect any derivative losses (net of tax), included in AOCI, to be reclassified into earnings within the next 12 months.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income Loss	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)The following tables present changes in the accumulated balances for each component of other comprehensive income (loss), including current period other comprehensive income (loss) and reclassifications out of accumulated other comprehensive income (loss): (DOLLARS IN MILLIONS) Foreign (Losses) Gains on Derivatives Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2021 $ (1,133) $ 1 $ (291) $ (1,423) OCI before reclassifications (904) — 148 (756) Amounts reclassified from AOCI — — 10 10 Net current period other comprehensive income (loss) (904) — 158 (746) Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2022 $ (2,037) $ 1 $ (133) $ (2,169) (DOLLARS IN MILLIONS) Foreign (Losses) Gains on Derivatives Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2020 $ (285) $ (7) $ (406) $ (698) OCI before reclassifications (848) 1 97 (750) Amounts reclassified from AOCI — 7 18 25 Net current period other comprehensive income (loss) (848) 8 115 (725) Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2021 $ (1,133) $ 1 $ (291) $ (1,423) (DOLLARS IN MILLIONS) Foreign (Losses) Gains on Derivatives Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2019 $ (373) $ 2 $ (346) $ (717) OCI before reclassifications 88 (5) (74) 9 Amounts reclassified from AOCI — (4) 14 10 Net current period other comprehensive income (loss) 88 (9) (60) 19 Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2020 $ (285) $ (7) $ (406) $ (698) The following table provides details about reclassifications out of Accumulated other comprehensive loss to the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income: Year Ended December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Affected Line Item in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Losses) gains on derivatives qualifying as hedges Foreign currency contracts $ — $ (7) $ 6 Cost of goods sold Interest rate swaps — (1) (1) Interest expense Tax — 1 (1) Provision for income taxes Total $ — $ (7) $ 4 Total, net of income taxes (Losses) gains on pension and postretirement liability adjustments Prior service cost $ 7 $ 7 $ 7 (1) Actuarial losses (21) (38) (30) (1) Other items — 17 — (2) Tax 4 (4) 9 Provision for income taxes Total $ (10) $ (18) $ (14) Total, net of income taxes _______________________ (1) The amortization of prior service cost and actuarial loss is included in the computation of net periodic benefit cost. Refer to Note 15 to the Consolidated Financial Statements for additional information regarding net periodic benefit cost. (2) Represents certain amounts of pension income that were corrected in 2021.

Concentrations of Credit Risk

Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Concentrations of Credit Risk	CONCENTRATIONS OF CREDIT RISKThe Company does not have significant concentrations of risk in financial instruments. Temporary investments are made in a well-diversified portfolio of high-quality, liquid obligations of government, corporate and financial institutions. There are also limited concentrations of credit risk with respect to trade receivables because the Company has a large number of customers who are spread across many industries and geographic regions. The Company’s larger customers are each spread across many sub-categories of its segments and geographical regions. The Company had no customer that accounted for more than 10% of its consolidated net sales for the years ended 2022, 2021 and 2020.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Guarantees and Letters of Credit The Company has various bank guarantees, letters of credit and surety bonds which are available for use to support its ongoing business operations, satisfy governmental requirements associated with pending litigation in various jurisdictions and the payment of customs duties. At December 31, 2022, the Company had total bank guarantees, commercial guarantees, standby letters of credit and surety bonds of approximately $434 million with various financial institutions. Included in the above aggregate amount was a total of approximately $14 million for other assessments in Brazil for various income tax and indirect tax disputes related to fiscal years 1998-2011. There was a total of approximately $116 million outstanding under the bank guarantees, standby letters of credit and commercial guarantees as of December 31, 2022. In order to challenge the assessments in these cases in Brazil, the Company has been required to, and has separately pledged assets, principally property, plant and equipment, to cover assessments in the amount of approximately $8 million as of December 31, 2022. Lines of Credit The Company has various lines of credit which are available to support its ongoing business operations. As of December 31, 2022, the Company had available lines of credit of approximately $1.859 billion with various financial institutions, in addition to the $902 million of capacity under the Credit Facility. There were total draw downs of approximately $297 million pursuant to these lines of credit as of December 31, 2022, including approximately $187 million related to the issuance of commercial paper and $100 million related to borrowings under the Amended Revolving Credit Facility. Refer to Note 9 for additional information. Litigation The Company assesses contingencies related to litigation and/or other matters to determine the degree of probability and range of possible loss. A loss contingency is accrued in the Company’s Consolidated Financial Statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly sensitive and requires judgments about future events. On at least a quarterly basis, the Company reviews contingencies related to litigation to determine the adequacy of accruals. The amount of ultimate loss may differ from these estimates and further events may require the Company to increase or decrease the amounts it has accrued on any matter. Periodically, the Company assesses its insurance coverage for all known claims, where applicable, taking into account aggregate coverage by occurrence, limits of coverage, self-insured retentions and deductibles, historical claims experience and claims experience with its insurance carriers. The liabilities are recorded at management’s best estimate of the probable outcome of the lawsuits and claims, taking into consideration the facts and circumstances of the individual matters as well as past experience on similar matters. At each balance sheet date, the key issues that management assesses are whether it is probable that a loss as to asserted or unasserted claims has been incurred and if so, whether the amount of loss can be reasonably estimated. The Company records the expected liability with respect to claims in Other liabilities and expected recoveries from its insurance carriers in Other assets. The Company recognizes a receivable when it believes that realization of the insurance receivable is probable under the terms of the insurance policies and its payment experience to date. Litigation Matters On August 12, 2019, Marc Jansen filed a putative securities class action against IFF, its then Chairman and CEO, and its then-CFO, in the United States District Court for the Southern District of New York. The lawsuit was filed after IFF disclosed that preliminary results of investigations indicated that Frutarom businesses operating principally in Russia and Ukraine had made improper payments to representatives of customers. On March 16, 2020, an amended complaint was filed, which added Frutarom and certain former officers of Frutarom as defendants. The amended complaint alleges, among other things, that defendants made materially false and misleading statements or omissions concerning IFF’s acquisition of Frutarom, the integration of the two companies, and the companies’ financial reporting and results. The amended complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, and under the Israeli Securities Act-1968, against all defendants, and under Section 20(a) of the Securities Exchange Act of 1934 against the individual defendants, on behalf of a putative class of persons and entities who purchased or otherwise acquired IFF securities on the New York Stock Exchange between May 7, 2018 and August 12, 2019 and persons and entities who purchased or otherwise acquired IFF securities on the Tel Aviv Stock Exchange between October 9, 2018 and August 12, 2019. The amended complaint seeks an award of unspecified compensatory damages, costs, and expenses. IFF, its officers, and Frutarom filed a motion to dismiss the case on June 26, 2020, which was granted on March 30, 2021. On April 28, 2021, lead plaintiffs filed a notice of appeal to the United States Court of Appeals for the Second Circuit. Lead plaintiffs are pursuing the appeal only against Frutarom and certain former officers of Frutarom. The parties have submitted their briefs to the Court of Appeals. The Second Circuit held oral argument on February 10, 2022. On September 30, 2022, the Second Circuit affirmed the dismissal of Plaintiffs' claims. On October 14, 2022, Plaintiffs filed a Petition for Rehearing En Banc , which the Second Circuit denied on January 4, 2023. Two motions to approve securities class actions were filed in the Tel Aviv District Court, Israel, in August 2019, similarly alleging, among other things, false and misleading statements largely in connection with IFF’s acquisition of Frutarom and the above-mentioned improper payments. One motion (“Borg”) asserts claims under the U.S. federal securities laws against IFF, its former Chairman and CEO, and its former CFO. On November 8, 2020, IFF and its officers filed their response to the Borg motion. On April 20, 2021, Mr. Borg filed a motion to stay the proceeding pending an appellate decision in the U.S. proceeding. On June 15, 2021, August 11, 2021, November 9, 2021, January 9, 2022, April 7, 2022 and July 10, 2022, the U.S. lead plaintiffs filed update notices with the Israeli court regarding the appeal in the U.S. proceeding. The other motion (“Oman”) (following an initial amendment) asserted claims under the Israeli Securities Act-1968 against IFF, its former Chairman and CEO, and its former CFO, and against Frutarom and certain former Frutarom officers and directors, as well as claims under the Israeli Companies Act-1999 against certain former Frutarom officers and directors. On February 17, 2021, the court granted a motion by the Oman plaintiff to remove IFF and its officers from the motion and to add factual allegations from the US amended complaint. The amended Oman motion was filed on July 4, 2021. On August 29, 2021, the former Frutarom officers and certain former Frutarom directors filed a motion to dismiss the case. On September 30, 2021, Frutarom notified the court that it joins the legal arguments made in the motion to dismiss. On February 22, 2022, the court denied the motion to dismiss. On July 14, 2022, the court approved the parties’ motion to mediate the dispute, which postpones all case deadlines until after the mediation. Also stayed is a request to appeal the court’s denial of the motion to dismiss filed by the former Frutarom officers and certain former Frutarom directors. The parties held the first of multiple mediation meetings on September 13, 2022 and November 22, 2022. On October 29, 2019, IFF and Frutarom filed a claim in the Tel Aviv District Court, Israel, against Ori Yehudai, the former President and CEO of Frutarom, and against certain former directors of Frutarom, challenging the bonus of US $20 million granted to Yehudai in 2018. IFF and Frutarom allege, among other things, that Yehudai was not entitled to receive the bonus because he breached his fiduciary duty by, among other things, knowing of the above-mentioned improper payments and failing to prevent them from being made. The parties agreed, pursuant to the court’s recommendation, to attempt to resolve the dispute through mediation, and a court decision is pending with regard to the order in which this claim and the class action described below will be heard. On March 11, 2020, an IFF shareholder filed a motion to approve a class action in Israel against, among others, Frutarom, Yehudai, and Frutarom’s former board of directors, alleging that former minority shareholders of Frutarom were harmed as a result of the US $20 million bonus paid to Yehudai. The parties to this motion agreed to attempt to resolve the dispute through mediation to take place regarding the aforesaid claim against Yehudai. On July 27, 2021, counsel to the movant in the class action filed a notice with the court that the mediation process ended without an agreement. On August 26, 2021, a motion to dismiss the class action application was filed by Yehudai and certain former directors of Frutarom. On September 9, 2021, an additional motion to dismiss was filed by other former directors of Frutarom together with ICC Industries, Inc. and its affiliates. On December 9, 2021, the court denied the motions to dismiss. Responses to the class action motion were filed in May 2022, and applicant’s response was filed in December 2022. Investigation On June 3, 2020, the Israel Police’s National Fraud Investigation Unit and the Israeli Securities Authority commenced an investigation into Frutarom and certain of its former executives, based on suspected bribery of foreign officials, money laundering, and violations of the Israeli Securities Act-1968. As part of the investigation, the National Fraud Investigation Unit and the Israeli Securities Authority have provided IFF and Frutarom with various orders, mainly requesting that IFF and Frutarom provide certain documents and materials. In addition, a seizure of assets was imposed on Frutarom and certain of its affiliates. IFF has been working to ensure compliance with such orders, all in accordance with, and subject to, Israeli law. On August 25, 2021, the Israeli Police informed Frutarom that they have decided to remove the temporary criminal seizure of assets order from the real estate assets of Frutarom and its related companies, which was done in parallel with the transfer of the case to the District Attorney’s Office in Israel. China Facilities Hangzhou Ingredients Plant As previously disclosed, in 2014 the Company agreed to relocate an ingredients facility in Hangzhou, China to Jiande, China. In connection with such relocation, the Company entered into a land swap and relocation agreement with the local authority pursuant to which the Company agreed to transfer ownership of the land underlying the facility in exchange for various elements of compensation, including cash and land use rights for the new facility. The Company initially determined that the gain, if any, would be recognized upon final transfer of ownership. During the fourth quarter of 2019, the Company completed the final environmental cleanup activities and transferred ownership of the land to the local authority. The amount of the gain ultimately recognized in the fourth quarter of 2019 was $4 million. The amount was recorded as a component of Other income, net. The net book value of the plant in Jiande, China was approximately $59 million as of December 31, 2022. Guangzhou Taste Plant During the fourth quarter of 2016, the Company was notified that certain governmental authorities have begun to evaluate a change in the zoning of the Guangzhou Taste plant. The zoning, if changed, would prevent the Company from continuing to manufacture product at the existing plant. The ultimate outcome of any change that the governmental authorities may propose, the timing of such a change, and the nature of any compensation arrangements that might be provided to the Company are uncertain. To address the governmental authorities' requirements, the Company has been transferring certain production capabilities from the Guangzhou Taste plant to a newly built facility in Zhangjiagang. The net book value of the Guangzhou and Zhangjiagang Taste plants was approximately $51 million and $37 million, respectively, as of December 31, 2022. Guangzhou Scent Plant During the second quarter of 2019, the Company was notified that certain governmental authorities had changed the zoning where the Guangzhou Scent plant is located. The zoning change did not affect the current operations but prevents expansions or other increases in the operating capacity of the plant. The Company believes that it is possible that the zoning may be enforced in the future such that it would not be able to continue manufacturing at the existing site. The ultimate outcome of any change that the governmental authorities may propose, the timing of such a change, and the nature of any compensation arrangements that might be provided to the Company are uncertain. The net book value of the Guangzhou Scent plant was approximately $7 million as of December 31, 2022. Zhejiang Ingredients Plant In the fourth quarter of 2017, the Company concluded discussions with the government regarding the relocation of its Fragrance Ingredients plant in Zhejiang and, based on the agreements reached, expects to receive total compensation payments up to approximately $50 million. The relocation compensation will be paid to the Company over the period of the relocation. The Company received payments totaling $30 million through the end of 2019. In the third quarter of 2020, the Company received a payment of approximately $13 million. A final payment is expected to be received in March 2023 upon final delivery of the land to the government. Production at the facility ceased during 2019. In the second quarter of 2020, the Company transferred ownership of the site to the government. The land remediation activities have been completed in November 2022, however the Company is still in process of completing the final land restoration activities in order to restore the land to its original height, per the government’s request. This process is expected to be completed in February 2023 and final delivery of the land to the government is expected to be completed in March 2023. During the second quarter of 2020, the remaining net book value of the plant was written off. Products previously manufactured at the Zhejiang Ingredients plant are now being produced at the Company’s Ingredients plant in Jiande. Total China Operations The total net book value of all plants in China was approximately $243 million as of December 31, 2022. If the Company is required to close a plant, or operate one at significantly reduced production levels on a permanent basis, the Company may be required to record charges that could have a material impact on its consolidated financial results of operations, financial position and cash flows in future periods. Environmental Proceedings The Company is reporting the following environmental matter in compliance with SEC requirements to disclose environmental proceedings where a governmental authority is a party and that involve potential monetary sanctions of $300,000 or greater. On May 27, 2022, the Solae, LLC Memphis site (“Solae”) was served an Administrative Order and Assessment (the “Order”) by the City of Memphis related to alleged wastewater discharge violations. Solae submitted an appeal of the Order on June 24, 2022. Discussions with the City regarding potential resolution of the violations and penalties related to said violations are ongoing. Additionally, the Solae facility has undertaken capital project efforts, some of which began prior to the issuance of the Order, that are anticipated to address, on a schedule consistent with the Order, deadlines for attaining compliance with current wastewater permit requirements. This matter is not expected to have a material adverse effect on the Company’s financial position, cash flows or results of operations. Other Contingencies The Company has contingencies involving third parties (such as labor, contract, technology or product-related claims or litigation) as well as government-related items in various jurisdictions in which it operates pertaining to such items as value-added taxes, other indirect taxes, customs and duties and sales and use taxes. It is possible that cash flows or results of operations, in any period, could be materially affected by the unfavorable resolution of one or more of these contingencies. The most significant government-related contingencies exist in Brazil. With regard to the Brazilian matters, the Company believes it has valid defenses for the underlying positions under dispute; however, in order to pursue these defenses, the Company is required to, and has provided, bank guarantees and pledged assets in the aggregate amount of approximately $22 million. The Brazilian matters take an extended period of time to proceed through the judicial process and there are a limited number of rulings to date. Brazil Tax Credits In 2017 the Brazilian Supreme Court (“BSC”) ruled that Brazilian tax authorities should not include a value added tax known as “ICMS” in the calculation of certain indirect taxes (“PIS/COFINS”). By removing the ICMS from the calculation of the indirect tax base, the Court effectively eliminated a “tax on tax”. The Brazilian tax authorities filed an appeal seeking clarification of certain matters, including the amount of ICMS to which taxpayers would be entitled in order to reduce their indirect tax base (i.e. the gross rate or the net rate). In light of the BSC's decision, in November 2017, the Company filed suit consistent with the BSC decision to require that ICMS be excluded from the PIS/COFINS calculation and received a favorable preliminary decision that was confirmed by the BSC in September 2018. This preliminary ruling granted the Company the right to prospectively exclude ICMS amounts from the PIS/COFINS calculation, but left open the issue of whether the Company could recover the gross or net amount of ICMS amounts paid on PIS/COFINS for the period from November 2011 to December 2018. In January 2020, the Company was informed of a favorable ruling from the Brazilian tax authorities confirming that the Company was entitled to recover the overpayments of certain indirect taxes (known as PIS/COFINS) for the period from November 2011 to December 2018, plus interest on the amount of the overpayments. The overpayments arose from the inclusion of a value added tax known as ICMS in the calculation of the PIS/COFINS tax. The ruling did not, however, settle the question of whether the Company is eligible to recover overpayments based on the gross or the net amount of ICMS amounts paid on PIS/COFINS. The Company calculated the amount of overpayments using the gross method which yields a higher amount than the application of the net method. A final ruling on the gross versus net amount issue was made by the BSC who affirmed the use of the gross calculation with respect to claims submitted prior to March 2017. Although the Company had not submitted a claim until after March 2017, the Company believes that the Supreme Court, whilst confirming the use of the gross method of calculation, does not override the January 2020 ruling by the Brazilian tax authorities with respect to the timeframe for the calculation. In addition to the $8 million recognized in the fourth quarter of 2019, during the first quarter of 2020 the Company recognized $4 million as an additional recovery on the existing claim. During 2020, the Company also recognized $3 million related to a claim from another of its subsidiaries in Brazil. The income was recognized as a reduction in Selling and Administrative expenses. Avicel® PH NF (Pharma Solutions) The Company has determined that certain grades of microcrystalline cellulose (Avicel® PH 101, 102, and 200 NF and Avicel® RC-591 NF) were found to be out-of-specification. The Company does not expect the OOS conductivity issue to affect the functionality of Avicel® NF grades or to pose a human health hazard. Corrective actions have been implemented to improve operational and laboratory conditions. Based on the information available, as of December 31, 2022, payments associated with the issue were approximately $34 million, and the Company has a current accrual of approximately $19 million. The total amount of exposure may increase if additional customers present claims or other exposures are identified. Other The Company determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that either a loss is reasonably possible or a loss in excess of accrued amounts is reasonably possible and the amount of losses or range of losses is determinable. For all third party contingencies (including labor, contract, technology, tax, product-related claims and business litigation), the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is $0 to approximately $46 million. The estimates included in this amount are based on the Company’s analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate amount may not represent the ultimate loss to the Company from the matters in question. Thus, the Company’s exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above.

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	12 Months Ended
	Dec. 31, 2022
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interests	REDEEMABLE NON-CONTROLLING INTERESTS Through certain subsidiaries of the Company’s Frutarom acquisition, there are certain non-controlling interests that carry redemption features. The non-controlling interest holders have the right, over a stipulated period of time, to sell their respective interests to Frutarom, and Frutarom has the option to purchase these interests (subject to the same timing). In most cases, these options carry similar price and conditions of exercise, and will be settled on a pre-agreed formula based on a multiple of the average EBITDA of consecutive quarters to be achieved during the period ending prior to the exercise date. The following table sets forth the details of the Company's redeemable non-controlling interests: (DOLLARS IN MILLIONS) Redeemable Balance at December 31, 2019 $ 99 Impact of foreign exchange translation 13 Share of profit or loss attributable to redeemable non-controlling interests 3 Redemption value adjustment for the current period (2) Measurement period adjustments (1) Dividends paid (2) Exercises of redeemable non-controlling interests (12) Balance at December 31, 2020 $ 98 Impact of foreign exchange translation 1 Share of profit or loss attributable to redeemable non-controlling interests 6 Redemption value adjustment for the current period 2 Dividends paid (2) Balance at December 31, 2021 $ 105 Impact of foreign exchange translation (6) Share of profit or loss attributable to redeemable non-controlling interests 4 Redemption value adjustment for the current period 5 Exercises of redeemable non-controlling interests (49) Balance at December 31, 2022 $ 59

Business Divestiture

Business Divestiture	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Business Divestiture	BUSINESS DIVESTITURE Divestiture of Microbial Control During the third quarter of 2021, the Company announced it had entered into an agreement to sell its Microbial Control business unit, which was a part of the Health & Biosciences segment. The Company acquired the Microbial Control business unit as part of the Merger with N&B. The Company completed the divestiture of the Microbial Control business unit on July 1, 2022 and received cash proceeds of approximately $1.254 billion, of which approximately $36 million was attributable to future services to be provided under certain transition service agreements as described below. Certain transaction costs related to the divestiture of approximately $11 million, which was contingent upon the consummation of the divestiture, were determined to be direct costs to sell and, as such, were adjusted against the fair value of the sale consideration. In addition, approximately $15 million of cash proceeds held in escrow were released to the Company upon satisfaction of certain conditions. The sale consideration was further reduced by approximately $3 million for certain post-closing adjustments, which were primarily related to cash, indebtedness and working capital balances. The Company entered into transition services agreements with the buyer for providing certain general accounting, information technology and other services up to 19 months following the date of the sale for minimal consideration. The fair value of these transition service agreements was determined to be approximately $36 million, which was adjusted against the sale consideration and recognized as deferred transition services income. For the year ended December 31, 2022, the transition services income under the transition services agreements was approximately $11 million and was recognized as a reduction to the costs incurred to provide services under the transition service agreements, which was included in Selling and administrative expenses on the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. The following table summarizes the fair value of the sale consideration received in connection with the divestiture: (DOLLARS IN MILLIONS) Cash proceeds from the buyer $ 1,254 Escrow proceeds 15 Proceeds attributable to transition service agreements (36) Direct costs to sell (11) Net cash settlement for post-closing adjustments (3) Fair value of sale consideration $ 1,219 The net proceeds received from business divestiture presented under Cash flows from investing activities represent the cash portion of the sale consideration, which was determined as the fair value of sale consideration reduced by the amount held in escrow and the Cash transferred to the buyer on the closing balance sheet as part of the transaction. The following table summarizes the different components of net proceeds received from business divestiture presented under Cash flows from investing activities: (DOLLARS IN MILLIONS) Fair value of sale consideration $ 1,219 Cash transferred to the buyer on the closing balance sheet (49) Employee reimbursement receivable (1) Net proceeds received from business divestiture $ 1,169 The carrying amount of net assets associated with the Microbial Control business unit was approximately $1.208 billion. The major classes of assets and liabilities sold consisted of the following: (DOLLARS IN MILLIONS) June 30, 2022 Assets Current assets $ 263 Goodwill and other intangible assets, net 867 Equity method investment 74 Other assets 80 Total assets $ 1,284 Liabilities Accounts payable $ 41 Other liabilities 35 Total liabilities $ 76 As a result of the divestiture, the Company recognized a pre-tax gain of approximately $11 million presented in Other income, net on the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the year ended December 31, 2022. The Company also recognized the income tax effects associated with the divestiture of approximately $96 million based on preliminary estimates as of December 31, 2022. During the fourth quarter of 2022, the Company announced it had entered into an agreement to sell a portion of its Savory Solutions business, which is part of the Nourish segment. In addition, in the first quarter of 2023, the Company announced it had entered into an agreement to sell its Flavor Specialty Ingredients business within the Scent segment. Both transactions are subject to customary closing conditions and are expected to close in the second quarter and third quarter of 2023, respectively. The sales do not constitute a strategic shift of the Company’s operations and do not, and will not, have major effects on the Company’s operations and financial results; therefore, the transactions do not meet the discontinued operations criteria. It was determined that the assets and liabilities of these businesses met the criteria to be presented as “held for sale.” As a result, as of December 31, 2022, such assets and liabilities were classified as held for sale and are reported on the Consolidated Balance Sheets. The Company expects that the sale proceeds less costs to sell will exceed the preliminary estimate of the carrying value of the net assets for both businesses. The carrying value is subject to change based on developments leading up to the closing date. Included in the Company’s Consolidated Balance Sheets as of December 31, 2022 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2022 Assets Cash and cash equivalents $ 52 Trade receivables, net 85 Inventories 157 Property, plant and equipment, net 92 Goodwill 348 Other intangible assets, net 428 Operating lease right-of-use assets 13 Other assets 25 Total assets held-for-sale $ 1,200 Liabilities Accounts payable $ 56 Deferred tax liability (1) 92 Other liabilities 64 Total liabilities held-for-sale $ 212 _______________________ (1) The Company is currently analyzing the tax impact of the sale transaction and has included preliminary numbers for the deferred tax liability, which are subject to further updates. Microbial Control During the third quarter of 2021, the Company announced it had entered into an agreement to sell its Microbial Control business unit, which is a part of the Health & Biosciences segment. The Company acquired the Microbial Control business unit as part of the Merger with N&B. See Note 4 for additional information. Included in the Company’s Consolidated Balance Sheets as of December 31, 2021 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2021 Assets Trade receivables, net $ 63 Inventories 125 Property, plant and equipment, net 30 Goodwill 536 Other intangible assets, net 349 Operating lease right-of-use assets 5 Other assets 14 Total assets held-for-sale $ 1,122 Liabilities Accounts payable $ 69 Deferred tax liability 24 Other liabilities 8 Total liabilities held-for-sale $ 101

Assets Held For Sale

Assets Held For Sale	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets Held For Sale	BUSINESS DIVESTITURE Divestiture of Microbial Control During the third quarter of 2021, the Company announced it had entered into an agreement to sell its Microbial Control business unit, which was a part of the Health & Biosciences segment. The Company acquired the Microbial Control business unit as part of the Merger with N&B. The Company completed the divestiture of the Microbial Control business unit on July 1, 2022 and received cash proceeds of approximately $1.254 billion, of which approximately $36 million was attributable to future services to be provided under certain transition service agreements as described below. Certain transaction costs related to the divestiture of approximately $11 million, which was contingent upon the consummation of the divestiture, were determined to be direct costs to sell and, as such, were adjusted against the fair value of the sale consideration. In addition, approximately $15 million of cash proceeds held in escrow were released to the Company upon satisfaction of certain conditions. The sale consideration was further reduced by approximately $3 million for certain post-closing adjustments, which were primarily related to cash, indebtedness and working capital balances. The Company entered into transition services agreements with the buyer for providing certain general accounting, information technology and other services up to 19 months following the date of the sale for minimal consideration. The fair value of these transition service agreements was determined to be approximately $36 million, which was adjusted against the sale consideration and recognized as deferred transition services income. For the year ended December 31, 2022, the transition services income under the transition services agreements was approximately $11 million and was recognized as a reduction to the costs incurred to provide services under the transition service agreements, which was included in Selling and administrative expenses on the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. The following table summarizes the fair value of the sale consideration received in connection with the divestiture: (DOLLARS IN MILLIONS) Cash proceeds from the buyer $ 1,254 Escrow proceeds 15 Proceeds attributable to transition service agreements (36) Direct costs to sell (11) Net cash settlement for post-closing adjustments (3) Fair value of sale consideration $ 1,219 The net proceeds received from business divestiture presented under Cash flows from investing activities represent the cash portion of the sale consideration, which was determined as the fair value of sale consideration reduced by the amount held in escrow and the Cash transferred to the buyer on the closing balance sheet as part of the transaction. The following table summarizes the different components of net proceeds received from business divestiture presented under Cash flows from investing activities: (DOLLARS IN MILLIONS) Fair value of sale consideration $ 1,219 Cash transferred to the buyer on the closing balance sheet (49) Employee reimbursement receivable (1) Net proceeds received from business divestiture $ 1,169 The carrying amount of net assets associated with the Microbial Control business unit was approximately $1.208 billion. The major classes of assets and liabilities sold consisted of the following: (DOLLARS IN MILLIONS) June 30, 2022 Assets Current assets $ 263 Goodwill and other intangible assets, net 867 Equity method investment 74 Other assets 80 Total assets $ 1,284 Liabilities Accounts payable $ 41 Other liabilities 35 Total liabilities $ 76 As a result of the divestiture, the Company recognized a pre-tax gain of approximately $11 million presented in Other income, net on the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the year ended December 31, 2022. The Company also recognized the income tax effects associated with the divestiture of approximately $96 million based on preliminary estimates as of December 31, 2022. During the fourth quarter of 2022, the Company announced it had entered into an agreement to sell a portion of its Savory Solutions business, which is part of the Nourish segment. In addition, in the first quarter of 2023, the Company announced it had entered into an agreement to sell its Flavor Specialty Ingredients business within the Scent segment. Both transactions are subject to customary closing conditions and are expected to close in the second quarter and third quarter of 2023, respectively. The sales do not constitute a strategic shift of the Company’s operations and do not, and will not, have major effects on the Company’s operations and financial results; therefore, the transactions do not meet the discontinued operations criteria. It was determined that the assets and liabilities of these businesses met the criteria to be presented as “held for sale.” As a result, as of December 31, 2022, such assets and liabilities were classified as held for sale and are reported on the Consolidated Balance Sheets. The Company expects that the sale proceeds less costs to sell will exceed the preliminary estimate of the carrying value of the net assets for both businesses. The carrying value is subject to change based on developments leading up to the closing date. Included in the Company’s Consolidated Balance Sheets as of December 31, 2022 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2022 Assets Cash and cash equivalents $ 52 Trade receivables, net 85 Inventories 157 Property, plant and equipment, net 92 Goodwill 348 Other intangible assets, net 428 Operating lease right-of-use assets 13 Other assets 25 Total assets held-for-sale $ 1,200 Liabilities Accounts payable $ 56 Deferred tax liability (1) 92 Other liabilities 64 Total liabilities held-for-sale $ 212 _______________________ (1) The Company is currently analyzing the tax impact of the sale transaction and has included preliminary numbers for the deferred tax liability, which are subject to further updates. Microbial Control During the third quarter of 2021, the Company announced it had entered into an agreement to sell its Microbial Control business unit, which is a part of the Health & Biosciences segment. The Company acquired the Microbial Control business unit as part of the Merger with N&B. See Note 4 for additional information. Included in the Company’s Consolidated Balance Sheets as of December 31, 2021 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2021 Assets Trade receivables, net $ 63 Inventories 125 Property, plant and equipment, net 30 Goodwill 536 Other intangible assets, net 349 Operating lease right-of-use assets 5 Other assets 14 Total assets held-for-sale $ 1,122 Liabilities Accounts payable $ 69 Deferred tax liability 24 Other liabilities 8 Total liabilities held-for-sale $ 101

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts and Reserves	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts and Reserves	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS AND RESERVES (IN MILLIONS) For the Year Ended December 31, 2022 Balance at Additions (deductions) charged to costs and expenses Acquisitions Accounts Translation Other Balance at end of period Allowance for doubtful accounts $ 46 $ 19 $ — $ — $ (12) $ — $ 53 Valuation allowance on credit and operating loss carryforwards and other net deferred tax assets 232 51 — — (21) — 262 For the Year Ended December 31, 2021 Balance at Additions charged to costs and expenses Acquisitions Accounts Translation Other (1) Balance at Allowance for doubtful accounts $ 21 $ 6 $ — $ (1) $ — $ 20 $ 46 Valuation allowance on credit and operating loss carryforwards and other net deferred tax assets 257 (18) 9 — (16) — 232 For the Year Ended December 31, 2020 Balance at Additions charged to costs and expenses Acquisitions Accounts Translation Other Balance at Allowance for doubtful accounts $ 16 $ 6 $ — $ (1) $ — $ — $ 21 Valuation allowance on credit and operating loss carryforwards and other net deferred tax assets 204 35 — — 18 — 257 _______________________ (1) The amount relates to adjustment to allowances for bad debts as a result of purchase price allocation related to the Merger with N&B.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations International Flavors & Fragrances Inc. and its subsidiaries (the “Registrant,” “IFF,” “the Company,” “we,” “us” and “our”) is a leading creator and manufacturer of food, beverage, health & biosciences, scent and pharma solutions and complementary adjacent products, including cosmetic active and natural health ingredients, which are used in a wide variety of consumer products. Our products are sold principally to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, sweeteners, dietary supplements, food protection, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products.
Basis of Accounting, Policy	Basis of Presentation On February 1, 2021 (the “Closing Date”), the Company completed the combination (the “Merger”) of IFF and DuPont de Nemours, Inc (“DuPont”) nutrition and biosciences business (the “N&B Business”), which had been transferred to Nutrition and Biosciences, Inc., a Delaware corporation and wholly owned subsidiary of DuPont (“N&B”) in a Reverse Morris Trust transaction. See Note 3 for additional information. As a result, the Company’s Consolidated Financial Statements for the period ended December 31, 2022 reflect the results of N&B for the full twelve months of 2022, whereas the period ended December 31, 2021 reflect the results of N&B from the Closing Date and the period ended December 31, 2020 do not reflect any results of N&B. Certain reclassifications have been made to the prior periods’ financial information in order to conform to the current period’s presentation.
Fiscal Year End	Fiscal Year End Effective 2021, the Company changed its fiscal year end from a 52/53-week fiscal year ending on the Friday closest to the last day of the quarter, to a calendar year of the twelve-month period from January 1 to December 31. The Company elected to change its fiscal year end in connection with the Merger with N&B to align the Company’s fiscal year with N&B’s. The 2022, 2021 and 2020 fiscal years were 52 week periods. For ease of presentation, December 31 is used consistently throughout the financial statements and notes to represent the period-end date. For the 2022 and 2021 fiscal years, the actual closing dates were December 31 and for the 2020 fiscal year, the actual closing date was January 1.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and judgments that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The inputs into our judgments and estimates take into account the current economic implications of the novel coronavirus (“COVID-19”), the events in Russia and Ukraine, and the ongoing adverse macroeconomic environment on our critical and significant accounting estimates, including estimates associated with future cash flows that are used in assessing the risk of impairment of certain assets. Actual results could differ from those estimates.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of International Flavors & Fragrances Inc. and those of its subsidiaries. Significant intercompany balances and transactions have been eliminated. To the extent a subsidiary is not wholly owned, any related non-controlling interests are included as a separate component of Shareholders’ Equity.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from contracts with customers when the contract or purchase order has received approval and commitment from both parties, has the rights of the parties and payment terms (which can vary by customer) identified, has commercial substance, collectability of consideration is probable, and control has transferred. The revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those goods. Sales, value added, and other taxes the Company collects are excluded from revenues. The Company receives payment in accordance with standard customer terms. Sales are reduced, at the time revenue is recognized, for applicable discounts, rebates and sales allowances based on historical experience. Related accruals are included in Other current liabilities in the accompanying Consolidated Balance Sheets. The Company considers shipping and handling activities undertaken after the customer has obtained control of the related goods as a fulfillment activity. Net sales include shipping and handling charges billed to customers. Cost of goods sold includes all costs incurred in connection with shipping and handling.
Foreign Currency Translation	Foreign Currency Translation The Company translates the assets and liabilities of non-U.S. subsidiaries into U.S. dollars at year-end exchange rates. Income and expense items are translated at average exchange rates during the year. Cumulative translation adjustments are shown as a separate component of Shareholders’ Equity.
Research and Development	Research and Development Research and development (“R&D”) expenses relate to the development of new and improved products, technical product support and compliance with governmental regulation. All research and development costs are expensed as incurred.
Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with maturities of three months or less at date of purchase.
Restricted Cash	Restricted Cash Restricted cash is comprised of cash or cash equivalents which has been placed into an account that is restricted for a specific use and from which the Company cannot withdraw the cash on demand.
Accounts Receivable	Accounts Receivable The Company has certain factoring agreements in the U.S. and The Netherlands under which it can factor up to €250 million of its trade receivables. The factoring agreements supplement the Company's existing factoring programs that are sponsored by certain customers. Under all of the arrangements, the Company sells the trade receivables on a non-recourse basis to unrelated financial institutions and accounts for the transactions as sales of receivables. The applicable receivables are removed from the Company’s Consolidated Balance Sheets when the cash proceeds are received by the Company. The Company sold approximately $1.030 billion, $668 million and $351 million of receivables in 2022, 2021 and 2020, respectively. The outstanding principal amounts of receivables under these arrangements amounted to approximately $212 million, $153 million and $57 million, respectively, as of December 31, 2022, 2021 and 2020. The proceeds from the sales of receivables are included in net cash from operating activities in the Consolidated Statements of Cash Flows. The cost of participating in these programs was approximately $12 million, $6 million and $4 million in 2022, 2021 and 2020, respectively, and is included as a component of interest expense.
Expected Credit Loss	Expected Credit Losses The Company is exposed to credit losses primarily through its sales of products. To determine the appropriate allowance for expected credit losses, the Company considers certain credit quality indicators, such as aging, collection history, and creditworthiness of debtors. Regional and Global Credit committees review and approve specific customer allowance reserves. The allowance for expected credit losses is primarily based on two primary factors: i) the aging of the different categories of trade receivables, and ii) a specific reserve for accounts identified as uncollectible. The Company also considers current and future economic conditions in the determination of the allowance. At December 31, 2022, the Company reported $1.818 billion of trade receivables, net of allowances of $53 million. Based on the aging analysis as of December 31, 2022, approximately 1% of the Company’s accounts receivable were past due by over 365 days based on the payment terms of the invoice.
Inventories	InventoriesInventories are stated at the lower of cost (on a weighted-average basis) or net realizable value.
Leases	Leases The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the customer has the right to control the use of the identified asset. When the Company determines the arrangement is a lease, or contains a lease, at inception, it then determines whether the lease is an operating lease or a finance lease at the commencement date. The Company leases property and equipment, principally under operating leases. The Company records a right of use asset and related obligation at the present value of lease payments and, over the term of the lease, depreciates the right of use asset and accretes the obligation to future value. Some of the leases include rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. The Company has elected not to separate non-lease components from lease components for all classes of leased assets.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are recorded at cost. Depreciation is calculated on a straight-line basis, principally over the following estimated useful lives: buildings and improvements, 1 to 50 years; machinery and equipment, 1 to 40 years; information technology hardware and software, 1 to 23 years; and leasehold improvements which are included in buildings and improvements, the estimated life of the improvements or the remaining term of the lease, whichever is shorter.
Finite-Lived Intangible Assets	Finite-Lived Intangible Assets Finite-lived intangible assets include customer relationships, patents, trade names, technological know-how and other intellectual property valued at acquisition and amortized on a straight-line basis over the following estimated useful lives: customer relationships, 10 to 27 years; patents, 11 to 15 years; trade names, 4 to 28 years; and technological know-how, 5 to 28 years. The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered. An estimate of undiscounted future cash flows produced by an asset or group of assets is compared to the carrying value to determine whether impairment exists. If assets are determined to be impaired, the loss is measured based on an estimate of fair value using various valuation techniques, including a discounted estimate of future cash flows.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets During the second quarter of 2022, the sales and margins declined for certain entities within Russia due to supply chain issues, reduced product demand and exchange rate volatility. Additionally, future growth is expected to be limited given operating conditions in Russia, which inhibit the required future investment. In connection with uncertainties related to the Company’s operations in Russia and Ukraine, the Company updated its analysis of the undiscounted cash flows of the applicable asset groups to determine if the cash flows exceeded the carrying values of the applicable asset groups. With respect to an asset group in the Nourish segment, that manufactures and sells in Russia and related markets, it was determined that the undiscounted cash flows were insufficient to cover the carrying value and that an impairment charge was required to write-down the long-lived assets to their fair values. The fair value of such asset group was determined based on a discounted cash flow approach which involved estimating the future cash flows for the business discounted to their present values. The discount rate used in the determination of such fair value was based on consideration of the risks inherent in the cash flows and market as of the valuation date. As a result of this assessment, the Company recognized an impairment charge of $120 million in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the year ended December 31, 2022, which was allocated on a pro rata basis to intangible assets and property, plant and equipment within the asset group in the amounts of approximately $92 million and $28 million, respectively.
Goodwill	Goodwill Goodwill represents the difference between the total purchase price and the fair value of identifiable assets and liabilities acquired in business acquisitions. The Company tests goodwill for impairment at the reporting unit level as of November 30 every year or more frequently if events or changes in circumstances indicate the asset might be impaired. A reporting unit is an operating segment or one level below an operating segment (referred to as a component) to which goodwill is assigned when initially recorded. The Company identifies their reporting units by assessing whether the components of their reporting units constitute businesses for which discrete financial information is available and management of each reporting unit regularly reviews the operating results of those components. The Company determined that it has six reporting units under the Nourish, Health & Biosciences, Scent and Pharma Solutions segments: (1) Nourish, (2) Fragrance Compounds, (3) Fragrance Ingredients, (4) Cosmetic Actives, (5) Health & Biosciences and (6) Pharma Solutions. These reporting units were determined based on the level at which the performance is measured and reviewed by segment management. In cases where the components of an operating segment have similar economic characteristics, they are aggregated into a single reporting unit. When testing goodwill for impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount. If the Company elects to bypass the qualitative assessment for any reporting units, or if a qualitative assessment indicates it is more likely than not that the estimated carrying value of a reporting unit exceeds its fair value, the Company performs a quantitative goodwill impairment test. Under the quantitative goodwill impairment test, if a reporting unit’s carrying amount exceeds its fair value, the Company will record an impairment charge based on that difference, and the impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For the third quarter of 2022, the Company determined that the carrying value of the Health & Biosciences reporting unit exceeded its fair value and recorded a goodwill impairment charge of $2.250 billion in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the year ended December 31, 2022 (see Note 6 for additional information).
Income Taxes	Income Taxes The Company accounts for taxes under the asset and liability method. Under this method, deferred income taxes are recognized for temporary differences between the financial statement and tax return bases of assets and liabilities, based on enacted tax rates and other provisions of the tax law. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized as income in the period in which such change is enacted. Future tax benefits are recognized to the extent that the realization of such benefits is more likely than not, and a valuation allowance is established for any portion of a deferred tax asset that management believes may not be realized. The Company recognizes uncertain tax positions that it has taken or expects to take on a tax return. Pursuant to accounting requirements, the Company first determines whether it is “more likely than not” its tax position will be sustained if the relevant tax authority were to audit the position with full knowledge of all the relevant facts and other information. For those tax positions that meet this threshold, the Company measures the amount of tax benefit based on the largest amount of tax benefit that it has a greater than 50% chance of realizing in a final settlement with the relevant authority. Those tax positions failing to qualify for initial recognition are recognized in the first interim period in which they meet the more likely than not standard. The Company maintains a cumulative risk portfolio relating to all of its uncertainties in income taxes in order to perform this analysis, but the evaluation of its tax positions requires significant judgment and estimation in part because, in certain cases, tax law is subject to varied interpretation, and whether a tax position will ultimately be sustained may be uncertain. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.
Retirement Benefits	Retirement Benefits Current service costs of retirement plans and postretirement health care and life insurance benefits are accrued. Prior service costs resulting from plan improvements are amortized over periods ranging from 10 to 20 years.
Financial Instruments	Financial Instruments Derivative financial instruments are used to manage interest and foreign currency exposures. The gain or loss on the hedging instrument is recorded in earnings at the same time as the transaction being hedged is recorded in earnings. The associated asset or liability related to the open hedge instrument is recorded in Prepaid expenses and Other current assets or Other current liabilities, as applicable. The Company records all derivative financial instruments on the balance sheet at fair value. Changes in a derivative’s fair value are recognized in earnings unless specific hedge criteria are met. If the derivative is designated as a fair value hedge, the changes in the fair value of the derivative and of the hedged item attributable to the hedged risk are recognized in Net (loss) income. If the derivative is designated as a cash flow hedge, the effective portions of changes in the fair value of the derivative are recorded in Accumulated Other Comprehensive Income (Loss) (“AOCI”) in the accompanying Consolidated Balance Sheets and are subsequently recognized in Net income when the hedged item affects earnings. Ineffective portions of changes in the fair value of cash flow hedges, if any, are recognized as a charge or credit to earnings.
Software Costs	Software Costs The Company capitalizes direct internal and external development costs for certain significant projects associated with internal-use software and amortizes these costs over seven years. Neither preliminary evaluation costs nor costs associated with the software after implementation are capitalized. Costs related to projects that are not significant are expensed as incurred.
Net Income (Loss) Per Share	Net (Loss) Income Per Share Under the two-class method, earnings are adjusted by accretion of amounts to redeemable non-controlling interests recorded at redemption value. The adjustments represent in-substance dividend distributions to the non-controlling interest holders as the holders have a contractual right to receive a specified amount upon redemption. As a result, earnings are adjusted to reflect this in-substance distribution that is different from other common shareholders. In addition, the Company has unvested share based payment awards with a right to receive nonforfeitable dividends and thus are considered participating securities which are required to be included in the computation of basic and diluted earnings per share. Basic (loss) income per share represents the amount of earnings available to each share of common stock outstanding during the period. Basic (loss) income per share includes the effect of issuing shares of common stock, where (i) for 2021, the prepaid stock purchase contracts (“SPCs”) were converted using the final settlement rate on September 14, 2021 (see Note 11 for additional information) and for 2020, the prepaid SPCs were converted into the minimum number of shares of common stock under the if-converted method, and (ii) an adjustment to (loss) income to reflect adjustments made to record the redeemable value of redeemable non-controlling interests. Diluted (loss) income per share also includes the effect of issuing shares of common stock, assuming (i) stock options and warrants are exercised, (ii) restricted stock units are fully vested under the treasury stock method, and (iii) for 2021, the incremental effect of the prepaid SPCs were converted using the final settlement rate on September 14, 2021 (see Note 11 for additional information) and for 2020, the incremental effect of the prepaid SPCs were converted into the maximum number of shares of common stock under the if-converted method.
Stock-Based Compensation	Stock-Based Compensation Compensation cost of all stock-based awards is measured at fair value on the date of grant and recognized over the service period for which awards are expected to vest. The cost of such stock-based awards is principally recognized on a straight-line attribution basis over their respective vesting periods, net of estimated forfeitures.
Financing Costs	Financing Costs Costs incurred in the issuance of debt are deferred and amortized as part of interest expense over the stated life of the applicable debt instrument. Unamortized deferred financing costs relating to debt are presented as a reduction in the amount of debt outstanding on the Consolidated Balance Sheets. Unamortized deferred financing costs relating to the revolving credit facility are recorded in Other assets on the Consolidated Balance Sheets.
Redeemable Non-controlling Interests	Redeemable Non-controlling Interests Non-controlling interests in subsidiaries that are redeemable for cash or other assets outside of the Company’s control are classified as mezzanine equity, outside of equity and liabilities, at the greater of the carrying value or the redemption value. The increases or decreases in the estimated redemption amount are recorded with corresponding adjustments against Capital in excess of par value and are reflected in the computation of earnings per share using the two-class method.
Held for Sale	Held for Sale Assets and liabilities to be disposed of by sale (“disposal groups”) are reclassified into assets and liabilities held for sale on the Company’s Consolidated Balance Sheets. The reclassification occurs when an agreement to sell exists, or management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying value or fair value less costs to sell and are not depreciated or amortized. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The fair value of a disposal group, less any costs to sell, is assessed each reporting period it remains classified as held for sale and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. See Note 21 for additional information.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848.” The ASU was issued to provide an update on ASU 2020-04 and ASU 2021-01 that were issued in March 2020 and January 2021, respectively, which provided optional accounting guidance for a limited period of time to ease the potential burden in accounting for reference rate reform. The guidance provides optional expedients and exceptions to existing accounting requirements for contract modifications and hedge accounting related to transitioning from discontinued reference rates, such as London Interbank Offered Rate (“LIBOR”), to alternative reference rates, if certain criteria are met. With the issuance of ASU 2022-06, the sunset date of Topic 848 has been deferred from December 31, 2022 to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The Company is currently evaluating the impact of this guidance, but does not expect this guidance to have a material impact on its Consolidated Financial Statements. In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance.” The ASU requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This guidance is effective for all entities for annual periods beginning after December 15, 2021 and early adoption is permitted. This guidance was adopted by the Company as of January 1, 2022 using the prospective method of adoption. The adoption of this guidance did not have a material impact on the Consolidated Financial Statements. In October 2021, the FASB issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” The ASU is intended to provide specific guidance on how to recognize and measure acquired contract assets and liabilities from revenue contracts in a business combination. An acquirer needs to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted, including adoption in an interim period. The Company early adopted ASU 2021-08 during the second quarter of 2022. The adoption of this guidance did not have a material impact on the Consolidated Financial Statements.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	The Company's inventories consisted of the following: December 31, (DOLLARS IN MILLIONS) 2022 2021 Raw materials $ 1,073 $ 854 Work in process 442 287 Finished goods 1,636 1,375 Total $ 3,151 $ 2,516
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Company’s statement of cash flows periods ended December 31, 2022, 2021 and 2020 to the amounts reported in the Company’s balance sheets as of December 31, 2022, 2021 and 2020. (DOLLARS IN MILLIONS) December 31, 2022 December 31, 2021 December 31, 2020 Current assets Cash and cash equivalents $ 483 $ 711 $ 650 Cash and cash equivalents included in Assets held for sale 52 — — Restricted cash 10 4 7 Non-current assets Restricted cash included in Other assets 7 1 3 Cash, cash equivalents and restricted cash $ 552 $ 716 $ 660
Contract with Customer, Contract Asset, Contract Liability, and Receivable	Contract Assets and Liabilities With respect to a small number of contracts for the sale of compounds, the Company has an “enforceable right to payment for performance to date” and as the products do not have an alternative use, the Company recognizes revenue for these contracts over time and records a contract asset using the output method. The output method recognizes revenue on the basis of direct measurements of the value to the customer of the goods or services transferred to date relative to the remaining goods or services promised under the contract. As of December 31, 2022 and 2021, the Company’s gross accounts receivable was $1.871 billion and $1.952 billion, respectively. The Company’s contract assets and contract liabilities as of December 31, 2022 and 2021 were not material.
Accounts Receivable, Allowance for Credit Loss	The following is a roll forward of the Company’s allowances for bad debts for the years ended December 31, 2021 and 2022: (DOLLARS IN MILLIONS) Allowance for Bad Debts Balance at December 31, 2020 $ 21 Bad debt expense 6 Write-offs (1) Other adjustments (1) 20 Balance at December 31, 2021 46 Bad debt expense (2) 19 Foreign exchange (12) Balance at December 31, 2022 $ 53 _______________________ (1) The adjustment to allowances for bad debts was a result of purchase price allocation related to the Merger with N&B. (2) The bad debt expense included approximately $11 million related to expected credit losses on receivables from customers located in Russia and Ukraine (for export and domestic sales) due to recent events in those countries. The Company will continue to evaluate its credit exposure related to Russia and Ukraine.

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Movements in Restructuring and Related Accruals	Movements in severance-related accruals during 2020, 2021 and 2022 are as follows: (DOLLARS IN MILLIONS) Balance at January 1, 2020 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at December 31, 2020 2017 Productivity Program Severance $ 1 $ (1) $ — $ — $ — Frutarom Integration Initiative Severance 4 2 — (3) 3 Fixed asset write down — 12 (12) — — Other (1) 3 2 — (2) 3 2019 Severance Program Severance 13 (1) — (6) 6 Other Restructuring Charges Severance — 3 — (1) 2 Total restructuring $ 21 $ 17 $ (12) $ (12) $ 14 (DOLLARS IN MILLIONS) Balance at January 1, 2021 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at December 31, 2021 Frutarom Integration Initiative Severance $ 3 $ 5 $ — $ (3) $ 5 Fixed asset write down — 5 (5) — — Other (1) 3 — — — 3 2019 Severance Program Severance 6 — — (1) 5 Other Restructuring Charges Severance 2 — — (1) 1 Other (2) — 1 — (1) — N&B Merger Restructuring Liability Severance — 27 — (12) 15 Other (3) — 3 (3) — — Total restructuring $ 14 $ 41 $ (8) $ (18) $ 29 (DOLLARS IN MILLIONS) Balance at January 1, 2022 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at December 31, 2022 Frutarom Integration Initiative Severance $ 5 $ 1 $ — $ (2) $ 4 Fixed asset write down — 3 (3) — — Other (1) 3 (2) — (1) — 2019 Severance Program Severance 5 (5) — — — Other Restructuring Charges Severance 1 — — — 1 N&B Merger Restructuring Liability Severance 15 8 — (14) 9 Other (3) — 7 (2) (4) 1 Total restructuring $ 29 $ 12 $ (5) $ (21) $ 15 _______________________ (1) Includes supplier contract termination costs, consulting and advisory fees. (2) Includes charges related to legal settlement costs. (3) Includes lease impairment charges and losses incurred from restructuring activities as a result of the Merger with N&B. Charges by Segment The following table summarizes the total amount of costs incurred in connection with these restructuring programs and activities by segment: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Nourish $ 8 $ 32 $ 10 Health & Biosciences 2 5 — Scent 1 3 7 Pharma Solutions 1 1 — Total Restructuring and other charges $ 12 $ 41 $ 17

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Business Acquisitions, by Acquisition	Purchase Price The following table summarizes the aggregate purchase price consideration paid to acquire N&B (in millions, except share and per share data): (DOLLARS IN MILLIONS) Fair value of common stock issued to DuPont stockholders (1) $ 15,929 Fair value attributable to pre-merger service for replacement equity awards (2) 25 Pension funding adjustment (3) (12) Total purchase consideration $ 15,942 _______________________ (1) The fair value of common stock issued to DuPont stockholders represents 141,740,461 shares of the Company's common stock determined based on the number of fully diluted shares of IFF common stock, immediately prior to the Closing Date, multiplied by the quotient of 55.4%/44.6% and IFF common stock closing share price of $112.38 on the New York Stock Exchange on the Closing Date. (2) At the time of the Transactions, each outstanding stock option, cash-settled stock appreciation right (“SAR”), restricted stock unit (“RSU”) award, and restricted stock award (“RSA”) with respect to DuPont common stock held by employees of N&B were canceled and converted into similar classes of equity awards of IFF’s Class A Common Stock. Further, each outstanding Performance Share Unit (“PSU”) award with respect to DuPont common stock held by employees of N&B were canceled and converted into IFF’s RSU awards. The conversion was based on the ratio of the volume-weighted average per share closing price of DuPont stock on the twenty trading days prior to the Closing Date and IFF’s stock on the twenty trading days following the Closing Date. The fair value of replacement equity-based awards attributable to pre-Merger service was recorded as part of the consideration transferred in the Merger (see Note 13 for additional information). (3) The Merger related agreements provided that if the net pension balance of N&B as of the Closing Date differs from $220 million, such differential amount would be settled in cash. The Company estimated the amount that it would receive and, accordingly, made an adjustment of $12 million to the total purchase consideration. The following table summarizes the fair values of the assets acquired and liabilities assumed as of February 1, 2021, presenting both the preliminary and final purchase price allocations: (DOLLARS IN MILLIONS) Preliminary Estimated Fair Value as Reported in the First Quarter of 2021 Measurement Period Adjustments (1)(2) Final Fair Value as Reported in the Fourth Quarter of 2021 Cash and cash equivalents $ 207 $ (14) $ 193 Receivables 962 (9) 953 Inventory 1,615 (25) 1,590 Prepaid expenses and other current assets 342 32 374 Property, plant and equipment 3,242 (176) 3,066 Deferred income taxes 75 8 83 Intangible assets 9,176 47 9,223 Other assets 702 116 818 Accounts payable and accrued liabilities (1,028) (51) (1,079) Accrued payroll and employee benefits (163) 15 (148) Deferred tax liabilities (3) (2,369) (26) (2,395) Long-term debt (7,636) — (7,636) Other long-term liabilities (907) 12 (895) Total identifiable net assets assumed 4,218 (71) 4,147 Non-controlling interest (26) 4 (22) Goodwill (4) 11,762 55 11,817 Purchase price $ 15,954 $ (12) $ 15,942 _______________________ (1) The preliminary fair value purchase price allocation of the assets and liabilities acquired in the N&B Merger as reported in the first quarter of 2021 were updated during the nine months ended December 31, 2021 to reflect updated fair values for intangible assets, property, plant and equipment, equity method investments and inventory. In addition, the carrying amounts of certain assets and liabilities were updated based on additional analysis of acquired assets and liabilities that existed at the Closing Date. (2) During the fourth quarter of 2021, the Company recorded an adjustment to reflect the receipt of approximately $53 million in cash from DuPont as a result of finalization of adjustments to the Special Cash Payment paid to DuPont by N&B, prior to the close of the Transactions. (3) The change to deferred tax liabilities was primarily a result of the finalization of the jurisdictional allocation of the tangible and intangible assets. All measurement period adjustments were offset against goodwill. (4) The cumulative impact of the adjustments during the nine months ended December 31, 2021 resulted in a $55 million increase to goodwill.
Schedule of intangible assets acquired	The fair value and useful lives of the identifiable intangible assets assumed as of February 1, 2021 were as follows: (DOLLARS IN MILLIONS) Amounts Useful Lives Indefinite-lived intangible assets In-process research and development $ 13 Indefinite Finite-lived intangible assets Trade names 261 4 to 22 years Customer relationships 6,734 11 to 27 years Technological know-how 2,194 5 to 18 years Other 21 2 years Total finite-lived intangible assets 9,210 Total $ 9,223
Unaudited pro forma information	The unaudited pro forma results for the year ended December 31, 2021 and 2020 were as follows: Year Ended December 31, (DOLLARS IN MILLIONS) 2021 2020 Unaudited pro forma net sales $ 12,163 $ 11,143 Unaudited pro forma net income attributable to the Company 687 192

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment, Net [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment, net consisted of the following amounts: (DOLLARS IN MILLIONS) December 31, 2022 2021 Asset Type Land $ 199 $ 223 Buildings and improvements 1,697 1,764 Machinery and equipment 3,344 3,442 Information technology 291 271 Construction in process 649 461 Total Property, Plant and Equipment 6,180 6,161 Accumulated depreciation (1,977) (1,793) Total Property, Plant and Equipment, Net $ 4,203 $ 4,368

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill by Operating Segment	Goodwill In the first quarter of 2021, in connection to the Merger, the Company reorganized its reporting structure. In connection with this reorganization, goodwill was reassigned among reporting units using a relative fair value approach based on the fair value of the elements transferred and the fair value of the elements remaining within the original reporting units. The Company tested goodwill for impairment on a pre-reorganization basis and determined there was no impairment for the affected reporting units. In connection with the reorganization, $985 million of goodwill previously included in the legacy Taste segment, now the Nourish segment, was moved to the Scent and Health & Biosciences segments amounting to $257 million and $728 million, respectively. Movements in goodwill attributable to each reportable segment during the years ended December 31, 2021 and 2022 were as follows: (DOLLARS IN MILLIONS) Nourish Health & Biosciences Scent Pharma Solutions Total Balance at December 31, 2020 $ 4,859 $ — $ 734 $ — $ 5,593 Acquisitions (1) 2,900 6,712 876 1,329 11,817 Transferred to assets held for sale (2) — (536) — — (536) Reduction from business divestiture (27) — — — (27) Foreign exchange (192) (155) (39) (47) (433) Reallocation (985) 728 257 — — Balance at December 31, 2021 6,555 6,749 1,828 1,282 16,414 Acquisitions (3) — 45 — — 45 Impairment — (2,250) — — (2,250) Transferred to assets held for sale (4) (306) — (42) — (348) Foreign exchange (199) (223) (41) (43) (506) Balance at December 31, 2022 $ 6,050 $ 4,321 $ 1,745 $ 1,239 $ 13,355 _______________________ (1) Acquisitions relate to the Merger with N&B. See Note 3 for additional information. (2) Transferred to assets held for sale relate to the Microbial Control business unit that was classified as “held for sale” as of December 31, 2021. (3) Acquisitions relate to the acquisition of Health Wright. See Note 3 for additional information. (4) Transferred to assets held for sale relate to the portion of the Savory Solutions business and Flavor Specialty Ingredients business that were classified as “held for sale” as of December 31, 2022. See Note 21 for additional information.
Schedule of Other Intangible Assets	Other intangible assets, net consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Asset Type Customer relationships $ 8,318 $ 8,935 Technological know-how 2,339 2,494 Trade names & patents 358 411 Other 47 50 Total carrying value 11,062 11,890 Accumulated Amortization Customer relationships (1,252) (887) Technological know-how (589) (388) Trade names & patents (97) (68) Other (42) (41) Total accumulated amortization (1,980) (1,384) Other intangible assets, net $ 9,082 $ 10,506
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Amortization expense for the next five years and thereafter, based on valuations and determinations of useful lives, is expected to be as follows: December 31, (DOLLARS IN MILLIONS) 2023 2024 2025 2026 2027 Estimated future intangible amortization expense $ 703 $ 702 $ 699 $ 697 $ 598

Other Assets And Liabilities,_2

Other Assets And Liabilities, Current and Noncurrent (Tables)	12 Months Ended
	Dec. 31, 2022
Other Assets [Abstract]
Schedule of Other Assets	Other assets consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Finance lease right-of-use assets $ 22 $ 21 Deferred income taxes 158 82 Overfunded pension plans 180 136 Cash surrender value of life insurance contracts 45 52 Equity method investments 10 86 Other (1) 284 239 Total $ 699 $ 616 _______________________ (1) Includes land usage rights in China, long term deposits and receivables on certain derivative instruments.
Schedule of Other Current Assets	Prepaid expenses and other current assets consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Value-added tax receivable $ 212 $ 178 Income tax receivable 129 131 Packaging materials 148 128 Prepaid expenses 144 160 Other 137 131 Total $ 770 $ 728
Other Current Liabilities	Other current liabilities consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Rebates and incentives payable $ 99 $ 113 Value-added tax payable 65 50 Interest payable 55 48 Current pension and other postretirement benefit obligation 10 11 Accrued insurance (including workers’ compensation) 9 10 Restructuring and other charges 15 29 Current operating lease obligation 86 109 Accrued freight 18 — Accrued commissions payable 11 13 Accrued income taxes 313 94 Accrued expenses payable 256 270 Other 91 85 Total $ 1,028 $ 832

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Instrument [Line Items]
Components of Debt	Debt consisted of the following at December 31: (DOLLARS IN MILLIONS) Effective Interest Rate 2022 2021 2022 Notes (3) 0.69 % $ — $ 300 2023 Notes (1) 3.30 % 300 300 2024 Euro Notes (1) 1.88 % 532 565 2025 Notes (3) 1.22 % 1,000 1,001 2026 Euro Notes (1) 1.93 % 845 900 2027 Notes (3) 1.56 % 1,215 1,218 2028 Notes (1) 4.57 % 398 397 2030 Notes (3) 2.21 % 1,510 1,511 2040 Notes (3) 3.04 % 774 775 2047 Notes (1) 4.44 % 495 494 2048 Notes (1) 5.12 % 787 786 2050 Notes (3) 3.21 % 1,571 1,572 2024 Term Loan Facility (4) 3.65 % 625 625 2026 Term Loan Facility (4) 4.92 % 625 625 Commercial Paper (5) 187 324 Amended Revolving Credit facility (6) 100 — Bank overdrafts and other 6 7 Total debt $ 10,970 $ 11,400 Less: Short term borrowings (2) (597) (632) Total Long-term debt $ 10,373 $ 10,768 _______________________ (1) Amount is net of unamortized discount and debt issuance costs. (2) Includes bank borrowings, overdrafts, current portion of long-term debt and commercial paper. (3) Assumed by the Company as part of the N&B Merger. Amount is net of unamortized premium and debt issuance costs. (4) Assumed by the Company as part of the N&B Merger and recorded at fair value. (5) The effective interest rate of commercial paper issuances fluctuate as short-term interest rates and demand fluctuate, and deferred debt issuance costs are immaterial. Additionally, the effective interest rate of commercial paper is not meaningful as issuances do not materially differ from short-term interest rates. Proceeds from the issuance of commercial paper include $225 million of proceeds with original maturities greater than three months. (6) The interest rate on the Amended Revolving Credit Facility is, at the applicable borrower's option, a per annum rate equal to either (x) an eurocurrency rate plus an applicable margin varying from 1.000% to 1.625% or (y) a base rate plus an applicable margin varying from 0.000% to 0.625%, in each case depending on the public debt ratings for non-credit enhanced long-term senior unsecured debt issued by the Company.
Debt Instrument Redemption	However, no make-whole premium will be paid for redemptions of each note on or after the following date: Note Redemption Date 2023 Notes February 1, 2023 2024 Euro Notes December 14, 2023 2026 Euro Notes June 25, 2026 2028 Notes June 26, 2028 2047 Notes December 1, 2046 2048 Notes March 26, 2048
Schedule of Maturities of Long-term Debt	The following table shows the contractual maturities of the Company's long-term debt as of December 31, 2022. Payments Due by Period (DOLLARS IN MILLIONS) Total Less than 1 Year 1-3 Years 3-5 Years More than Total Outstanding Borrowings $ 10,580 $ 300 $ 2,156 $ 2,674 $ 5,450
Nutrition & Biosciences, Inc [Member]
Debt Instrument [Line Items]
Debt Instrument Redemption	The redemption dates of each of the N&B Senior Notes are provided in the table below: Notes Redemption Date 2025 Notes September 1, 2025 2027 Notes August 15, 2027 2030 Notes August 1, 2030 2040 Notes May 15, 2040 2050 Notes June 1, 2050

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lease Costs	The components of lease expense were as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Operating lease cost $ 187 $ 168 $ 62 Finance lease cost 8 7 4 Supplemental cash flow information related to leases was as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow for operating leases $ 135 $ 129 $ 52 Financing cash flow for finance leases 7 6 4 Right-of-use assets obtained in exchange for lease obligations Operating leases 60 88 63 Finance leases 7 15 6 Weighted average remaining lease term and discount rate were as follows: December 31, 2022 2021 Weighted average remaining lease term in years Operating leases 10.1 11.1 Finance leases 4.0 4.3 Weighted average discount rate Operating leases 4.03 % 2.73 % Finance leases 2.59 % 1.85 %
Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 Operating Leases Operating lease right-of-use assets $ 636 $ 767 Current operating lease obligations (2) 86 109 Operating lease liabilities 565 670 Total operating lease liabilities $ 651 $ 779 Finance Leases Finance lease right-of-use assets (1) $ 22 $ 21 Current finance lease obligations (2) 5 5 Finance lease liabilities (3) 12 15 Total finance lease liabilities $ 17 $ 20 _______________________ (1) Presented in Other assets in the Consolidated Balance Sheets. (2) Presented in Other current liabilities in the Consolidated Balance Sheets. (3) Presented in Other liabilities in the Consolidated Balance Sheets.
Lessee, Operating Lease, Liability, Maturity	Maturities of lease liabilities as of December 31, 2022 were as follows: (DOLLARS IN MILLIONS) Operating Leases Finance Leases Total 2023 $ 111 $ 6 $ 117 2024 103 3 106 2025 89 4 93 2026 78 3 81 2027 66 2 68 Thereafter 363 — 363 Total undiscounted liabilities 810 18 828 Less: Imputed interest (159) (1) (160) Total lease liabilities $ 651 $ 17 $ 668

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Earnings before Income Taxes	Earnings before income taxes consisted of the following: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 U.S. loss before taxes $ (1,918) $ (493) $ (142) Foreign income before taxes 293 847 583 Total (loss) income before taxes $ (1,625) $ 354 $ 441
Schedule of Income Tax Provision	The income tax provision consisted of the following: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Current tax provision Federal $ 102 $ (5) $ (9) State and local 49 13 1 Foreign 325 303 150 Total current tax provision 476 311 142 Deferred tax provision Federal (77) (121) (8) State and local (111) (34) (2) Foreign (49) (81) (58) Total deferred tax benefit (237) (236) (68) Total provision for income taxes $ 239 $ 75 $ 74
Schedule of Reconciliation between U.S. Federal Statutory Income Tax Rate to Actual Effective Tax Rate	Reconciliation between the U.S. federal statutory income tax rate to the actual effective tax rate was as follows: December 31, 2022 2021 2020 Statutory tax rate 21.0 % 21.0 % 21.0 % Tax effect of non-deductible goodwill impairment (29.1) — — Difference in effective tax rate on foreign earnings and remittances (1) — 8.0 (6.9) Tax benefit from supply chain optimization 0.8 (5.8) (5.0) Unrecognized tax benefit, net of reversals 0.9 0.7 5.7 Tax impact on gains on business disposal (5.9) 4.0 — Deferred taxes on deemed repatriation (2) (5.6) 2.7 (0.2) Global intangible low-taxed income (0.8) 4.1 5.3 Foreign-derived intangible income 1.1 (1.6) (0.3) U.S. foreign tax credit - general limitation 0.1 (3.1) (1.9) Research and development credit 0.8 (1.4) (1.0) Acquisition costs — 2.4 1.0 Establishment (release) of valuation allowance on state deferred — (3.0) (0.4) State and local taxes including rate changes (3) 4.3 (4.8) (0.6) Other, net (2.3) (2.0) 0.1 Effective tax rate (14.7) % 21.2 % 16.8 % _______________________ (1) For 2021, the rate includes rate change impacts related to the Netherlands and United Kingdom. (2) For 2022, the rate includes establishment of the “held for sale” deferred tax liabilities due to a change in assertion. (3) For 2022, the rate includes rate change impacts related to the remeasurement of the state tax rate on deferred taxes.
Schedule of Deferred Tax Assets and Liabilities	The deferred tax assets and liabilities consisted of the following amounts: December 31, (DOLLARS IN MILLIONS) 2022 2021 Employee and retiree benefits $ 61 $ 148 Credit and net operating loss carryforwards 315 312 Amortizable research and development expenses 84 42 Interest limitation 3 43 Inventory 19 32 Lease obligations 151 189 Other, net 140 79 Gross deferred tax assets 773 845 Property, plant and equipment, net (229) (265) Intangible assets (1) (2,049) (2,486) Right-of-use assets (151) (187) Loss on foreign currency translation (23) (30) Deferred taxes on deemed repatriation (166) (81) Gross deferred tax liabilities (2,618) (3,049) Valuation allowance (262) (232) Total net deferred tax liabilities $ (2,107) $ (2,436)
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Balance of unrecognized tax benefits at beginning of year $ 130 $ 99 $ 75 Gross amount of increases in unrecognized tax benefits as a result of positions taken during a prior year (1) 1 42 11 Gross amount of decreases in unrecognized tax benefits as a result of positions taken during a prior year (18) (3) — Gross amount of increases in unrecognized tax benefits as a result of positions taken during the current year 31 5 24 The amounts of decreases in unrecognized benefits relating to settlements with taxing authorities (27) (1) (2) Reduction in unrecognized tax benefits due to the lapse of applicable statute of limitation (5) (12) (9) Balance of unrecognized tax benefits at end of year $ 112 $ 130 $ 99 _______________________ (1) For 2021, the amount includes positions related to N&B opening balance sheet amounts.

Net Income Per Share (Tables)

Net Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Reconciliation of Shares Used in Computations of Basic and Diluted Net Income Per Share	Basic and diluted net (loss) income per share is based on the weighted average number of shares outstanding. A reconciliation of shares used in the computation of basic and diluted net (loss) income per share is as follows: December 31, (AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS) 2022 2021 2020 Net (Loss) Income Net (loss) income attributable to IFF shareholders $ (1,871) $ 270 $ 363 Adjustment related to (increase) decrease in redemption value of redeemable non-controlling interests in excess of earnings allocated 3 (2) 2 Net (loss) income attributable to IFF shareholders $ (1,868) $ 268 $ 365 Shares Weighted average common shares outstanding (basic) (1) 255 243 112 Adjustment for assumed dilution (2) : Stock options and restricted stock awards — — 1 SPC portion of the TEUs — — 1 Weighted average shares assuming dilution (diluted) 255 243 114 Net (Loss) Income per Share Net (loss) income per share - basic (3) $ (7.32) $ 1.11 $ 3.25 Net (loss) income per share - diluted (4) (7.32) 1.10 3.21 _______________________ (1) On September 15, 2021, additional shares of IFF's common stock were issued in settlement of the SPC portion of the TEUs. For the year ended December 31, 2020, the TEUs were assumed to be outstanding at the minimum settlement amount for basic earnings per share (“EPS”). See below for additional information. (2) Effect of dilutive securities includes dilution under stock plans and incremental impact of TEUs. See below for additional information. (3) For the years ended December 31, 2022, 2021 and 2020, the basic net (loss) income per share cannot be recalculated based on the information presented in the table above due to the effects of rounding. (4) For the years ended December 31, 2022 and 2020, the diluted net (loss) income per share cannot be recalculated based on the information presented in the table above due to the effects of rounding.

Stock Compensation Plans (Table

Stock Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Expense Included in Consolidated Statement of Income and Comprehensive Income	Total stock-based compensation expense included in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income was as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Equity-based awards $ 49 $ 54 $ 36 Liability-based awards 2 8 4 Total stock-based compensation 51 62 40 Less tax benefit (8) (13) (8) Total stock-based compensation, net of tax $ 43 $ 49 $ 32
SSAR's and Stock Option Activity	SSARs and options activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Shares Subject to Weighted SSARs/ December 31, 2021 287 $ 107.48 235 Granted 134 126.91 Exercised (84) 106.66 Canceled (6) 117.04 December 31, 2022 331 $ 115.35 182 Expected to Vest at December 31, 2022 142 $ 122.27
SSAR's and Stock Option Outstanding	SSARs and options outstanding at December 31, 2022 was as follows: Price Range Number Weighted Average Weighted Aggregate Over $65 331 5.65 $ 115.35 $ 2 SSARs and options exercisable as of December 31, 2022 was as follows: Price Range Number Weighted Average Weighted Aggregate Over $65 182 5.05 $ 109.50 $ 2
RSU Activity	RSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Number of Shares Weighted Average December 31, 2021 777 $ 126.20 Granted 556 115.13 Vested (322) 124.62 Forfeited (58) 129.36 Change due to performance conditions, net (16) 120.48 December 31, 2022 937 $ 120.81 Cash RSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Cash RSUs Weighted Average December 31, 2021 116 $ 150.65 Granted 43 104.84 Vested (38) 130.67 Forfeited (2) 107.00 December 31, 2022 119 $ 104.84
PRSU Activity	The following table summarizes the Company's PRSU activity for the years ended December 31, 2022, 2021 and 2020: (DOLLARS IN MILLIONS) Issued Shares Aggregate Purchase Price Covered Shares 2022 43,690 $ 6 21,845 2021 61,870 $ 9 30,935 2020 66,160 $ 9 33,080 PRSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Number of Weighted Average December 31, 2021 155 $ 138.36 Granted 44 126.49 Vested (95) 138.06 Forfeited (14) 135.50 December 31, 2022 90 $ 133.36
Cash RSU Activity	RSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Number of Shares Weighted Average December 31, 2021 777 $ 126.20 Granted 556 115.13 Vested (322) 124.62 Forfeited (58) 129.36 Change due to performance conditions, net (16) 120.48 December 31, 2022 937 $ 120.81 Cash RSU activity was as follows: (SHARE AMOUNTS IN THOUSANDS) Cash RSUs Weighted Average December 31, 2021 116 $ 150.65 Granted 43 104.84 Vested (38) 130.67 Forfeited (2) 107.00 December 31, 2022 119 $ 104.84

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Reportable Segment Information	Reportable segment information is as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Net sales Nourish $ 6,829 $ 6,264 $ 2,886 Health & Biosciences 2,339 2,329 134 Scent 2,301 2,254 2,064 Pharma Solutions 971 809 — Consolidated $ 12,440 $ 11,656 $ 5,084 December 31, (DOLLARS IN MILLIONS) 2022 2021 Segment assets Nourish $ 17,008 $ 17,449 Health & Biosciences 10,877 14,774 Scent 4,310 4,078 Pharma Solutions 3,212 3,357 Consolidated $ 35,407 $ 39,658 December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Segment Adjusted Operating EBITDA: Nourish $ 1,176 $ 1,172 $ 599 Health & Biosciences 634 625 40 Scent 423 463 416 Pharma Solutions 222 165 — Total 2,455 2,425 1,055 Depreciation & Amortization (1,179) (1,156) (325) Interest Expense (336) (289) (132) Other Income, net 37 58 7 Acquisition Related Costs (a) 4 — — Restructuring and Other Charges (12) (41) (17) Gains (Losses) on Sale of Fixed Assets 3 1 (4) Impairment of Goodwill (b) (2,250) — — Impairment of Long-Lived Assets (c) (120) — — Shareholder Activism Related Costs (d) (3) (7) — Business Divestiture Costs (e) (110) (42) — Employee Separation Costs (f) (11) (29) (3) Strategic Initiative Costs (g) (3) — — Global Shared Services Implementation Costs (h) (5) — — Frutarom Acquisition Related Costs (i) (1) (2) (1) Compliance Review & Legal Defense Costs (j) — — (3) N&B Inventory Step-Up Costs — (368) — N&B Transaction Related Costs (k) — (91) (29) Integration Related Costs (l) (94) (105) (107) (Loss) Income Before Taxes $ (1,625) $ 354 $ 441 _______________________ (a) Represents costs related to the acquisition of Health Wright Products, primarily consulting and legal fees, offset in part by earn out adjustments. (b) Represents costs related to the impairment of goodwill in the Health & Biosciences reporting unit. (c) Represents costs related to the impairment of intangible and fixed assets of an asset group that operates primarily in Russia. (d) Represents shareholder activist related costs, primarily professional fees. (e) Represents costs, including establishment of deferred tax liabilities, related to the Company's sales and planned sales of businesses, primarily legal and professional fees. (f) Represents costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated or will separate from the Company. (g) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts, primarily consulting fees. (h) Represents costs related to the Company's efforts of restructuring the Global Shared Services Centers, primarily consulting fees. (i) Represents transaction-related costs and expenses related to the acquisition of Frutarom, primarily includes earn-out payments, net of adjustments. (j) Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits. (k) Represents transaction costs and expenses related to the transaction with N&B, primarily legal and professional fees. (l) Represents costs related to integration activities since 2018, primarily for Frutarom and N&B. For 2022, represents costs primarily related to external consulting fees and internal integration costs, including salaries of individuals who are fully dedicated to integration efforts. For 2021 and 2020, represents costs primarily related to performance stock awards and consulting fees for advisory services. Segment capital expenditures and depreciation and amortization consisted as follows: Capital Expenditures Depreciation and Amortization (DOLLARS IN MILLIONS) 2022 2021 2020 2022 2021 2020 Nourish $ 215 $ 183 $ 98 $ 596 $ 594 $ 211 Health & Biosciences 160 139 7 363 353 36 Scent 56 41 87 81 84 78 Pharma Solutions 73 30 — 139 125 — Consolidated $ 504 $ 393 $ 192 $ 1,179 $ 1,156 $ 325
Long-lived Assets by Geographic Areas	Long-lived assets, net, by country, consisted as follows: December 31, (DOLLARS IN MILLIONS) 2022 2021 United States $ 1,771 $ 2,041 China 258 259 Denmark 250 251 Finland 212 196 France 187 188 Germany 181 156 Other 1,344 1,277 Consolidated $ 4,203 $ 4,368
Net Sales by Geographic Area	Net sales are attributed to individual regions based upon the destination of product delivery and are as follows: Net Sales by Geographic Area (DOLLARS IN MILLIONS) 2022 2021 2020 Europe, Africa and Middle East $ 4,219 $ 4,093 $ 1,987 Greater Asia 2,876 2,728 1,162 North America 3,853 3,499 1,228 Latin America 1,492 1,336 707 Consolidated $ 12,440 $ 11,656 $ 5,084 Net Sales by Geographic Area (DOLLARS IN MILLIONS) 2022 2021 2020 Net sales related to the U.S. $ 3,611 $ 3,211 $ 1,093 Net sales attributed to all foreign countries 8,829 8,445 3,991

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Plan Assets and Benefit Obligations of Defined Benefit Pension Plans	The plan assets and benefit obligations of the defined benefit pension plans are measured at December 31 of each year. U.S. Plans Non-U.S. Plans (DOLLARS IN MILLIONS) 2022 2021 2020 2022 2021 2020 Components of net periodic benefit cost Service cost for benefits earned (1) $ 1 $ 1 $ 1 $ 34 $ 41 $ 24 Interest cost on projected benefit obligation (2) 15 71 17 17 10 13 Expected return on plan assets (2) (21) (106) (28) (42) (55) (46) Net amortization of deferrals (2) 8 29 8 11 19 15 Settlements and curtailments (2) — — — — (10) 5 Net periodic benefit cost (income) 3 (5) (2) 20 5 11 Defined contribution and other retirement plans 33 36 13 29 33 7 Total expense $ 36 $ 31 $ 11 $ 49 $ 38 $ 18 Changes in plan assets and benefit obligations recognized in OCI Net actuarial (gain) loss $ — $ 12 $ (143) $ (135) Recognized actuarial loss (8) (9) (12) (10) Prior service cost — — — (2) Recognized prior service (cost) credit — — 1 1 Currency translation adjustment — — (27) (16) Total (gain) loss recognized in OCI (before tax effects) $ (8) $ 3 $ (181) $ (162) _______________________ (1) Included as a component of Operating Profit. (2) Included as a component of Other Income (Expense), net.
Amounts Expected to be Recognized in Net Periodic Cost	Postretirement Benefits (DOLLARS IN MILLIONS) 2022 2021 2020 Components of net periodic benefit cost Service cost for benefits earned $ 1 $ 1 $ 1 Interest cost on projected benefit obligation 1 7 2 Net amortization and deferrals (5) (20) (5) Total credit $ (3) $ (12) $ (2) Changes in plan assets and benefit obligations recognized in OCI Net actuarial loss $ (16) $ (3) Recognized actuarial loss (1) (2) Recognized prior service credit 6 6 Total recognized in OCI (before tax effects) $ (11) $ 1
Weighted-Average Actuarial Assumption Used to Determine Expense	The weighted-average actuarial assumptions used to determine expense at December 31 of each year are: U.S. Plans Non-U.S. Plans 2022 2021 2020 2022 2021 2020 Discount rate 2.86 % 2.51 % 3.26 % 1.43 % 0.85 % 1.49 % Expected return on plan assets 3.80 % 3.80 % 5.60 % 3.52 % 4.21 % 4.62 % Rate of compensation increase 3.25 % 3.25 % 3.25 % 2.72 % 2.56 % 2.46 %
Changes in Postretirement Benefit Obligation and Plan Assets	Changes in the postretirement benefit obligation and plan assets, as applicable, are detailed in the following table: U.S. Plans Non-U.S. Plans Postretirement Benefits (DOLLARS IN MILLIONS) 2022 2021 2022 2021 2022 2021 Benefit obligation at beginning of year $ 662 $ 682 $ 1,501 $ 1,294 $ 66 $ 69 Service cost for benefits earned 1 1 34 42 1 1 Interest cost on projected benefit obligation 15 12 17 10 2 1 Actuarial (gain) loss (139) (5) (468) (146) (16) (4) Plan amendments — — — (2) — — Adjustments for expense/tax contained in service cost — — (2) (2) — — Plan participants’ contributions — — 4 4 — — Benefits paid (38) (37) (32) (34) (2) (4) Curtailments/settlements — — (21) (39) — — Translation adjustments — — (104) (93) — — Acquisitions/Transferred Liabilities — — — 465 — 3 Other (1) 9 1 2 (1) — Benefit obligation at end of year $ 500 $ 662 $ 930 $ 1,501 $ 50 $ 66 Fair value of plan assets at beginning of year $ 649 $ 678 $ 1,320 $ 1,145 Actual return on plan assets (118) 3 (286) 25 Employer contributions 5 5 31 32 Participants’ contributions — — 4 4 Benefits paid (38) (37) (32) (34) Settlements — — (21) (24) Translation adjustments — — (96) (74) Acquisitions/Transferred Assets — — — 247 Other — — — (1) Fair value of plan assets at end of year $ 498 $ 649 $ 920 $ 1,320 Funded status at end of year $ (2) $ (13) $ (10) $ (181)
Amounts Recognized in Balance Sheet	The amounts recognized in the balance sheet are detailed in the following table: U.S. Plans Non-U.S. Plans (DOLLARS IN MILLIONS) 2022 2021 2022 2021 Other assets $ 51 $ 53 $ 129 $ 83 Other current liabilities (6) (5) (1) (2) Retirement liabilities (47) (61) (138) (262) Net amount recognized $ (2) $ (13) $ (10) $ (181)
Amounts Recognized in Accumulated Other Comprehensive Income	The amounts recognized in AOCI are detailed in the following table: U.S. Plans Non-U.S. Plans Postretirement Benefits (DOLLARS IN MILLIONS) 2022 2021 2022 2021 2022 2021 Net actuarial (gain) loss $ 129 $ 137 $ 110 $ 291 $ (3) $ 14 Prior service cost (credit) — — (3) (3) (9) (15) Total AOCI (before tax effects) $ 129 $ 137 $ 107 $ 288 $ (12) $ (1)
Accumulated Benefit Obligation	U.S. Plans Non-U.S. Plans (DOLLARS IN MILLIONS) 2022 2021 2022 2021 Accumulated Benefit Obligation — end of year $ 495 $ 654 $ 870 $ 1,410 Information for Pension Plans with an ABO in excess of Plan Assets: Projected benefit obligation $ 49 $ 63 $ 169 $ 944 Accumulated benefit obligation 49 62 150 330 Fair value of plan assets — — 86 840 Weighted-average assumptions used to determine obligations at December 31 Discount rate 5.42 % 2.86 % 4.02 % 1.43 % Rate of compensation increase 3.75 % 3.25 % 3.00 % 2.72 %
Estimated Future Benefit Payments	(DOLLARS IN MILLIONS) U.S. Plans Non-U.S. Plans Postretirement Estimated Future Benefit Payments 2023 $ 39 $ 34 $ 3 2024 39 34 3 2025 39 36 4 2026 40 38 4 2027 39 39 4 2028 - 2032 188 223 18 Contributions Required Company Contributions in the Following Year (2023) $ 5 $ 32 $ —
Percentage of Assets Invested	The percentage of assets in the Company’s pension plans, by type, is as follows: U.S. Plans Non-U.S. Plans 2022 2021 2022 2021 Cash and cash equivalents 2 % 1 % 3 % 6 % Equities 47 % 45 % 18 % 18 % Fixed income 51 % 54 % 37 % 34 % Property — % — % 9 % 6 % Alternative and other investments — % — % 33 % 36 %
Fair Value Hierarchy of Plan Assets	The following tables present the Company’s plan assets for the U.S. and non-U.S. plans using the fair value hierarchy as of December 31, 2022 and 2021. The plans’ assets were accounted for at fair value and are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and their placement within the fair value hierarchy levels. For more information on a description of the fair value hierarchy, see Note 16. U.S. Plans for the Year Ended December 31, 2022 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash Equivalents $ — $ 9 $ — $ 9 Fixed Income Securities Government & Government Agency Bonds — 6 — 6 Corporate Bonds — 73 — 73 Municipal Bonds — 5 — 5 Assets measured at net asset value (1) 404 Total $ — $ 93 $ — $ 497 Receivables $ 1 Total $ 498 U.S. Plans for the Year Ended December 31, 2021 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash Equivalents $ — $ 5 $ — $ 5 Fixed Income Securities Government & Government Agency Bonds — 15 — 15 Corporate Bonds — 77 — 77 Municipal Bonds — 4 — 4 Assets measured at net asset value (1) 547 Total $ — $ 101 $ — $ 648 Receivables $ 1 Total $ 649 _______________________ (1) Investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in the table above are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets. The total amount measured at net asset value includes approximately $234 million and $294 million in pooled equity funds and $170 million and $253 million in fixed income mutual funds for the years ended December 31, 2022 and 2021, respectively. Non-U.S. Plans for the Year Ended December 31, 2022 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash $ 14 $ 9 $ — $ 23 Equity Securities U.S. Large Cap 73 — — 73 U.S. Mid Cap 6 — — 6 Non-U.S. Large Cap 79 — — 79 Non-U.S. Mid Cap 4 — — 4 Non-U.S. Small Cap 1 — — 1 Emerging Markets 7 — — 7 Fixed Income Securities U.S. Corporate Bonds 35 — — 35 Non-U.S. Treasuries/Government Bonds 144 — — 144 Non-U.S. Corporate Bonds 34 75 — 109 Non-U.S. Asset-Backed Securities — 46 — 46 Non-U.S. Other Fixed Income 2 — — 2 Alternative Types of Investments Insurance Contracts — 177 — 177 Derivative Financial Instruments — 56 — 56 Absolute Return Funds 4 2 — 6 Other — 64 3 67 Property Non-U.S. Property 4 — 81 85 Total $ 407 $ 429 $ 84 $ 920 Non-U.S. Plans for the Year Ended December 31, 2021 (DOLLARS IN MILLIONS) Level 1 Level 2 Level 3 Total Cash $ 37 $ 36 $ — $ 73 Equity Securities U.S. Large Cap 100 — — 100 Non-U.S. Large Cap 104 — — 104 Non-U.S. Mid Cap 1 — — 1 Non-U.S. Small Cap 1 — — 1 Emerging Markets 30 — — 30 Fixed Income Securities U.S. Corporate Bonds 42 — — 42 Non-U.S. Treasuries/Government Bonds 162 — — 162 Non-U.S. Corporate Bonds 58 137 — 195 Non-U.S. Asset-Backed Securities — 51 — 51 Non-U.S. Other Fixed Income 2 — — 2 Alternative Types of Investments Insurance Contracts — 265 — 265 Derivative Financial Instruments — 91 — 91 Absolute Return Funds 4 110 — 114 Other — 2 10 12 Property Non-U.S. Property 5 — 72 77 Total $ 546 $ 692 $ 82 $ 1,320
Reconciliation of Level 3 Non-U.S. Plan Assets Held	The following table presents a reconciliation of Level 3 non-U.S. plan assets held during the year ended December 31, 2022: Non-U.S. Plans (DOLLARS IN MILLIONS) Property Hedge Total Ending balance as of December 31, 2021 $ 72 $ 10 $ 82 Actual return on plan assets (2) (1) (3) Purchases, sales and settlements 11 (6) 5 Ending balance as of December 31, 2022 $ 81 $ 3 $ 84
Weighted Average Assumptions Used to Determine Postretirement Benefit Expense and Obligation	The following weighted average assumptions were used to determine the postretirement benefit expense and obligation for the years ended December 31: Expense Liability 2022 2021 2022 2021 Discount rate 2.90 % 2.60 % 5.40 % 2.90 % Current medical cost trend rate 6.75 % 7.00 % 6.50 % 6.75 % Ultimate medical cost trend rate 4.75 % 4.75 % 4.75 % 4.75 % Medical cost trend rate decreases to ultimate rate in year 2030 2030 2030 2030
Sensitivity of Disclosures to Changes in Selected Assumptions	The following table presents the sensitivity of disclosures to changes in selected assumptions for the year ended December 31, 2022: (DOLLARS IN MILLIONS) U.S. Pension Plans Non-U.S. Pension Plans Postretirement Benefit Plan 25 Basis Point Decrease in Discount Rate Change in PBO $ 12 $ 38 N/A Change in ABO 11 37 1 Change in pension expense — 5 — 25 Basis Point Decrease in Long-Term Rate of Return Change in pension expense 1 3 N/A

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Carrying Amount and Estimated Fair Value of Financial Instruments	The carrying value and the estimated fair values of financial instruments at December 31 consisted of the following: 2022 2021 (DOLLARS IN MILLIONS) Carrying Value Fair Carrying Value Fair LEVEL 1 Cash and cash equivalents (1) $ 483 $ 483 $ 711 $ 711 LEVEL 2 Credit facilities and bank overdrafts (2) 106 106 7 7 Derivatives Derivative assets (3) 20 20 — — Derivative liabilities (3) 56 56 7 7 Commercial paper (2) 187 187 324 324 Long-term debt: 2022 Notes (4) — — 300 300 2023 Notes (4) 300 298 300 308 2024 Euro Notes (4) 532 519 565 585 2025 Notes (4) 1,000 884 1,001 968 2026 Euro Notes (4) 845 774 900 960 2027 Notes (4) 1,215 1,006 1,218 1,180 2028 Notes (4) 398 380 397 452 2030 Notes (4) 1,510 1,188 1,511 1,466 2040 Notes (4) 774 535 775 762 2047 Notes (4) 495 390 494 585 2048 Notes (4) 787 685 786 1,026 2050 Notes (4) 1,571 1,021 1,572 1,556 2024 Term Loan Facility (5) 625 625 625 625 2026 Term Loan Facility (5) 625 625 625 625 _______________________ (1) The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments. (2) The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments. (3) The carrying amount approximates fair value as the instruments are marked-to-market and held at fair value on the Consolidated Balance Sheets. (4) The fair value of the Note is obtained from pricing services engaged by the Company, and the Company receives one price for each security. The fair value provided by the pricing services are estimated using pricing models, where the inputs to those models are based on observable market inputs or recent trades of similar securities. The inputs to the valuation techniques applied by the pricing services are typically benchmark yields, benchmark security prices, credit spreads, reported trades and broker-dealer quotes, all with reasonable levels of transparency. (5) The carrying amount approximates fair value as the Term Loans were assumed at fair value and the interest rate is reset frequently based on current market rates.
Derivative Instruments Notional Amount Outstanding	The following table shows the notional amount of the Company’s derivative instruments outstanding as of December 31, 2022 and December 31, 2021: December 31, (DOLLARS IN MILLIONS) 2022 2021 Foreign currency contracts (1) $ 92 $ 46 Commodity contracts (1) (1) 10 Cross currency swaps 1,400 300 ______________________ (1) Foreign currency contracts and commodity contracts are presented net of contracts bought and sold.
Derivative Instruments Measured at Fair Value	The following tables show the Company’s derivative instruments measured at fair value (Level 2 of the fair value hierarchy) as reflected in the Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021: December 31, 2022 (DOLLARS IN MILLIONS) Fair Value of Derivatives Fair Value of Derivatives Not Designated as Hedging Instruments Total Fair Value Derivative assets (1) Foreign currency contracts $ — $ 1 $ 1 Cross currency swaps 19 — 19 Total derivative assets $ 19 $ 1 $ 20 Derivative liabilities (2) Cross currency swaps $ 56 $ — $ 56 December 31, 2021 (DOLLARS IN MILLIONS) Fair Value of Derivatives Designated as Hedging Instruments Fair Value of Derivatives Not Designated as Hedging Instruments Total Fair Value Derivative liabilities (2) Foreign currency contracts $ — $ 2 $ 2 Cross currency swaps 5 — 5 Total derivative liabilities $ 5 $ 2 $ 7 _______________________ (1) Derivative assets are recorded to Other assets in the Consolidated Balance Sheets. (2) Derivative liabilities are recorded as Other current liabilities in the Consolidated Balance Sheets.
Derivative Instruments Which Were Not Designated as Hedging Instruments	The following table shows the effect of the Company’s derivative instruments which were not designated as hedging instruments in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the years ended December 31, 2022 and December 31, 2021: (DOLLARS IN MILLIONS) Amount of Gain (Loss) Location of Gain (Loss) 2022 2021 Foreign currency contracts $ 7 $ 6 Other (income) expense, net
Derivative Instruments Designated as Cash Flow and Net Investment Hedging Instruments	The following table shows the effect of the Company’s derivative instruments designated as cash flow and net investment hedging instruments, net of tax, in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income for the years ended December 31, 2022 and December 31, 2021: Amount of Gain (Loss) Location of Gain Amount of Gain (Loss) Reclassified from AOCI For the years ended For the years ended (DOLLARS IN MILLIONS) 2022 2021 2022 2021 Derivatives in Cash Flow Hedging Relationships: Foreign currency contracts $ — $ 7 Cost of goods sold $ — $ (6) Interest rate swaps (1) — 1 Interest expense — (1) Derivatives in Net Investment Hedging Relationships: Cross currency swaps (16) 14 N/A — — Non-Derivatives in Net Investment Hedging Relationships: 2024 Euro Notes 27 38 N/A — — 2021 Euro Notes & 2026 Euro Notes 43 72 N/A — — Total $ 54 $ 132 $ — $ (7) _______________________ (1) Interest rate swaps were entered into as pre-issuance hedges for the Company's bond offerings.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)	The following tables present changes in the accumulated balances for each component of other comprehensive income (loss), including current period other comprehensive income (loss) and reclassifications out of accumulated other comprehensive income (loss): (DOLLARS IN MILLIONS) Foreign (Losses) Gains on Derivatives Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2021 $ (1,133) $ 1 $ (291) $ (1,423) OCI before reclassifications (904) — 148 (756) Amounts reclassified from AOCI — — 10 10 Net current period other comprehensive income (loss) (904) — 158 (746) Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2022 $ (2,037) $ 1 $ (133) $ (2,169) (DOLLARS IN MILLIONS) Foreign (Losses) Gains on Derivatives Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2020 $ (285) $ (7) $ (406) $ (698) OCI before reclassifications (848) 1 97 (750) Amounts reclassified from AOCI — 7 18 25 Net current period other comprehensive income (loss) (848) 8 115 (725) Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2021 $ (1,133) $ 1 $ (291) $ (1,423) (DOLLARS IN MILLIONS) Foreign (Losses) Gains on Derivatives Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2019 $ (373) $ 2 $ (346) $ (717) OCI before reclassifications 88 (5) (74) 9 Amounts reclassified from AOCI — (4) 14 10 Net current period other comprehensive income (loss) 88 (9) (60) 19 Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2020 $ (285) $ (7) $ (406) $ (698)
Reclassifications of Accumulated Other Comprehensive Income to Consolidated Statement of Comprehensive Income	The following table provides details about reclassifications out of Accumulated other comprehensive loss to the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income: Year Ended December 31, (DOLLARS IN MILLIONS) 2022 2021 2020 Affected Line Item in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Losses) gains on derivatives qualifying as hedges Foreign currency contracts $ — $ (7) $ 6 Cost of goods sold Interest rate swaps — (1) (1) Interest expense Tax — 1 (1) Provision for income taxes Total $ — $ (7) $ 4 Total, net of income taxes (Losses) gains on pension and postretirement liability adjustments Prior service cost $ 7 $ 7 $ 7 (1) Actuarial losses (21) (38) (30) (1) Other items — 17 — (2) Tax 4 (4) 9 Provision for income taxes Total $ (10) $ (18) $ (14) Total, net of income taxes _______________________ (1) The amortization of prior service cost and actuarial loss is included in the computation of net periodic benefit cost. Refer to Note 15 to the Consolidated Financial Statements for additional information regarding net periodic benefit cost. (2) Represents certain amounts of pension income that were corrected in 2021.

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interests (Tables)	12 Months Ended
	Dec. 31, 2022
Noncontrolling Interest [Abstract]
Schedule of Redeemable Noncontrolling Interest	The following table sets forth the details of the Company's redeemable non-controlling interests: (DOLLARS IN MILLIONS) Redeemable Balance at December 31, 2019 $ 99 Impact of foreign exchange translation 13 Share of profit or loss attributable to redeemable non-controlling interests 3 Redemption value adjustment for the current period (2) Measurement period adjustments (1) Dividends paid (2) Exercises of redeemable non-controlling interests (12) Balance at December 31, 2020 $ 98 Impact of foreign exchange translation 1 Share of profit or loss attributable to redeemable non-controlling interests 6 Redemption value adjustment for the current period 2 Dividends paid (2) Balance at December 31, 2021 $ 105 Impact of foreign exchange translation (6) Share of profit or loss attributable to redeemable non-controlling interests 4 Redemption value adjustment for the current period 5 Exercises of redeemable non-controlling interests (49) Balance at December 31, 2022 $ 59

Discontinued Operations and Dis

Discontinued Operations and Disposal Groups (Tables)	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held for Sale	The following table summarizes the fair value of the sale consideration received in connection with the divestiture: (DOLLARS IN MILLIONS) Cash proceeds from the buyer $ 1,254 Escrow proceeds 15 Proceeds attributable to transition service agreements (36) Direct costs to sell (11) Net cash settlement for post-closing adjustments (3) Fair value of sale consideration $ 1,219 (DOLLARS IN MILLIONS) Fair value of sale consideration $ 1,219 Cash transferred to the buyer on the closing balance sheet (49) Employee reimbursement receivable (1) Net proceeds received from business divestiture $ 1,169 (DOLLARS IN MILLIONS) June 30, 2022 Assets Current assets $ 263 Goodwill and other intangible assets, net 867 Equity method investment 74 Other assets 80 Total assets $ 1,284 Liabilities Accounts payable $ 41 Other liabilities 35 Total liabilities $ 76 Included in the Company’s Consolidated Balance Sheets as of December 31, 2022 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2022 Assets Cash and cash equivalents $ 52 Trade receivables, net 85 Inventories 157 Property, plant and equipment, net 92 Goodwill 348 Other intangible assets, net 428 Operating lease right-of-use assets 13 Other assets 25 Total assets held-for-sale $ 1,200 Liabilities Accounts payable $ 56 Deferred tax liability (1) 92 Other liabilities 64 Total liabilities held-for-sale $ 212 _______________________ (1) The Company is currently analyzing the tax impact of the sale transaction and has included preliminary numbers for the deferred tax liability, which are subject to further updates. Included in the Company’s Consolidated Balance Sheets as of December 31, 2021 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2021 Assets Trade receivables, net $ 63 Inventories 125 Property, plant and equipment, net 30 Goodwill 536 Other intangible assets, net 349 Operating lease right-of-use assets 5 Other assets 14 Total assets held-for-sale $ 1,122 Liabilities Accounts payable $ 69 Deferred tax liability 24 Other liabilities 8 Total liabilities held-for-sale $ 101

Assets Held For Sale (Tables)

Assets Held For Sale (Tables)	12 Months Ended
	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held for Sale	The following table summarizes the fair value of the sale consideration received in connection with the divestiture: (DOLLARS IN MILLIONS) Cash proceeds from the buyer $ 1,254 Escrow proceeds 15 Proceeds attributable to transition service agreements (36) Direct costs to sell (11) Net cash settlement for post-closing adjustments (3) Fair value of sale consideration $ 1,219 (DOLLARS IN MILLIONS) Fair value of sale consideration $ 1,219 Cash transferred to the buyer on the closing balance sheet (49) Employee reimbursement receivable (1) Net proceeds received from business divestiture $ 1,169 (DOLLARS IN MILLIONS) June 30, 2022 Assets Current assets $ 263 Goodwill and other intangible assets, net 867 Equity method investment 74 Other assets 80 Total assets $ 1,284 Liabilities Accounts payable $ 41 Other liabilities 35 Total liabilities $ 76 Included in the Company’s Consolidated Balance Sheets as of December 31, 2022 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2022 Assets Cash and cash equivalents $ 52 Trade receivables, net 85 Inventories 157 Property, plant and equipment, net 92 Goodwill 348 Other intangible assets, net 428 Operating lease right-of-use assets 13 Other assets 25 Total assets held-for-sale $ 1,200 Liabilities Accounts payable $ 56 Deferred tax liability (1) 92 Other liabilities 64 Total liabilities held-for-sale $ 212 _______________________ (1) The Company is currently analyzing the tax impact of the sale transaction and has included preliminary numbers for the deferred tax liability, which are subject to further updates. Included in the Company’s Consolidated Balance Sheets as of December 31, 2021 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) December 31, 2021 Assets Trade receivables, net $ 63 Inventories 125 Property, plant and equipment, net 30 Goodwill 536 Other intangible assets, net 349 Operating lease right-of-use assets 5 Other assets 14 Total assets held-for-sale $ 1,122 Liabilities Accounts payable $ 69 Deferred tax liability 24 Other liabilities 8 Total liabilities held-for-sale $ 101

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting Policies - Additional Information (Detail) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2019 USD ($)
Organization And Summary Of Significant Accounting Policies [Line Items]
Accounts receivable, before allowance for credit loss	$ 1,871	$ 1,952
Cash and cash equivalents	483	711	$ 650
Restricted cash	10	4	7
Cash and cash equivalents	52	0	0
Restricted Cash, Noncurrent	7	1	3
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	552	716	660		$ 624
Proceeds from sale of accounts receivable	1,030	668	351
Trade receivables, held-for-sale, amount	212	153	57
Receivables, Net, Current	1,818
Accounts Receivable, Allowance for Credit Loss	$ 53	46	21
Accounts Receivables, Outstanding By Over 365 Days	1%			1%
Accounts Receivable, Credit Loss Expense (Reversal)	$ 19	6
Accounts Receivable, Allowance for Credit Loss, Writeoff		(1)
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)		20
Accounts Receivable, Allowance for Credit Loss, Foreign Currency Translation	(12)
Operating lease right-of-use assets	636	767
Operating Lease, Liability	651	779
Cumulative adjustment relating to the adoption of ASC 2016-16	17,714	21,117	6,322		6,229
Impairment of long-lived assets	120	0	0
Impairment of goodwill	$ 2,250	0	0
Minimum percentage chance of tax benefit realization in final settlement	50%			50%
Prior service costs from plan improvements amortization period, minimum, years	10 years
Prior service costs from plan improvements amortization period, maximum, years	20 years
Amortization period of internal and external development costs, years	7 years
Inventories	$ 3,151	2,516
Health & Biosciences
Organization And Summary Of Significant Accounting Policies [Line Items]
Impairment of goodwill	2,250
Russia And Ukraine Conflict
Organization And Summary Of Significant Accounting Policies [Line Items]
Accounts Receivable, Credit Loss Expense (Reversal)	11
Impairment of long-lived assets	120
Russia And Ukraine Conflict | Finite-Lived Intangible Assets
Organization And Summary Of Significant Accounting Policies [Line Items]
Asset impairment charges	92
Russia And Ukraine Conflict | Property, Plant and Equipment
Organization And Summary Of Significant Accounting Policies [Line Items]
Asset impairment charges	$ 28
Minimum | Customer Relationships
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	10 years
Minimum | Patents [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	11 years
Minimum | Trade Names [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	4 years
Minimum | Technological Know-how [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	5 years
Minimum | Buildings And Improvements [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property, plant and equipment, years	1 year
Minimum | Machinery and equipment [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property, plant and equipment, years	1 year
Minimum | Information Technology Hardware And Software [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property, plant and equipment, years	1 year
Maximum | Customer Relationships
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	27 years
Maximum | Patents [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	15 years
Maximum | Trade Names [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	28 years
Maximum | Technological Know-how [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Other intangible assets amortized period, years	28 years
Maximum | Buildings And Improvements [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property, plant and equipment, years	50 years
Maximum | Machinery and equipment [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property, plant and equipment, years	40 years
Maximum | Information Technology Hardware And Software [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of property, plant and equipment, years	23 years
Retained earnings
Organization And Summary Of Significant Accounting Policies [Line Items]
Cumulative adjustment relating to the adoption of ASC 2016-16	$ 955	3,641	4,156		$ 4,118
Trade Accounts Receivable With Factoring Agreements [Member]
Organization And Summary Of Significant Accounting Policies [Line Items]
Accounts receivable, factoring receivable program, maximum amount | €				€ 250
Payments to participate in factoring receivable program	$ 12	$ 6	$ 4

Nature of Operations and Summ_5

Nature of Operations and Summary of Significant Accounting Policies - Schedule of Inventory (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory, Raw Materials, Net of Reserves	$ 1,073	$ 854
Inventory, Work in Process, Net of Reserves	442	287
Inventory, Finished Goods, Net of Reserves	1,636	1,375
Total	$ 3,151	$ 2,516

Restructuring and Other Charg_3

Restructuring and Other Charges - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) Position Facility	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) Position	Sep. 30, 2022 USD ($)
Restructuring Cost and Reserve [Line Items]
Additional charges, net	$ 12	$ 41	$ 17
Restructuring Reserve [Roll Forward]
Balance	29	14	21
Additional Charges (Reversals), Net	12	41	17
Non-Cash Charges	(5)	(8)	(12)
Cash Payments	(21)	(18)	(12)
Balance	15	29	14	$ 21
Nutrition & Biosciences, Inc [Member]
Restructuring Reserve [Roll Forward]
Additional Charges (Reversals), Net	15
Restructuring and Related Cost, Cost Incurred to Date	$ 45
Frutarom Integration Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of sites closed | Facility	30
Number Of Sites Closed | Facility	22
Restructuring Reserve [Roll Forward]
Restructuring and Related Cost, Cost Incurred to Date	$ 39
Restructuring and Related Cost, Expected Cost	42
2017 Productivity Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring and Related Cost, Cost Incurred to Date			24
Severance
Restructuring Reserve [Roll Forward]
Balance	1	2	0
Additional Charges (Reversals), Net	0	0	3
Non-Cash Charges	0	0	0
Cash Payments	0	(1)	(1)
Balance	1	1	2	0
Restructuring and Related Cost, Cost Incurred to Date	4
Severance | Nutrition & Biosciences, Inc [Member]
Restructuring Reserve [Roll Forward]
Balance	15	0
Additional Charges (Reversals), Net	8	27
Non-Cash Charges	0	0
Cash Payments	(14)	(12)
Balance	$ 9	15	0
Restructuring and Related Cost, Number of Positions Eliminated | Position	240
Severance | Frutarom Integration Initiative [Member]
Restructuring Reserve [Roll Forward]
Balance	$ 5	3	4
Additional Charges (Reversals), Net	1	5	2
Non-Cash Charges	0	0	0
Cash Payments	(2)	(3)	(3)
Balance	4	5	3	4
Severance | 2019 Severance Initiatives [Member]
Restructuring Reserve [Roll Forward]
Balance	5	6	13
Additional Charges (Reversals), Net	(5)	0	(1)
Non-Cash Charges	0	0	0
Cash Payments	0	(1)	(6)
Balance	0	5	6	$ 13
Restructuring and Related Cost, Cost Incurred to Date					$ 15
Restructuring and Related Cost, Number of Positions Eliminated | Position				190
Severance | 2017 Productivity Program [Member]
Restructuring Reserve [Roll Forward]
Balance		0	1
Additional Charges (Reversals), Net			(1)
Non-Cash Charges			0
Cash Payments			0
Balance			0	$ 1
Other(1)
Restructuring Reserve [Roll Forward]
Balance	0	0
Additional Charges (Reversals), Net		1
Non-Cash Charges		0
Cash Payments		(1)
Balance		0	0
Other(1) | Nutrition & Biosciences, Inc [Member]
Restructuring Reserve [Roll Forward]
Balance	0	0
Additional Charges (Reversals), Net	7	3
Non-Cash Charges	(2)	(3)
Cash Payments	(4)	0
Balance	1	0	0
Other(1) | Frutarom Integration Initiative [Member]
Restructuring Reserve [Roll Forward]
Balance	3	3	3
Additional Charges (Reversals), Net	(2)	0	2
Non-Cash Charges	0	0	0
Cash Payments	(1)	0	(2)
Balance	0	3	3	3
Fixed asset write down | Frutarom Integration Initiative [Member]
Restructuring Reserve [Roll Forward]
Balance	0	0	0
Additional Charges (Reversals), Net	3	5	12
Non-Cash Charges	(3)	(5)	(12)
Cash Payments	0	0	0
Balance	0	0	0	$ 0
Scent [Member]
Restructuring Cost and Reserve [Line Items]
Additional charges, net	$ 1	$ 3	$ 7

Restructuring and Other Charg_4

Restructuring and Other Charges - Movements in Restructuring and Related Accruals (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Reserve [Roll Forward]
Balance	$ 29	$ 14	$ 21
Additional Charges (Reversals), Net	12	41	17
Non-Cash Charges	(5)	(8)	(12)
Cash Payments	(21)	(18)	(12)
Balance	15	29	14
Additional charges, net	12	41	17
Nutrition & Biosciences, Inc [Member]
Restructuring Reserve [Roll Forward]
Additional Charges (Reversals), Net	15
Severance
Restructuring Reserve [Roll Forward]
Balance	1	2	0
Additional Charges (Reversals), Net	0	0	3
Non-Cash Charges	0	0	0
Cash Payments	0	(1)	(1)
Balance	1	1	2
Severance | Nutrition & Biosciences, Inc [Member]
Restructuring Reserve [Roll Forward]
Balance	15	0
Additional Charges (Reversals), Net	8	27
Non-Cash Charges	0	0
Cash Payments	(14)	(12)
Balance	9	15	0
Other(1)
Restructuring Reserve [Roll Forward]
Balance	0	0
Additional Charges (Reversals), Net		1
Non-Cash Charges		0
Cash Payments		(1)
Balance		0	0
Other(1) | Nutrition & Biosciences, Inc [Member]
Restructuring Reserve [Roll Forward]
Balance	0	0
Additional Charges (Reversals), Net	7	3
Non-Cash Charges	(2)	(3)
Cash Payments	(4)	0
Balance	1	0	0
Scent [Member]
Restructuring Reserve [Roll Forward]
Additional charges, net	1	3	7
Pharma Solutions
Restructuring Reserve [Roll Forward]
Additional charges, net	1	1	0
Nourish
Restructuring Reserve [Roll Forward]
Additional charges, net	8	32	10
Health & Biosciences
Restructuring Reserve [Roll Forward]
Additional charges, net	2	5	0
Frutarom Integration Initiative [Member] | Severance
Restructuring Reserve [Roll Forward]
Balance	5	3	4
Additional Charges (Reversals), Net	1	5	2
Non-Cash Charges	0	0	0
Cash Payments	(2)	(3)	(3)
Balance	4	5	3
Frutarom Integration Initiative [Member] | Fixed asset write down
Restructuring Reserve [Roll Forward]
Balance	0	0	0
Additional Charges (Reversals), Net	3	5	12
Non-Cash Charges	(3)	(5)	(12)
Cash Payments	0	0	0
Balance	0	0	0
Frutarom Integration Initiative [Member] | Other(1)
Restructuring Reserve [Roll Forward]
Balance	3	3	3
Additional Charges (Reversals), Net	(2)	0	2
Non-Cash Charges	0	0	0
Cash Payments	(1)	0	(2)
Balance	0	3	3
2019 Severance Initiatives [Member] | Severance
Restructuring Reserve [Roll Forward]
Balance	5	6	13
Additional Charges (Reversals), Net	(5)	0	(1)
Non-Cash Charges	0	0	0
Cash Payments	0	(1)	(6)
Balance	$ 0	5	6
2017 Productivity Program [Member] | Severance
Restructuring Reserve [Roll Forward]
Balance		$ 0	1
Additional Charges (Reversals), Net			(1)
Non-Cash Charges			0
Cash Payments			0
Balance			$ 0

Acquisitions - Health Wright Pr

Acquisitions - Health Wright Products (Details) - USD ($) $ in Millions		12 Months Ended
	Apr. 01, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 13,355	$ 16,414	$ 5,593
Health Wright Products, Inc. (“Health Wright”)
Business Acquisition [Line Items]
Percentage of voting interest acquired	100%
Business combination, consideration transferred	$ 157
Contingent consideration, liability	31
Intangible assets	75
Goodwill	45
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		$ 5
Health Wright Products, Inc. (“Health Wright”) | Customer Relationships
Business Acquisition [Line Items]
Intangible assets	$ 74
Other intangible assets amortized period, years	19 years

Acquisitions - Nutrition & Bios

Acquisitions - Nutrition & Biosciences, Inc (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended	12 Months Ended
	Feb. 01, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Dec. 15, 2019
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)		$ 0.125	$ 0.125		$ 0.125
Goodwill		$ 16,414	$ 16,414	$ 5,593	$ 13,355
Net defined benefit plan assets		136	136		180
Cash paid to acquire business	$ 7,500
Nourish
Business Acquisition [Line Items]
Goodwill		6,555	6,555	4,859	6,050
Health & Biosciences
Business Acquisition [Line Items]
Goodwill		6,749	6,749	0	4,321
Pharma Solutions
Business Acquisition [Line Items]
Goodwill		1,282	1,282	0	1,239
Scent [Member]
Business Acquisition [Line Items]
Goodwill		1,828	1,828	734	$ 1,745
International Flavors & Fragrances Inc
Business Acquisition [Line Items]
Sale of Stock, Percentage of Ownership after Transaction	44.60%
Nutrition & Biosciences, Inc [Member]
Business Acquisition [Line Items]
Business acquisition, equity interest issued or issuable, number of shares	141,740,461
Common stock, par value (in dollars per share)	$ 0.125					$ 0.125
Business Acquisition, Net Sales			6,084
Business Acquisition, Net Income (Loss)			11
Fair value of common stock issued to DuPont stockholders	$ 15,929
Fair value attributable to pre-merger service for replacement equity awards	25
Pension funding adjustment	(12)
Business combination, consideration transferred	$ 15,942
Business acquisition share price	$ 112.38
Net pension balance differential amount settled in cash	$ 220
Cash and cash equivalents	207	193	193
Receivables	962	953	953
Inventory	1,615	1,590	1,590
Prepaid expenses and other current assets	342	374	374
Property, plant and equipment	3,242	3,066	3,066
Deferred income taxes	75	83	83
Intangible assets	9,176	9,223	9,223
Other assets	702	818	818
Accounts payable and accrued liabilities	(1,028)	(1,079)	(1,079)
Accrued payroll and employee benefits	(163)	(148)	(148)
Deferred tax liabilities	(2,369)	(2,395)	(2,395)
Long-term debt	(7,636)	(7,636)	(7,636)
Other long-term liabilities	(907)	(895)	(895)
Total identifiable net assets assumed	4,218	4,147	4,147
Non-controlling interest	(26)	(22)	(22)
Goodwill	11,762	11,817	11,817
Purchase price	15,954	15,942	15,942
Finite-lived intangible assets			9,210
Lease adjustment	15
Net defined benefit plan liabilities	221
Acquisition related costs	75
Transaction costs		91	91	29
Unaudited pro forma net sales			12,163	11,143
Unaudited pro forma net income attributable to the Company			687	$ 192
Cash paid to acquire business	7,359
Nutrition & Biosciences, Inc [Member] | In Process Research and Development
Business Acquisition [Line Items]
Indefinite-lived intangible assets			13
Nutrition & Biosciences, Inc [Member] | Microcrystalline Cellulose
Business Acquisition [Line Items]
Acquisition related costs	$ 61
Nutrition & Biosciences, Inc [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets			261
Nutrition & Biosciences, Inc [Member] | Customer Relationships
Business Acquisition [Line Items]
Finite-lived intangible assets			6,734
Nutrition & Biosciences, Inc [Member] | Technological Know-Hows
Business Acquisition [Line Items]
Finite-lived intangible assets			2,194
Nutrition & Biosciences, Inc [Member] | Other [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets			$ 21
Useful Lives			2 years
Nutrition & Biosciences, Inc [Member] | Nourish
Business Acquisition [Line Items]
Goodwill		2,900	$ 2,900
Nutrition & Biosciences, Inc [Member] | Health & Biosciences
Business Acquisition [Line Items]
Goodwill		6,712	6,712
Nutrition & Biosciences, Inc [Member] | Pharma Solutions
Business Acquisition [Line Items]
Goodwill		1,329	1,329
Nutrition & Biosciences, Inc [Member] | Scent [Member]
Business Acquisition [Line Items]
Goodwill		876	876
Nutrition & Biosciences, Inc [Member] | Restatement Adjustment
Business Acquisition [Line Items]
Cash and cash equivalents		(14)	(14)
Receivables		(9)	(9)
Inventory		(25)	(25)
Prepaid expenses and other current assets		32	32
Property, plant and equipment		(176)	(176)
Deferred income taxes		8	8
Intangible assets		47	47
Other assets		116	116
Accounts payable and accrued liabilities		(51)	(51)
Accrued payroll and employee benefits		15	15
Deferred tax liabilities		(26)	(26)
Long-term debt		0	0
Other long-term liabilities		12	12
Total identifiable net assets assumed		(71)	(71)
Non-controlling interest		4	4
Goodwill		55	55
Purchase price		(12)	$ (12)
Nutrition & Biosciences, Inc [Member] | Minimum
Business Acquisition [Line Items]
Dilutive Shares Quotient Multiplier	44.60%
Nutrition & Biosciences, Inc [Member] | Minimum | Trade Names [Member]
Business Acquisition [Line Items]
Useful Lives			4 years
Nutrition & Biosciences, Inc [Member] | Minimum | Customer Relationships
Business Acquisition [Line Items]
Useful Lives			11 years
Nutrition & Biosciences, Inc [Member] | Minimum | Technological Know-Hows
Business Acquisition [Line Items]
Useful Lives			5 years
Nutrition & Biosciences, Inc [Member] | Maximum
Business Acquisition [Line Items]
Dilutive Shares Quotient Multiplier	55.40%
Nutrition & Biosciences, Inc [Member] | Maximum | Trade Names [Member]
Business Acquisition [Line Items]
Useful Lives			22 years
Nutrition & Biosciences, Inc [Member] | Maximum | Customer Relationships
Business Acquisition [Line Items]
Useful Lives			27 years
Nutrition & Biosciences, Inc [Member] | Maximum | Technological Know-Hows
Business Acquisition [Line Items]
Useful Lives			18 years
Nutrition & Biosciences, Inc [Member] | DuPont de Nemours, Inc [Member]
Business Acquisition [Line Items]
Adjustment on cash payment from DuPont		$ 53
Nutrition & Biosciences, Inc [Member] | International Flavors & Fragrances Inc | DuPont de Nemours, Inc [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired	55.40%

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 6,180	$ 6,161
Accumulated depreciation	(1,977)	(1,793)
Property, plant and equipment, net	4,203	4,368
Depreciation expense	452	424	$ 132
Property, Plant and Equipment | Russia And Ukraine Conflict
Property, Plant and Equipment [Line Items]
Asset impairment charges	28
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	199	223
Buildings and improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,697	1,764
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,344	3,442
Information technology [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	291	271
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 649	$ 461

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2022
Goodwill [Line Items]
Goodwill, period increase (decrease)		$ 0
Reporting unit in excess of carrying amount				25%
Impairment of goodwill	$ 2,250	0	$ 0
Goodwill	13,355	16,414	5,593
Health & Biosciences
Goodwill [Line Items]
Goodwill, period increase (decrease)		(728)
Impairment of goodwill	2,250
Goodwill	4,321	6,749	0
Pharma Solutions
Goodwill [Line Items]
Goodwill, period increase (decrease)		0
Impairment of goodwill	0
Goodwill	1,239	$ 1,282	$ 0
Finite-Lived Intangible Assets | Russia And Ukraine Conflict
Goodwill [Line Items]
Asset impairment charges	92
Health & Biosciences
Goodwill [Line Items]
Reporting unit in excess of carrying amount				3%
Impairment of goodwill	$ 2,250

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net - Goodwill Rollforward (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Goodwill	$ 16,414	$ 5,593
Foreign exchange	(506)	(433)
Reallocation		0
Acquisitions	45	11,817
Transferred to assets held for sale(4)	(348)	(536)
Reduction from business divestiture		(27)
Goodwill	13,355	16,414	$ 5,593
Goodwill, Impairment Loss	(2,250)	0	0
Health & Biosciences
Goodwill [Roll Forward]
Goodwill, Impairment Loss	(2,250)
Nourish
Goodwill [Roll Forward]
Goodwill	6,555	4,859
Foreign exchange	(199)	(192)
Reallocation		(985)
Acquisitions	0	2,900
Transferred to assets held for sale(4)	(306)	0
Reduction from business divestiture		(27)
Goodwill	6,050	6,555	4,859
Goodwill, Impairment Loss	0
Health & Biosciences
Goodwill [Roll Forward]
Goodwill	6,749	0
Foreign exchange	(223)	(155)
Reallocation		728
Acquisitions	45	6,712
Transferred to assets held for sale(4)	0	(536)
Reduction from business divestiture		0
Goodwill	4,321	6,749	0
Goodwill, Impairment Loss	(2,250)
Scent [Member]
Goodwill [Roll Forward]
Goodwill	1,828	734
Foreign exchange	(41)	(39)
Reallocation		257
Acquisitions	0	876
Transferred to assets held for sale(4)	(42)	0
Reduction from business divestiture		0
Goodwill	1,745	1,828	734
Goodwill, Impairment Loss	0
Pharma Solutions
Goodwill [Roll Forward]
Goodwill	1,282	0
Foreign exchange	(43)	(47)
Reallocation		0
Acquisitions	0	1,329
Transferred to assets held for sale(4)	0	0
Reduction from business divestiture		0
Goodwill	1,239	$ 1,282	$ 0
Goodwill, Impairment Loss	$ 0

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, Net - Trademark and Other Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	$ 11,062	$ 11,890
Total accumulated amortization	(1,980)	(1,384)
Other intangible assets, net	9,082	10,506
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	8,318	8,935
Total accumulated amortization	(1,252)	(887)
Technological Know-how [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	2,339	2,494
Total accumulated amortization	(589)	(388)
Trade Names and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	358	411
Total accumulated amortization	(97)	(68)
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	47	50
Total accumulated amortization	$ (42)	$ (41)

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, Net - Amortization Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of acquisition-related intangibles	$ 727	$ 732	$ 193
2023	703
2024	702
2025	699
2026	697
2027	$ 598

Other Assets And Liabilities,_3

Other Assets And Liabilities, Current and Noncurrent - Schedule of Other Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Other Assets [Abstract]
Value-added tax receivable	$ 212	$ 178
Income tax receivable	129	131
Packaging materials	148	128
Prepaid expenses	144	160
Accounts and Other Receivables, Net, Current	137	131
Other Assets, Current	770	728
Finance lease right-of-use assets	22	21
Deferred Income Taxes and Other Assets, Noncurrent	158	82
Overfunded pension plans	180	136
Cash surrender value of life insurance contracts	45	52
Other	284	239
Total	699	616
Equity Method Investments	$ 10	$ 86

Other Assets And Liabilities,_4

Other Assets And Liabilities, Current and Noncurrent - Schedule of Other Current Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Rebates and incentives payable	$ 99	$ 113
Value-added tax payable	65	50
Interest payable	55	48
Current pension and other postretirement benefit obligation	10	11
Accrued insurance (including workers’ compensation)	9	10
Restructuring and other charges	$ 15	$ 29	$ 14	$ 21
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Total	Total
Current operating lease obligation	$ 86	$ 109
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Total	Total
Current financing lease obligation	$ 5	$ 5
Accrued freight	18	0
Accrued Sales Commission, Current	11	13
Accrued income taxes	313	94
Accrued expenses payable	256	270
Other	91	85
Total	$ 1,028	$ 832

Debt - Components of Debt (Deta

Debt - Components of Debt (Detail) € in Millions, $ in Millions

12 Months Ended

Sep. 15, 2022 USD ($)

Aug. 04, 2022

Sep. 30, 2021 USD ($)

Sep. 29, 2021 USD ($)

Sep. 25, 2021 EUR (€)

Jul. 28, 2021 USD ($)

Feb. 01, 2021 USD ($)

May 18, 2017 USD ($)

Mar. 14, 2016 EUR (€)

Apr. 04, 2013 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2019 USD ($)

Sep. 16, 2020 USD ($)

Aug. 25, 2020 USD ($)

May 15, 2020 USD ($)

Sep. 26, 2018 USD ($)

Sep. 25, 2018 USD ($)

Sep. 25, 2018 EUR (€)

Jun. 06, 2018 USD ($)

Debt Instrument [Line Items]

Commercial Paper

$ 187

$ 324

Debt, Long-Term and Short-Term, Combined Amount

10,970

11,400

Long-term Debt, Current Maturities

(597)

(632)

Long-term debt

10,373

10,768

Proceeds from Issuance of Commercial Paper

6,040

800

Repayments of Commercial Paper

6,177

476

Long-term Debt

10,580

Commercial paper with original maturities greater than 3 months

225

Proceeds from Issuance of Commercial Paper

6,040

800

Repayments of Commercial Paper

6,177

476

Revolving Loan Facility [Member]

Debt Instrument [Line Items]

Revolving credit facility

902

$ 1,000

Revolving credit facility

902

$ 1,000

Revolving Loan Facility [Member] | Citibank, N.A [Member]

Debt Instrument [Line Items]

Revolving credit facility

$ 2,000

2,000

Line of Credit Facility, Increase (Decrease), Net

2,500

Line of credit

100

Proceeds from Lines of Credit

550

0

Revolving credit facility

$ 2,000

$ 2,000

Senior Notes, Euro Notes, 2021 [Member]

Debt Instrument [Line Items]

Interest rate of debt

0.50%

0.50%

Repayments of Debt | €

€ 300

Senior notes | €

€ 300

Repayments of Debt | €

€ 300

Senior Notes, Due Two Thousand Twenty Two | Loans Payable [Member]

Debt Instrument [Line Items]

Interest rate of debt

0.69%

Senior Notes, Current

$ 0

300

Repayments of Debt

$ 300

Repayments of Debt

$ 300

Senior Notes, Due Two Thousand Twenty Two | Loans Payable [Member] | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Interest rate of debt

0.697%

Senior Notes, Current

$ 300

Senior Notes - 2023 [Member]

Debt Instrument [Line Items]

Interest rate of debt

3.20%

Senior notes

$ 300

Proceeds related to the issuance of Senior Notes

$ 298

Senior Notes - 2023 [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Interest rate of debt

3.30%

Senior Notes, Current

$ 300

Senior Notes, Euro Notes, 2024 [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.75%

Senior notes | €

€ 500

Debt instrument, term

8 years

Proceeds related to the issuance of Senior Notes | €

€ 496

Senior Notes, Euro Notes, 2026 [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.80%

1.80%

Senior notes | €

€ 800

Senior Notes - 2028 [Member]

Debt Instrument [Line Items]

Interest rate of debt

4.45%

Senior notes

$ 400

Senior notes - 2047 [Member]

Debt Instrument [Line Items]

Interest rate of debt

4.375%

Senior notes

$ 500

Proceeds related to the issuance of Senior Notes

$ 494

Senior Notes - 2048 [Member]

Debt Instrument [Line Items]

Interest rate of debt

5%

Senior notes

$ 800

Term Loan Credit Agreement [Member]

Debt Instrument [Line Items]

Repayments of Debt

$ 120

$ 120

$ 110

Repayments of Debt

$ 120

$ 120

$ 110

Term Loan Credit Agreement [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Revolving credit facility

$ 350

Revolving credit facility

$ 350

2022 Term Loan [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Revolving credit facility

$ 200

Revolving credit facility

$ 200

2024 Term Loan

Debt Instrument [Line Items]

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Third Full Fiscal Quarter

4.25

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Sixth Full Fiscal Quarter

4

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Ninth Full Fiscal Quarter

3.75

2026 Term Loan

Debt Instrument [Line Items]

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Third Full Fiscal Quarter

4.25

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Sixth Full Fiscal Quarter

4

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Ninth Full Fiscal Quarter

3.75

Bank overdrafts and other [Member]

Debt Instrument [Line Items]

Bank overdrafts and other

6

7

Revolving Loan Facility [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Line of credit

$ 100

0

Minimum | Revolving Loan Facility [Member] | Citibank, N.A [Member]

Debt Instrument [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

3.50

Minimum | 2024 Term Loan

Debt Instrument [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

3.50

Minimum | 2026 Term Loan

Debt Instrument [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

3.50

Maximum | Revolving Loan Facility [Member] | Citibank, N.A [Member]

Debt Instrument [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

4.50

Maximum | 2024 Term Loan

Debt Instrument [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

4.50

4.75

Maximum | 2026 Term Loan

Debt Instrument [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

4.50

4.75

Loans Payable [Member] | Senior Notes - 2023 [Member]

Debt Instrument [Line Items]

Senior notes

300

Loans Payable [Member] | Senior Notes, Euro Notes, 2024 [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.88%

Senior notes

$ 532

565

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Five

Debt Instrument [Line Items]

Interest rate of debt

1.22%

Senior notes

$ 1,000

1,001

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Five | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.23%

Senior notes

$ 1,000

Margin on variable rate

0.15%

Loans Payable [Member] | Senior Notes, Euro Notes, 2026 [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.93%

Senior notes

$ 845

900

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Seven

Debt Instrument [Line Items]

Interest rate of debt

1.56%

Senior notes

$ 1,215

1,218

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Seven | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.832%

Senior notes

$ 1,200

Margin on variable rate

0.25%

Loans Payable [Member] | Senior Notes - 2028 [Member]

Debt Instrument [Line Items]

Interest rate of debt

4.57%

Senior notes

$ 398

397

Loans Payable [Member] | Senior Notes, Due Two Thousand Thirty

Debt Instrument [Line Items]

Interest rate of debt

2.21%

Senior notes

$ 1,510

1,511

Loans Payable [Member] | Senior Notes, Due Two Thousand Thirty | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Interest rate of debt

2.30%

Senior notes

$ 1,500

Margin on variable rate

0.25%

Loans Payable [Member] | Senior Notes, Due Two Thousand Forty

Debt Instrument [Line Items]

Interest rate of debt

3.04%

Senior notes

$ 774

775

Loans Payable [Member] | Senior Notes, Due Two Thousand Forty | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Interest rate of debt

3.268%

Senior notes

$ 750

Margin on variable rate

0.30%

Loans Payable [Member] | Senior notes - 2047 [Member]

Debt Instrument [Line Items]

Interest rate of debt

4.44%

Senior notes

$ 495

494

Loans Payable [Member] | Senior Notes - 2048 [Member]

Debt Instrument [Line Items]

Interest rate of debt

5.12%

Senior notes

$ 787

786

Loans Payable [Member] | Senior Notes, Due Two Thousand Fifty

Debt Instrument [Line Items]

Interest rate of debt

3.21%

Senior notes

$ 1,571

1,572

Loans Payable [Member] | Senior Notes, Due Two Thousand Fifty | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Interest rate of debt

3.468%

Senior notes

$ 1,500

Margin on variable rate

0.30%

Loans Payable [Member] | 2024 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

3.65%

Senior notes

$ 625

625

Loans Payable [Member] | 2026 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

4.92%

Senior notes

$ 625

$ 625

Loans Payable [Member] | Nutrition & Biosciences, Inc Senior Notes | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Debt Instrument, Redemption Price, Percentage

100%

Unsecured Debt [Member] | 2024 Term Loan | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Debt, face amount

$ 625

Unsecured Debt [Member] | 2026 Term Loan | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Debt, face amount

625

Unsecured Debt [Member] | Senior Unsecured Notes [Member] | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Debt, face amount

6,250

$ 6,250

Unsecured Debt [Member] | Senior Unsecured Term Loan Facilities [Member] | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Debt, face amount

$ 1,250

Unsecured Debt [Member] | Minimum | Senior Unsecured Notes [Member] | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Debt instrument, term

2 years

Unsecured Debt [Member] | Maximum | Senior Unsecured Notes [Member] | Nutrition & Biosciences, Inc [Member]

Debt Instrument [Line Items]

Debt instrument, term

30 years

Senior Notes, Euro Notes, 2021 [Member]

Debt Instrument [Line Items]

Long-term Debt

$ 350

298

Senior Notes, Euro Notes, 2026 [Member]

Debt Instrument [Line Items]

Long-term Debt

$ 932

€ 794

Senior Notes - 2028 [Member]

Debt Instrument [Line Items]

Long-term Debt

397

Senior Notes - 2048 [Member]

Debt Instrument [Line Items]

Long-term Debt

$ 787

London Interbank Offered Rate (LIBOR) [Member] | Minimum | 2022 Term Loan [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.225%

London Interbank Offered Rate (LIBOR) [Member] | Maximum | 2022 Term Loan [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Interest rate of debt

2.475%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | Minimum | 2024 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

0.75%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | Minimum | 2026 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

1.125%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | Maximum | 2024 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

2%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | Maximum | 2026 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

2.375%

Base Rate [Member] | Minimum | Revolving Loan Facility [Member] | Citibank, N.A [Member]

Debt Instrument [Line Items]

Margin on variable rate

0%

Base Rate [Member] | Minimum | 2022 Term Loan [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Interest rate of debt

0.225%

Base Rate [Member] | Maximum | Revolving Loan Facility [Member] | Citibank, N.A [Member]

Debt Instrument [Line Items]

Margin on variable rate

0.625%

Base Rate [Member] | Maximum | 2022 Term Loan [Member] | Loans Payable [Member]

Debt Instrument [Line Items]

Interest rate of debt

1.475%

Base Rate [Member] | Loans Payable [Member] | Minimum | 2024 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

0%

Base Rate [Member] | Loans Payable [Member] | Minimum | 2026 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

0.125%

Base Rate [Member] | Loans Payable [Member] | Maximum | 2024 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

1%

Base Rate [Member] | Loans Payable [Member] | Maximum | 2026 Term Loan

Debt Instrument [Line Items]

Interest rate of debt

1.375%

Debt - Additional Information (

Debt - Additional Information (Detail) € in Millions, $ in Millions

12 Months Ended

Sep. 15, 2022 USD ($)

Aug. 04, 2022

Sep. 30, 2021 USD ($)

Sep. 29, 2021 USD ($)

Sep. 25, 2021 EUR (€)

Jul. 28, 2021 USD ($)

Feb. 01, 2021 USD ($)

Jun. 06, 2018 USD ($)

May 18, 2017 USD ($)

Mar. 14, 2016 USD ($)

Mar. 14, 2016 EUR (€)

Apr. 04, 2013 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2019 USD ($)

Sep. 16, 2020 USD ($)

Aug. 25, 2020 USD ($)

May 15, 2020 USD ($)

Sep. 26, 2018 USD ($)

Sep. 25, 2018 USD ($)

Sep. 25, 2018 EUR (€)

Mar. 14, 2016 EUR (€)

Schedule Of Borrowings [Line Items]

Repurchase price of principal amount of Senior Notes in percentage

101%

Long-term Debt

$ 10,580

Proceeds from Issuance of Commercial Paper

6,040

$ 800

Repayments of Commercial Paper

6,177

476

Revolving Loan Facility [Member]

Schedule Of Borrowings [Line Items]

Revolving credit facility

902

$ 1,000

Term Loan Credit Agreement [Member]

Schedule Of Borrowings [Line Items]

Repayments of Debt

$ 120

$ 120

$ 110

Term Loan Credit Agreement [Member] | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Revolving credit facility

$ 350

2022 Term Loan [Member] | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Revolving credit facility

$ 200

Senior Notes, Euro Notes, 2021 [Member]

Schedule Of Borrowings [Line Items]

Repayments of Debt | €

€ 300

Interest rate of debt

0.50%

0.50%

Senior notes | €

€ 300

Senior Notes, Euro Notes, 2024 [Member]

Schedule Of Borrowings [Line Items]

Debt instrument, term

8 years

8 years

Senior notes | €

€ 500

Interest rate of debt

1.75%

1.75%

Senior notes discount | €

€ 1

Proceeds related to the issuance of Senior Notes | €

€ 496

Underwriting discount | €

€ 3

Other deferred costs

$ 1

Gain (loss) on pre-issuance hedges

$ (3)

2026 Term Loan

Schedule Of Borrowings [Line Items]

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Third Full Fiscal Quarter

4.25

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Sixth Full Fiscal Quarter

4

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Ninth Full Fiscal Quarter

3.75

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To Credit Adjusted EBITDA With Step-Downs Over Time, Fourth Step-Down

3.50

2026 Term Loan | Minimum

Schedule Of Borrowings [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

3.50

2026 Term Loan | Maximum

Schedule Of Borrowings [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

4.50

4.75

Revolving Loan Facility [Member] | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Line of credit

$ 100

0

2024 Term Loan

Schedule Of Borrowings [Line Items]

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Third Full Fiscal Quarter

4.25

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Sixth Full Fiscal Quarter

4

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To EBITDA With Step-Downs Over Time, Ninth Full Fiscal Quarter

3.75

Debt Instrument, Covenant Compliance, Ratio Of Net Debt To Credit Adjusted EBITDA With Step-Downs Over Time, Fourth Step-Down

3.50

2024 Term Loan | Minimum

Schedule Of Borrowings [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

3.50

2024 Term Loan | Maximum

Schedule Of Borrowings [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

4.50

4.75

Senior Notes, Due Two Thousand Twenty Two | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Repayments of Debt

$ 300

Interest rate of debt

0.69%

Senior Notes, Current

$ 0

300

Senior Notes, Due Two Thousand Twenty Two | Loans Payable [Member] | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Interest rate of debt

0.697%

Senior Notes, Current

$ 300

Senior Notes, Euro Notes, 2026 [Member]

Schedule Of Borrowings [Line Items]

Senior notes | €

€ 800

Interest rate of debt

1.80%

1.80%

Senior Notes - 2028 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 400

Interest rate of debt

4.45%

Senior Notes - 2048 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 800

Interest rate of debt

5%

Senior Notes - 2023 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 300

Interest rate of debt

3.20%

Senior notes discount

$ 1

Proceeds related to the issuance of Senior Notes

298

Underwriting discount

2

Other deferred costs

$ 1

Senior Notes - 2023 [Member] | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Interest rate of debt

3.30%

Senior Notes, Current

$ 300

Senior notes - 2047 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 500

Interest rate of debt

4.375%

Senior notes discount

$ 2

Proceeds related to the issuance of Senior Notes

494

Underwriting discount

4

Other deferred costs

1

Gain (loss) on pre-issuance hedges

$ (5)

Loans Payable [Member] | Senior Notes, Euro Notes, 2024 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 532

565

Interest rate of debt

1.88%

Loans Payable [Member] | 2026 Term Loan

Schedule Of Borrowings [Line Items]

Senior notes

$ 625

625

Interest rate of debt

4.92%

Loans Payable [Member] | 2024 Term Loan

Schedule Of Borrowings [Line Items]

Senior notes

$ 625

625

Interest rate of debt

3.65%

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Five

Schedule Of Borrowings [Line Items]

Senior notes

$ 1,000

1,001

Interest rate of debt

1.22%

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Five | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Margin on variable rate

0.15%

Senior notes

$ 1,000

Interest rate of debt

1.23%

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Seven

Schedule Of Borrowings [Line Items]

Senior notes

$ 1,215

1,218

Interest rate of debt

1.56%

Loans Payable [Member] | Senior Notes, Due Two Thousand Twenty Seven | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Margin on variable rate

0.25%

Senior notes

$ 1,200

Interest rate of debt

1.832%

Loans Payable [Member] | Senior Notes, Due Two Thousand Thirty

Schedule Of Borrowings [Line Items]

Senior notes

$ 1,510

1,511

Interest rate of debt

2.21%

Loans Payable [Member] | Senior Notes, Due Two Thousand Thirty | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Margin on variable rate

0.25%

Senior notes

$ 1,500

Interest rate of debt

2.30%

Loans Payable [Member] | Senior Notes, Due Two Thousand Forty

Schedule Of Borrowings [Line Items]

Senior notes

$ 774

775

Interest rate of debt

3.04%

Loans Payable [Member] | Senior Notes, Due Two Thousand Forty | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Margin on variable rate

0.30%

Senior notes

$ 750

Interest rate of debt

3.268%

Loans Payable [Member] | Senior Notes, Due Two Thousand Fifty

Schedule Of Borrowings [Line Items]

Senior notes

$ 1,571

1,572

Interest rate of debt

3.21%

Loans Payable [Member] | Senior Notes, Due Two Thousand Fifty | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Margin on variable rate

0.30%

Senior notes

$ 1,500

Interest rate of debt

3.468%

Loans Payable [Member] | Senior Notes, Euro Notes, 2026 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 845

900

Interest rate of debt

1.93%

Loans Payable [Member] | Senior Notes - 2028 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 398

397

Interest rate of debt

4.57%

Loans Payable [Member] | Senior Notes - 2048 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 787

786

Interest rate of debt

5.12%

Loans Payable [Member] | Senior Notes - 2023 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

300

Loans Payable [Member] | Senior notes - 2047 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 495

494

Interest rate of debt

4.44%

Unsecured Debt [Member] | 2026 Term Loan | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Debt, face amount

$ 625

Unsecured Debt [Member] | 2024 Term Loan | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Debt, face amount

625

Unsecured Debt [Member] | Senior Unsecured Notes [Member] | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Debt, face amount

$ 6,250

$ 6,250

Unsecured Debt [Member] | Senior Unsecured Notes [Member] | Minimum | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Debt instrument, term

2 years

Unsecured Debt [Member] | Senior Unsecured Notes [Member] | Maximum | Nutrition & Biosciences, Inc [Member]

Schedule Of Borrowings [Line Items]

Debt instrument, term

30 years

Senior Notes, Euro Notes, 2021 [Member]

Schedule Of Borrowings [Line Items]

Long-term Debt

$ 350

€ 298

Senior Notes, Euro Notes, 2026 [Member]

Schedule Of Borrowings [Line Items]

Long-term Debt

$ 932

€ 794

Senior Notes - 2028 [Member]

Schedule Of Borrowings [Line Items]

Long-term Debt

$ 397

Senior Notes - 2048 [Member]

Schedule Of Borrowings [Line Items]

Long-term Debt

$ 787

London Interbank Offered Rate (LIBOR) [Member] | 2022 Term Loan [Member] | Minimum | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Interest rate of debt

1.225%

London Interbank Offered Rate (LIBOR) [Member] | 2022 Term Loan [Member] | Maximum | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Interest rate of debt

2.475%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | 2026 Term Loan | Minimum

Schedule Of Borrowings [Line Items]

Interest rate of debt

1.125%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | 2026 Term Loan | Maximum

Schedule Of Borrowings [Line Items]

Interest rate of debt

2.375%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | 2024 Term Loan | Minimum

Schedule Of Borrowings [Line Items]

Interest rate of debt

0.75%

London Interbank Offered Rate (LIBOR) [Member] | Loans Payable [Member] | 2024 Term Loan | Maximum

Schedule Of Borrowings [Line Items]

Interest rate of debt

2%

Base Rate [Member] | 2022 Term Loan [Member] | Minimum | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Interest rate of debt

0.225%

Base Rate [Member] | 2022 Term Loan [Member] | Maximum | Loans Payable [Member]

Schedule Of Borrowings [Line Items]

Interest rate of debt

1.475%

Base Rate [Member] | Loans Payable [Member] | 2026 Term Loan | Minimum

Schedule Of Borrowings [Line Items]

Interest rate of debt

0.125%

Base Rate [Member] | Loans Payable [Member] | 2026 Term Loan | Maximum

Schedule Of Borrowings [Line Items]

Interest rate of debt

1.375%

Base Rate [Member] | Loans Payable [Member] | 2024 Term Loan | Minimum

Schedule Of Borrowings [Line Items]

Interest rate of debt

0%

Base Rate [Member] | Loans Payable [Member] | 2024 Term Loan | Maximum

Schedule Of Borrowings [Line Items]

Interest rate of debt

1%

Citibank, N.A [Member] | Revolving Loan Facility [Member]

Schedule Of Borrowings [Line Items]

Revolving credit facility

$ 2,000

$ 2,000

Debt related commitment fees and debt issuance costs

$ 1

Line of credit

100

Proceeds from Lines of Credit

550

0

Repayments of Lines of Credit

$ 450

0

Line of Credit Facility, Increase (Decrease), Net

$ 2,500

Citibank, N.A [Member] | Revolving Loan Facility [Member] | Minimum

Schedule Of Borrowings [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

3.50

Citibank, N.A [Member] | Revolving Loan Facility [Member] | Maximum

Schedule Of Borrowings [Line Items]

Maximum ratio of net debt to EBI TDA with step-downs over time

4.50

Citibank, N.A [Member] | Base Rate [Member] | Revolving Loan Facility [Member] | Minimum

Schedule Of Borrowings [Line Items]

Margin on variable rate

0%

Citibank, N.A [Member] | Base Rate [Member] | Revolving Loan Facility [Member] | Maximum

Schedule Of Borrowings [Line Items]

Margin on variable rate

0.625%

Citibank, N.A [Member] | Eurocurrency Rate | Revolving Loan Facility [Member] | Minimum

Schedule Of Borrowings [Line Items]

Margin on variable rate

1%

Citibank, N.A [Member] | Eurocurrency Rate | Revolving Loan Facility [Member] | Maximum

Schedule Of Borrowings [Line Items]

Margin on variable rate

1.625%

Carrying Amount [Member] | Senior Notes - 2028 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 398

397

Carrying Amount [Member] | Senior Notes - 2048 [Member]

Schedule Of Borrowings [Line Items]

Senior notes

$ 787

$ 786

Debt - Schedule of Debt Maturit

Debt - Schedule of Debt Maturities (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Total	$ 10,580
Less than 1 Year	300
1-3 Years	5,450
3-5 Years	2,156
More than 5 Years	$ 2,674
Debt Instrument Redemption	However, no make-whole premium will be paid for redemptions of each note on or after the following date: Note Redemption Date 2023 Notes February 1, 2023 2024 Euro Notes December 14, 2023 2026 Euro Notes June 25, 2026 2028 Notes June 26, 2028 2047 Notes December 1, 2046 2048 Notes March 26, 2048

Tangible Equity Units (Details)

Tangible Equity Units (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Sep. 17, 2018	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Tangible equity units issued	16,500,000
Tangible equity units proceeds	$ 800
Price for basic share (in dollars per share)		$ 0.330911	$ 0.313400

Tangible Equity Units (Allocati

Tangible Equity Units (Allocation of TEU) (Details) $ in Millions	Sep. 17, 2018 USD ($)
Tangible Equity Units [Line Items]
Net Proceeds	$ 800

Tangible Equity Units Tangible

Tangible Equity Units Tangible Equity - Settlement of Shares (Details) - $ / shares	Sep. 15, 2021	Sep. 14, 2021
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services	5,460,031
Tangible Equity Units Final Settlement Rate		$ 0.330911

Leases (Details)

Leases (Details) - USD ($) $ in Millions	Dec. 31, 2022	Apr. 01, 2022	Dec. 31, 2021	Feb. 01, 2021
Lessee, Lease, Description [Line Items]
Remaining term lease	50 years
Renewal term	7 years
Operating lease right-of-use assets	$ 636		$ 767
Operating Lease, Liability	651		779
Finance Lease, Liability	$ 17		$ 20
Nutrition & Biosciences, Inc [Member]
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets				$ 525
Operating Lease, Liability				$ 523
Health Wright Products, Inc. (“Health Wright”)
Lessee, Lease, Description [Line Items]
Finance Lease, Liability		$ 21

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 187	$ 168	$ 62
Finance lease cost	$ 8	$ 7	$ 4

Leases - Cash Flow (Details)

Leases - Cash Flow (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating cash flow for operating leases	$ 135	$ 129	$ 52
Financing cash flow for finance leases	7	6	4
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	60	88	63
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 7	$ 15	$ 6

Leases - Balance Sheet (Details

Leases - Balance Sheet (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease right-of-use assets	$ 636	$ 767
Current operating lease obligation	86	109
Operating lease liabilities	565	670
Operating Lease, Liability	651	779
Finance Lease, Right-of-Use Asset	22	21
Current financing lease obligation	5	5
Finance Lease, Liability, Noncurrent	12	15
Finance Lease, Liability	$ 17	$ 20
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other liabilities	Other liabilities

Leases - Weighted Average (Deta

Leases - Weighted Average (Details)	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease weighted average remaining lease term	10 years 1 month 6 days	11 years 1 month 6 days
Finance lease weighted average remaining lease term	4 years	4 years 3 months 18 days
Operating lease weighted average discount rate	4.03%	2.73%
Finance lease weighted average discount rate	2.59%	1.85%

Leases - Schedule of Lease Matu

Leases - Schedule of Lease Maturities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease, less than 1 year	$ 111
Lessee, Operating Lease, Liability, to be Paid, Year Two	103
Lessee, Operating Lease, Liability, to be Paid, Year Three	89
Lessee, Operating Lease, Liability, to be Paid, Year Four	78
Lessee, Operating Lease, Liability, to be Paid, Year Five	66
Operating lease, After 5 years	363
Less Imputed Interest	(159)
Operating Lease, Liability	651	$ 779
Lessee, Operating Lease, Liability, to be Paid, Total	810
Financing lease, less than 1 year	6
Finance Lease, Liability, to be Paid, Year Two	3
Finance Lease, Liability, to be Paid, Year Three	4
Finance Lease, Liability, to be Paid, Year Four	3
Finance Lease, Liability, to be Paid, Year Five	2
Financing lease, After 5 years	0
Less Imputed Interest	(1)
Finance Lease, Liability	17	$ 20
Finance Lease, Liability, Payment, Due, Total	18
Lessee, Operating and Finance Lease, Liability, to be Paid, Year One	117
Lessee, Operating and Finance Lease, Liability, to be Paid, Year Two	106
Lessee, Operating and Finance Lease, Liability, to be Paid, Year Three	93
Lessee, Operating and Finance Lease, Liability, to be Paid, Year Four	81
Lessee, Operating and Finance Lease, Liability, to be Paid, Year Five	68
Lessee, Operating and Finance Lease, Liability, to be Paid, after Year Five	363
Lessee, Operating and Finance Lease, Payments, Due	828
Lessee, Operating and Finance Lease, Liability, Undiscounted Excess Amount	160
Operating and Finance Lease, Liability	$ 668

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2022	Apr. 01, 2022	Dec. 31, 2021	Feb. 01, 2021
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 636		$ 767
Operating Lease, Liability	651		779
Finance Lease, Right-of-Use Asset	22		21
Finance Lease, Liability	$ 17		$ 20
Nutrition & Biosciences, Inc [Member]
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets				$ 525
Operating Lease, Liability				$ 523
Health Wright Products, Inc. (“Health Wright”)
Lessee, Lease, Description [Line Items]
Finance Lease, Right-of-Use Asset		$ 22
Finance Lease, Liability		$ 21

Income Taxes - Schedule of Earn

Income Taxes - Schedule of Earnings before Income Taxes (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. loss before taxes	$ (1,918)	$ (493)	$ (142)
Foreign income before taxes	293	847	583
(Loss) income before taxes	$ (1,625)	$ 354	$ 441

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current tax provision
Federal	$ 102	$ (5)	$ (9)
State and local	49	13	1
Foreign	(325)	(303)	(150)
Total current income tax provision	476	311	142
Deferred tax provision
Federal	(77)	(121)	(8)
State and local	(111)	(34)	(2)
Foreign	(49)	(81)	(58)
Total deferred income tax provision	(237)	(236)	(68)
Total provision for income taxes	$ 239	$ 75	$ 74

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory tax rate	21%	21%	21%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount	(29.10%)	0%	0%
Difference in effective tax rate on foreign earnings and remittances(1)	0%	8%	(6.90%)
Tax benefit from supply chain optimization	0.80%	(5.80%)	(5.00%)
Unrecognized tax benefit, net of reversals	0.90%	0.70%	5.70%
Tax impact on gains on business disposal	(5.90%)	4%	0%
Deferred taxes on deemed repatriation(2)	(5.60%)	2.70%	(0.20%)
Global intangible low-taxed income	(0.80%)	4.10%	5.30%
Foreign-derived intangible income	1.10%	(1.60%)	(0.30%)
U.S. foreign tax credit - general limitation	0.10%	(3.10%)	(1.90%)
Research and development credit	0.80%	(1.40%)	(1.00%)
Acquisition costs	0%	2.40%	1%
Establishment (release) of valuation allowance on state deferred	0%	(3.00%)	(0.40%)
State and local taxes including rate changes(3)	4.30%	(4.80%)	(0.60%)
Other, net	(2.30%)	(2.00%)	0.10%
Effective tax rate	(14.70%)	21.20%	16.80%

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation between U.S. Federal Statutory Income Tax Rate to Actual Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory tax rate	21%	21%	21%
Release of valuation allowance on state deferred	0%	(3.00%)	(0.40%)
State and local taxes	4.30%	(4.80%)	(0.60%)
Other, net	(2.30%)	(2.00%)	0.10%
Effective tax rate	(14.70%)	21.20%	16.80%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Line Items]
Global Intangible Low-Taxed Income Expense	$ 112
Global Intangible Low-Taxed Income, Tax Credit, Foreign	$ 99
U.S. federal tax rate	21%	21%	21%
Dividend deduction percentage	100%
Valuation allowance	$ 262	$ 232
Operating loss carryforwards	315	312
Deferred tax asset	315
Valuation allowance for net operating loss carryforwards	261
Reduction in accrual for interest and penalties	1	19	$ 3
Unrecognized tax benefits, including interest	147
Tax Credit Carryforward, Valuation Allowance	1
Deferred Tax Liabilities, Deemed Repatriation	166	81
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations	5	12	9
Unrecognized Tax Benefits, Reduction Resulting From Lapse Of Applicable Statue of Limitations, Next Twelve Months	18
Other liabilities [Member]
Income Taxes [Line Items]
Unrecognized tax benefits that would impact effective tax rate	98	130	98
Other Current Liabilities [Member]
Income Taxes [Line Items]
Unrecognized tax benefits that would impact effective tax rate	14	1	1
2018 to 2037 [Member]
Income Taxes [Line Items]
Operating loss carryforwards	301
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	98
Tax credit carryforwards	14
Indefinite [Member]
Income Taxes [Line Items]
Operating loss carryforwards	203
Two Thousand Twenty Two To Two Thousand Forty One
Income Taxes [Line Items]
Operating loss carryforwards		272
Tax credit carryforwards		40
Other Liabilities [Member]
Income Taxes [Line Items]
Accrued interest and penalties	31	36	17
Other Current Liabilities [Member]
Income Taxes [Line Items]
Accrued interest and penalties	4	$ 1	$ 1
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Valuation allowance	1
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Deferred Tax Liabilities, Deemed Repatriation	166
Foreign Tax Authority [Member]
Income Taxes [Line Items]
Deferred Tax Liabilities, Deemed Repatriation	$ 0

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Employee and retiree benefits	$ 61	$ 148
Credit and net operating loss carryforwards	315	312
Deferred Tax Assets, in Process Research and Development	84	42
Interest limitation	3	43
Inventory	19	32
Deferred Tax Asset Lease Obligations	151	189
Other, net	140	79
Gross deferred tax assets	773	845
Property, plant and equipment, net	(229)	(265)
Intangible assets(1)	(2,049)	(2,486)
Deferred Tax Liabilities, Right of Use Assets	(151)	(187)
Loss on foreign currency translation	(23)	(30)
Deferred taxes on deemed repatriation	(166)	(81)
Gross deferred tax liabilities	(2,618)	(3,049)
Valuation allowance	(262)	(232)
Total net deferred tax liabilities	$ (2,107)	$ (2,436)

Income Taxes - Reconciliation_2

Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance of unrecognized tax benefits at beginning of year	$ 130	$ 99	$ 75
Gross amount of increases in unrecognized tax benefits as a result of positions taken during a prior year(1)	1	42	11
Gross amount of decreases in unrecognized tax benefits as a result of positions taken during a prior year	(18)	(3)	0
Gross amount of increases in unrecognized tax benefits as a result of positions taken during the current year	31	5	24
The amounts of decreases in unrecognized benefits relating to settlements with taxing authorities	(27)	(1)	(2)
Reduction in unrecognized tax benefits due to the lapse of applicable statute of limitation	(5)	(12)	(9)
Balance of unrecognized tax benefits at end of year	112	130	99
Income Taxes Disclosure [Line Items]
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	18	3	0
Gross amount of increases in unrecognized tax benefits as a result of positions taken during a prior year(1)	1	42	11
Other Current Liabilities [Member]
Income Taxes Disclosure [Line Items]
Accrued interest and penalties	4	1	1
Other Current Liabilities [Member]
Income Taxes Disclosure [Line Items]
Unrecognized tax benefits that would impact effective tax rate	$ 14	$ 1	$ 1

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 12,440	$ 11,656	$ 5,084
EMEA
Disaggregation of Revenue [Line Items]
Revenue	4,219	4,093	1,987
Asia
Disaggregation of Revenue [Line Items]
Revenue	2,876	2,728	1,162
North America [Member]
Disaggregation of Revenue [Line Items]
Revenue	3,853	3,499	1,228
Latin America
Disaggregation of Revenue [Line Items]
Revenue	$ 1,492	$ 1,336	$ 707

Net Income Per Share - Reconcil

Net Income Per Share - Reconciliation of Shares Used in Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net (Loss) Income
Net (loss) income attributable to IFF shareholders	$ (1,871)	$ 270	$ 363
Net (loss) income attributable to IFF shareholders	$ (1,868)	$ 268	$ 365
Shares
Average number of shares outstanding - basic (in shares)	255	243	112
Average number of shares outstanding - diluted (in shares)	255	243	114
Net income per share - basic (in dollars per share)
Net income per share - basic (in dollars per share)	$ (7.32)	$ 1.11	$ 3.25
Net income per share - diluted (in dollars per share)	$ (7.32)	$ 1.10	$ 3.21
(Increase) Decrease In Redemption Value, Redeemable Noncontrolling Interest	$ 3	$ (2)	$ 2
Employee Stock Option And Restricted Stock [Member]
Shares
Adjustment for assumed dilution (in shares)	0	0	1
SPC
Shares
Adjustment for assumed dilution (in shares)	0	0	1

Net Income Per Share - Addition

Net Income Per Share - Additional Information (Detail) - $ / shares		12 Months Ended
	Feb. 01, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 15, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, par value (in dollars per share)		$ 0.125	$ 0.125
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		300,000
Difference Amount Between Basic Net Income (Loss) Per Share		$ 0	0	$ 0
Difference Amount Between Diluted Net Income (Loss) Per Share		$ 0	$ 0.01	$ 0.04
Share Equivalents
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		300,000	0	0
Nutrition & Biosciences, Inc [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Business acquisition, equity interest issued or issuable, number of shares	141,740,461
Common stock, par value (in dollars per share)	$ 0.125				$ 0.125
Nutrition & Biosciences, Inc [Member] | International Flavors & Fragrances Inc | DuPont de Nemours, Inc [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Percentage of voting interest acquired	55.40%

Net Income Per Share - TEU (Det

Net Income Per Share - TEU (Details) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Sep. 15, 2021	Sep. 17, 2018	Dec. 31, 2021	Dec. 31, 2020	Sep. 14, 2021
Earnings Per Share [Abstract]
Tangible equity units issued		16,500,000
Tangible equity units proceeds		$ 800
Price for basic share (in dollars per share)			$ 0.330911	$ 0.313400
Price for diluted share (usd per share)			$ 0.330911	$ 0.383900
Stock Issued During Period, Shares, Issued for Services	5,460,031
Tangible Equity Units Final Settlement Rate					$ 0.330911

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 01, 2017	Oct. 31, 2017	Aug. 31, 2015	Dec. 31, 2012
Equity [Abstract]
Dividends declared per share (in dollars per share)	$ 3.20	$ 3.12	$ 3.04
Dividends payable	$ 206	$ 201	$ 82
Dividend per share declared (in dollars per share)	$ 0.81	$ 0.79	$ 0.77
Shares authorized under repurchase program							$ 250
Additional authorized amount				$ 250		$ 250
Remaining authorized amended repurchase amount					$ 56
Remaining authorized repurchase amount				$ 300

Stock Compensation Plans - Addi

Stock Compensation Plans - Additional Information (Detail) - USD ($) $ in Millions		1 Months Ended			12 Months Ended
	Feb. 01, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares subject to outstanding awards (in shares)					1,403,092
Shares remaining available for future awards (in shares)					1,777,205
Target payout, cycle					3 years
Percentage of target dollar value of the award converted to a number of notional shares					50%
Total stock-based compensation					$ 51	$ 62	$ 40
Nutrition & Biosciences, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business acquisition, equity interest issued or issuable, number of shares	141,740,461
Equity Issued in Business Combination, Fair Value Disclosure	$ 25
Total stock-based compensation					$ 11
Business Acquisition, Post-Combination Service Period					3 years
Long-Term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target payout percentage, cash					50%
Target payout percentage, stock					50%
2017 - 2019 Cycle [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation, shares (in shares)				7,484
2018-2020 Cycle [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation, shares (in shares)			0
Two Thousand Twenty-One Plan [Domain]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)						2,290,000
Two Thousand Nineteen To Two Thousand Twenty-One Cycle | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation, shares (in shares)		0
RSU's [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years					3 years
RSU's [Member] | Nutrition & Biosciences, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business acquisition, equity interest issued or issuable, number of shares	258,572
SSAR's [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term, in years					7 years
SSAR's [Member] | Nutrition & Biosciences, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business acquisition, equity interest issued or issuable, number of shares	5,816
Share-based Payment Arrangement, Option | Nutrition & Biosciences, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Business acquisition, equity interest issued or issuable, number of shares	335,347

Stock Compensation Plans - Stoc

Stock Compensation Plans - Stock-Based Compensation Expense Included in Consolidated Statement of Income and Comprehensive Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 51	$ 62	$ 40
Less tax benefit	(8)	(13)	(8)
Total stock-based compensation, net of tax	43	49	32
Equity-based awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	49	54	36
Liability-based awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 2	$ 8	$ 4

Stock Compensation Plans - SSAR

Stock Compensation Plans - SSAR's and Stock Option - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SSAR's [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term, in years	7 years
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted	$ 4
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted, weighted average period, in years	1 year 10 months 28 days
SSAR's and Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, exercisable (USD per share)	$ 109.50	$ 109.77	$ 118.10
Intrinsic value of options/SSAR's exercised	$ 2	$ 3

Stock Compensation Plans - SS_2

Stock Compensation Plans - SSAR's and Stock Option Activity (Detail) - SSAR's and Options [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Shares Subject to SSARs/Options
Beginning balance (in shares)	287
Granted (in shares)	134
Exercised (in shares)	(84)
Cancelled (in shares)	(6)
Ending balance (in shares)	331	287
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 107.48
Granted (in dollars per share)	126.91
Exercised (in dollars per share)	106.66
Cancelled (in dollars per share)	117.04
Ending balance (in dollars per share)	$ 115.35	$ 107.48
SSARs/ Options Exercisable (in shares)	182	235
Expected to Vest (in shares)	142
Expected to Vest (in dollars per share)	$ 122.27

Stock Compensation Plans - SS_3

Stock Compensation Plans - SSAR's and Stock Option Outstanding (Detail) - SSAR's and Options [Member] - Over $65 $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding (in shares) | shares	331
Weighted Average Remaining Contractual Life (in years)	5 years 7 months 24 days
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 115.35
Aggregate Intrinsic Value | $	$ 2
Number Exercisable (in shares) | shares	182
Weighted Average Remaining Contractual Life (in years)	5 years 18 days
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 109.50
Aggregate Intrinsic Value | $	$ 2

Stock Compensation Plans - SS_4

Stock Compensation Plans - SSAR's and Stock Option Exercisable (Detail) - SSAR's and Options [Member] - Over $65 $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Exercisable (in shares) | shares	182
Weighted Average Remaining Contractual Life (in years)	5 years 18 days
Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 109.50
Aggregate Intrinsic Value | $	$ 2

Stock Compensation Plans - Rest

Stock Compensation Plans - Restricted Stock Units Plan - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
RSU's [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	100%
Vesting period, in years	3 years
Total fair value of vested	$ 40
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted	$ 58
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted, weighted average period, in years	1 year 11 months 23 days
Purchased Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of vested	$ 13
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted	$ 4
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted, weighted average period, in years	1 year 10 months 13 days

Stock Compensation Plans - RSU,

Stock Compensation Plans - RSU, PRS and Cash RSU Activity (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
RSU's [Member]
Number of Shares
Beginning balance (in shares)	777,000
Granted (in shares)	556,000
Vested (in shares)	(322,000)
Forfeited (in shares)	(58,000)
Change due to performance conditions, net (in shares)	(16,000)
Ending balance (in shares)	937,000	777,000
Weighted Average Grant Date Fair Value Per Share
Beginning balance (in dollars per share)	$ 126.20
Granted (in dollars per share)	115.13
Vested (in dollars per share)	124.62
Forfeited (in dollars per share)	129.36
Change due to performance conditions, net (in dollars per share)	120.48
Ending balance (in dollars per share)	$ 120.81	$ 126.20
Cash RSU's [Member]
Number of Shares
Beginning balance (in shares)	116,000
Granted (in shares)	43,000
Vested (in shares)	(38,000)
Forfeited (in shares)	(2,000)
Ending balance (in shares)	119,000	116,000
Weighted Average Grant Date Fair Value Per Share
Beginning balance (in dollars per share)	$ 150.65
Granted (in dollars per share)	104.84
Vested (in dollars per share)	130.67
Forfeited (in dollars per share)	107
Ending balance (in dollars per share)	$ 104.84	$ 150.65
Purchased Restricted Stock Unit
Number of Shares
Beginning balance (in shares)	155,000
Granted (in shares)	44,000
Vested (in shares)	(95,000)
Forfeited (in shares)	(14,000)
Ending balance (in shares)	90,000	155,000
Weighted Average Grant Date Fair Value Per Share
Beginning balance (in dollars per share)	$ 138.36
Granted (in dollars per share)	126.49
Vested (in dollars per share)	138.06
Forfeited (in dollars per share)	135.50
Ending balance (in dollars per share)	$ 133.36	$ 138.36
Issued Shares (in shares)	43,690	61,870	66,160
Aggregate purchase price (in dollars per share)	$ 6	$ 9	$ 9
Covered shares (in shares)	21,845	30,935	33,080

Stock Compensation Plans - Purc

Stock Compensation Plans - Purchased Restricted Stock Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
PRSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of vested	$ 40
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted	$ 58
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted, weighted average period, in years	1 year 11 months 23 days
Purchased Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued Shares (in shares)	43,690	61,870	66,160
Aggregate Purchase Price	$ 6	$ 9	$ 9
Covered shares (in shares)	21,845	30,935	33,080
Total fair value of vested	$ 13
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted	$ 4
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted, weighted average period, in years	1 year 10 months 13 days

Stock Compensation Plans - Liab

Stock Compensation Plans - Liability Awards - Additional Information (Detail) - Cash RSU's [Member] $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage granted in cash to eligible employees	100%
Vesting percentage	100%
Vesting period, in years	3 years
Total fair value of vested	$ 5
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted	$ 5
Unrecognized compensation cost related to non-vested stock options and SSAR, RSU, PRS and Cash RSU awards granted, weighted average period, in years	1 year 9 months 21 days

Segment Information - Additiona

Segment Information - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) segment customer category	Dec. 31, 2021 USD ($) customer	Dec. 31, 2020 USD ($) customer
Segment Reporting Information [Line Items]
Number of fragrance categories | category	2
Property, plant and equipment	$ 4,203	$ 4,368
Number of Operating Segments | segment	4
Strategic Initiative Costs	$ (3)	0	$ 0
U.S. Plans
Segment Reporting Information [Line Items]
Property, plant and equipment	1,771	2,041
CHINA
Segment Reporting Information [Line Items]
Property, plant and equipment	$ 258	$ 259
Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Number of customers that accounted for more than 10% of consolidated net sales | customer	0	0	0
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark
Segment Reporting Information [Line Items]
Number Of Customers | customer	0	0	0
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark | Customer One
Segment Reporting Information [Line Items]
Concentration risk threshold	10%	10%	10%
Customer Concentration Risk [Member] | Non-US [Member] | Sales [Member]
Segment Reporting Information [Line Items]
Concentration risk threshold	6%	7%	6%

Segment Information - Reportabl

Segment Information - Reportable Segment Information (Detail) - USD ($) $ in Millions		12 Months Ended
	Feb. 01, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Segment assets		$ 35,407	$ 39,658
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		(1,625)	354	$ 441
Restructuring and Other Charges, net		(12)	(41)	(17)
Gain on Sale of Assets		3	1	(4)
Interest expense		(336)	(289)	(132)
Other income (expense), net		37	58	7
Revenue		12,440	11,656	5,084
Segment Adjusted Operating EBITDA		2,455	2,425	1,055
Shareholder Activism Related Costs		(3)	(7)	0
Business Divestiture Costs		(110)	(42)	0
Other Depreciation and Amortization		(1,179)	(1,156)	(325)
Goodwill, Impairment Loss		(2,250)	0	0
Impairment, Long-Lived Asset, Held-for-Use		(120)	0	0
Global Shared Services Implementation Costs		(5)	0	0
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Acquisition Related Costs		4	0	0
Integration Related Costs		(94)	(105)	(107)
Restructuring and Other Charges, net		(12)	(41)	(17)
Gain on Sale of Assets		3	1	(4)
Employee separation costs		(11)	(29)	(3)
Legal Fees		0	0	(3)
Nourish
Segment Reporting Information [Line Items]
Restructuring and Other Charges, net		(8)	(32)	(10)
Goodwill, Impairment Loss		0
Health & Biosciences
Segment Reporting Information [Line Items]
Restructuring and Other Charges, net		(2)	(5)	0
Goodwill, Impairment Loss		(2,250)
Scent [Member]
Segment Reporting Information [Line Items]
Restructuring and Other Charges, net		(1)	(3)	(7)
Goodwill, Impairment Loss		0
Pharma Solutions
Segment Reporting Information [Line Items]
Restructuring and Other Charges, net		(1)	(1)	0
Goodwill, Impairment Loss		0
Operating Segments [Member] | Nourish
Segment Reporting Information [Line Items]
Segment assets		17,008	17,449
Revenue		6,829	6,264	2,886
Segment Adjusted Operating EBITDA		1,176	1,172	599
Operating Segments [Member] | Health & Biosciences
Segment Reporting Information [Line Items]
Segment assets		10,877	14,774
Revenue		2,339	2,329	134
Segment Adjusted Operating EBITDA		634	625	40
Operating Segments [Member] | Scent [Member]
Segment Reporting Information [Line Items]
Segment assets		4,310	4,078
Revenue		2,301	2,254	2,064
Segment Adjusted Operating EBITDA		423	463	416
Operating Segments [Member] | Pharma Solutions
Segment Reporting Information [Line Items]
Segment assets		3,212	3,357
Revenue		971	809	0
Segment Adjusted Operating EBITDA		222	165	0
Nutrition & Biosciences, Inc [Member]
Segment Reporting Information [Line Items]
Acquisition Related Costs	$ (75)
Transaction costs			91	29
Nutrition & Biosciences, Inc [Member] | Corporate and Other [Member]
Segment Reporting Information [Line Items]
Acquisition Related Costs		0	(91)	(29)
Business Combination, Inventory Step-Up Costs		0	(368)	0
Frutarom Industries Ltd. [Member] | Corporate and Other [Member]
Segment Reporting Information [Line Items]
Acquisition Related Costs		$ (1)	$ (2)	$ (1)

Segment Information - Capital E

Segment Information - Capital Expenditure and Depreciation and Amortization by Segment (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Capital Expenditures	$ 504	$ 393	$ 192
Depreciation and amortization	1,179	1,156	325
Operating Segments [Member] | Nourish
Segment Reporting Information [Line Items]
Capital Expenditures	215	183	98
Depreciation and amortization	596	594	211
Operating Segments [Member] | Health & Biosciences
Segment Reporting Information [Line Items]
Capital Expenditures	160	139	7
Depreciation and amortization	363	353	36
Operating Segments [Member] | Scent [Member]
Segment Reporting Information [Line Items]
Capital Expenditures	56	41	87
Depreciation and amortization	81	84	78
Operating Segments [Member] | Pharma Solutions
Segment Reporting Information [Line Items]
Capital Expenditures	73	30	0
Depreciation and amortization	$ 139	$ 125	$ 0

Segment Information - Net Sales

Segment Information - Net Sales by Geographic Area (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net sales	$ 12,440	$ 11,656	$ 5,084
Europe, Africa and Middle East [Member]
Segment Reporting Information [Line Items]
Net sales	4,219	4,093	1,987
Greater Asia [Member]
Segment Reporting Information [Line Items]
Net sales	2,876	2,728	1,162
North America [Member]
Segment Reporting Information [Line Items]
Net sales	3,853	3,499	1,228
Latin America
Segment Reporting Information [Line Items]
Net sales	1,492	1,336	707
Geographic Distribution, Domestic [Member]
Segment Reporting Information [Line Items]
Net sales	3,611	3,211	1,093
Geographic Distribution, Foreign [Member]
Segment Reporting Information [Line Items]
Net sales	$ 8,829	$ 8,445	$ 3,991

Segment Information Segment Inf

Segment Information Segment Information - Schedule of Long Lived Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 4,203	$ 4,368
U.S. Pension Plans [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,771	2,041
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	258	259
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,344	1,277
DENMARK
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	250	251
FINLAND
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	212	196
FRANCE
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	187	188
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 181	$ 156

Employee Benefits - Additional

Employee Benefits - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Feb. 01, 2021 USD ($) benefit_plan
Defined Benefit Plan Disclosure [Line Items]
Percentage of matching contribution if compensation percentage below low range	100%
Matching participant's contribution, percentage on compensation	4%
Percentage of matching contribution if compensation percentage between high range and low range	75%
Matching participant's contribution, percentage on compensation, range low	4%
Matching participant's contribution, percentage on compensation, range high	8%
Percentage of employees eligible to accrue benefits under the defined plan	50%
Matching participant's contribution, average percentage on compensation	6%
Retirement liabilities	$ 231,000,000	$ 385,000,000
Capital in excess of par value related to deferred compensation plan	25,000,000	26,000,000
Total cash surrender value of life insurance contracts	$ 45,000,000	52,000,000
Percentage of active employees with pension and or other retirement benefit plans covered	20%
Nutrition & Biosciences, Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Net defined benefit plan liabilities			$ 221,000,000
Number of defined benefit plans assumed | benefit_plan			20
Deferred Compensation Plan
Defined Benefit Plan Disclosure [Line Items]
Retirement liabilities	$ 53,000,000	64,000,000
Pension Plan | U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement liabilities	47,000,000	61,000,000
Contribution to the plans	$ 5,000,000	5,000,000
Pension Plan | U.S. Plans | Equities
Defined Benefit Plan Disclosure [Line Items]
Target percentage of investment in equity securities	10%
Pension Plan | U.S. Plans | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target percentage of investment in equity securities	90%
Pension Plan | U.S. Plans | Qualified Plan
Defined Benefit Plan Disclosure [Line Items]
Contribution to the plans	$ 0
Pension Plan | U.S. Plans | Nonqualified Plan
Defined Benefit Plan Disclosure [Line Items]
Contribution to the plans	5,000,000
Pension Plan | Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Retirement liabilities	138,000,000	262,000,000
Contribution to the plans	$ 31,000,000	$ 32,000,000
Pension Plan | Non-U.S. Plans | Property | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target percentage of investment in equity securities	15%
Pension Plan | Non-U.S. Plans | Equities | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target percentage of investment in equity securities	15%
Pension Plan | Non-U.S. Plans | Fixed Income Securities | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target percentage of investment in equity securities	35%
Pension Plan | Non-U.S. Plans | Alternative Type of Investments | Maximum
Defined Benefit Plan Disclosure [Line Items]
Target percentage of investment in equity securities	35%
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Contribution to the plans	$ 2,000,000

Employee Benefits - Plan Assets

Employee Benefits - Plan Assets and Benefit Obligations of Defined Benefit Pension Plans (Detail) - Pension Plan - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost for benefits earned	$ 1	$ 1	$ 1
Interest cost on projected benefit obligation	15	12	17
Expected return on plan assets	(21)	(106)	(28)
Net amortization and deferrals	8	29	8
Settlements and curtailments	0	0	0
Net periodic benefit cost (income)	3	(5)	(2)
Defined contribution and other retirement plans	33	36	13
Total expense	36	31	11
Net actuarial (gain) loss	0	12
Recognized actuarial loss	(8)	(9)
Prior service cost	0	0
Recognized prior service (cost) credit	0	0
Currency translation adjustment	0	0
Total (gain) loss recognized in OCI (before tax effects)	(8)	3
U.S. Plans | Restatement Adjustment
Defined Benefit Plan Disclosure [Line Items]
Interest cost on projected benefit obligation		71
Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost for benefits earned	34	42	24
Interest cost on projected benefit obligation	17	10	13
Expected return on plan assets	(42)	(55)	(46)
Net amortization and deferrals	11	19	15
Settlements and curtailments	0	(10)	5
Net periodic benefit cost (income)	20	5	11
Defined contribution and other retirement plans	29	33	7
Total expense	49	38	$ 18
Net actuarial (gain) loss	(143)	(135)
Recognized actuarial loss	(12)	(10)
Prior service cost	0	(2)
Recognized prior service (cost) credit	1	1
Currency translation adjustment	(27)	(16)
Total (gain) loss recognized in OCI (before tax effects)	$ (181)	(162)
Non-U.S. Plans | Restatement Adjustment
Defined Benefit Plan Disclosure [Line Items]
Service cost for benefits earned		$ 41

Employee Benefits - Components

Employee Benefits - Components of Net Periodic Benefit Cost and Changes in Plan Assets and Benefit Obligations Recognized in OCI (Detail) - Postretirement Benefits - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Service cost for benefits earned	$ 1	$ 1	$ 1
Interest cost on projected benefit obligation	1	7	2
Net amortization and deferrals	(5)	(20)	(5)
Net periodic benefit cost (income)	(3)	(12)	$ (2)
Net actuarial (gain) loss	(16)	(3)
Recognized actuarial loss	(1)	(2)
Recognized prior service credit	6	6
Total (gain) loss recognized in OCI (before tax effects)	$ (11)	$ 1

Employee Benefits - Weighted-Av

Employee Benefits - Weighted-Average Actuarial Assumption Used to Determine Expense (Detail) - Pension Plan	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.86%	2.51%	3.26%
Expected return on plan assets	3.80%	3.80%	5.60%
Rate of compensation increase	3.25%	3.25%	3.25%
Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Discount rate	1.43%	0.85%	1.49%
Expected return on plan assets	3.52%	4.21%	4.62%
Rate of compensation increase	2.72%	2.56%	2.46%

Employee Benefits - Changes in

Employee Benefits - Changes in Postretirement Benefit Obligation and Plan Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Postretirement Benefits
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	$ 66	$ 69
Service cost for benefits earned	1	1	$ 1
Interest cost on projected benefit obligation	1	7	2
Actuarial (gain) loss	(16)	(4)
Plan amendments	0	0
Adjustments for expense/tax contained in service cost	0	0
Plan participants’ contributions	0	0
Benefits paid	(2)	(4)
Curtailments/settlements	0	0
Translation adjustments	0	0
Acquisitions/Transferred Liabilities	0	3
Other	(1)	0
Benefit obligation at end of year	50	66	69
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Employer contributions	2
Postretirement Benefits | Restatement Adjustment
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Interest cost on projected benefit obligation	2	1
U.S. Plans | Pension Plan
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	662	682
Service cost for benefits earned	1	1	1
Interest cost on projected benefit obligation	15	12	17
Actuarial (gain) loss	(139)	(5)
Plan amendments	0	0
Adjustments for expense/tax contained in service cost	0	0
Plan participants’ contributions	0	0
Benefits paid	(38)	(37)
Curtailments/settlements	0	0
Translation adjustments	0	0
Acquisitions/Transferred Liabilities	0	0
Other	(1)	9
Benefit obligation at end of year	500	662	682
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	649	678
Actual return on plan assets	(118)	3
Employer contributions	5	5
Plan participants’ contributions	0	0
Benefits paid	(38)	(37)
Settlements	0	0
Translation adjustments	0	0
Acquisitions/Transferred Assets	0	0
Other	0	0
Fair value of plan assets at end of year	498	649	678
Funded status at end of year	(2)	(13)
U.S. Plans | Pension Plan | Restatement Adjustment
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Interest cost on projected benefit obligation		71
Non-U.S. Plans | Pension Plan
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	1,501	1,294
Service cost for benefits earned	34	42	24
Interest cost on projected benefit obligation	17	10	13
Actuarial (gain) loss	(468)	(146)
Plan amendments	0	(2)
Adjustments for expense/tax contained in service cost	(2)	(2)
Plan participants’ contributions	4	4
Benefits paid	(32)	(34)
Curtailments/settlements	(21)	(39)
Translation adjustments	(104)	(93)
Acquisitions/Transferred Liabilities	0	465
Other	1	2
Benefit obligation at end of year	930	1,501	1,294
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,320	1,145
Actual return on plan assets	(286)	25
Employer contributions	31	32
Plan participants’ contributions	4	4
Benefits paid	(32)	(34)
Settlements	(21)	(24)
Translation adjustments	(96)	(74)
Acquisitions/Transferred Assets	0	247
Other	0	(1)
Fair value of plan assets at end of year	920	1,320	$ 1,145
Funded status at end of year	$ (10)	(181)
Non-U.S. Plans | Pension Plan | Restatement Adjustment
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Service cost for benefits earned		$ 41

Employee Benefits - Amounts Rec

Employee Benefits - Amounts Recognized in Balance Sheet (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Other assets	$ 180	$ 136
Retirement liabilities	(231)	(385)
U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Other assets	51	53
Other current liabilities	(6)	(5)
Retirement liabilities	(47)	(61)
Net amount recognized	(2)	(13)
Non-U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Other assets	129	83
Other current liabilities	(1)	(2)
Retirement liabilities	(138)	(262)
Net amount recognized	$ (10)	$ (181)

Employee Benefits - Amounts R_2

Employee Benefits - Amounts Recognized in Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Net actuarial (gain) loss	$ (3)	$ 14
Prior service cost (credit)	(9)	(15)
Total AOCI (before tax effects)	(12)	(1)
U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Net actuarial (gain) loss	129	137
Prior service cost (credit)	0	0
Total AOCI (before tax effects)	129	137
Non-U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Net actuarial (gain) loss	110	291
Prior service cost (credit)	(3)	(3)
Total AOCI (before tax effects)	$ 107	$ 288

Employee Benefits - Accumulated

Employee Benefits - Accumulated Benefit Obligation (Detail) - Pension Plan - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Accumulated Benefit Obligation — end of year	$ 495	$ 654
Projected benefit obligation	49	63
Accumulated benefit obligation	49	62
Fair value of plan assets	$ 0	$ 0
Discount rate	5.42%	2.86%
Rate of compensation increase	3.75%	3.25%
Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Accumulated Benefit Obligation — end of year	$ 870	$ 1,410
Projected benefit obligation	169	944
Accumulated benefit obligation	150	330
Fair value of plan assets	$ 86	$ 840
Discount rate	4.02%	1.43%
Rate of compensation increase	3%	2.72%

Employee Benefits - Estimated F

Employee Benefits - Estimated Future Benefit Payments (Detail) $ in Millions	Dec. 31, 2022 USD ($)
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
2023	$ 3
2024	3
2025	4
2026	4
2027	4
2028 - 2032	18
Required Company Contributions in the Following Year (2023)	0
U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
2023	39
2024	39
2025	39
2026	40
2027	39
2028 - 2032	188
Required Company Contributions in the Following Year (2023)	5
Non-U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
2023	34
2024	34
2025	36
2026	38
2027	39
2028 - 2032	223
Required Company Contributions in the Following Year (2023)	$ 32

Employee Benefits - Percentage

Employee Benefits - Percentage of Assets Invested (Detail) - Pension Plan	Dec. 31, 2022	Dec. 31, 2021
U.S. Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	2%	1%
U.S. Plans | Equities
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	47%	45%
U.S. Plans | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	51%	54%
U.S. Plans | Property
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	0%	0%
U.S. Plans | Alternative and other investments
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	0%	0%
Non-U.S. Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	3%	6%
Non-U.S. Plans | Equities
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	18%	18%
Non-U.S. Plans | Fixed income
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	37%	34%
Non-U.S. Plans | Property
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	9%	6%
Non-U.S. Plans | Alternative and other investments
Defined Benefit Plan Disclosure [Line Items]
Percentage of assets invested	33%	36%

Employee Benefits - Fair Value

Employee Benefits - Fair Value Hierarchy of Plan Assets (Detail) - Pension Plan - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 498,000	$ 649,000	$ 678,000
U.S. Plans | Fair Value Of Plan Assets Before Receivables [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	497,000	648,000
U.S. Plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9,000	5,000
U.S. Plans | Government & Government Agency Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,000	15,000
U.S. Plans | Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	73,000	77,000
U.S. Plans | Municipal Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,000	4,000
U.S. Plans | Pooled Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	404,000	547,000
U.S. Plans | Receivables
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,000	1,000
U.S. Plans | Level 1 | Fair Value Of Plan Assets Before Receivables [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 1 | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 1 | Government & Government Agency Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 1 | Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 1 | Municipal Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 2 | Fair Value Of Plan Assets Before Receivables [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	93,000	101,000
U.S. Plans | Level 2 | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9,000	5,000
U.S. Plans | Level 2 | Government & Government Agency Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,000	15,000
U.S. Plans | Level 2 | Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	73,000	77,000
U.S. Plans | Level 2 | Municipal Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5,000	4,000
U.S. Plans | Level 3 | Fair Value Of Plan Assets Before Receivables [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 3 | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 3 | Government & Government Agency Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 3 | Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Level 3 | Municipal Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
U.S. Plans | Fair Value Measured at Net Asset Value Per Share | Pooled Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	234,000	294,000
U.S. Plans | Fair Value Measured at Net Asset Value Per Share | Fixed Income Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	170,000	253,000
Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	920,000	1,320,000	$ 1,145,000
Non-U.S. Plans | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	23,000	73,000
Non-U.S. Plans | U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	73,000	100,000
Non-U.S. Plans | U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,000
Non-U.S. Plans | Non-U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	79,000	104,000
Non-U.S. Plans | Non-U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,000	1,000
Non-U.S. Plans | Non-U.S. Small Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,000	1,000
Non-U.S. Plans | Emerging Markets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,000	30,000
Non-U.S. Plans | U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,000	42,000
Non-U.S. Plans | Non-U.S. Treasuries/Government Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	144,000	162,000
Non-U.S. Plans | Non-U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	109,000	195,000
Non-U.S. Plans | Non-U.S. Asset-Backed Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46,000	51,000
Non-U.S. Plans | Non-U.S. Other Fixed Income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,000	2,000
Non-U.S. Plans | Insurance Contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	177,000	265,000
Non-U.S. Plans | Derivative Financial Instruments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	56,000	91,000
Non-U.S. Plans | Absolute Return Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,000	114,000
Non-U.S. Plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	67,000	12,000
Non-U.S. Plans | Property
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	85,000	77,000
Non-U.S. Plans | Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	920,000	1,320,000
Non-U.S. Plans | Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	407,000	546,000
Non-U.S. Plans | Level 1 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	14,000	37,000
Non-U.S. Plans | Level 1 | U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	73,000	100,000
Non-U.S. Plans | Level 1 | U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	6,000
Non-U.S. Plans | Level 1 | Non-U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	79,000	104,000
Non-U.S. Plans | Level 1 | Non-U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,000	1,000
Non-U.S. Plans | Level 1 | Non-U.S. Small Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,000	1,000
Non-U.S. Plans | Level 1 | Emerging Markets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7,000	30,000
Non-U.S. Plans | Level 1 | U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35,000	42,000
Non-U.S. Plans | Level 1 | Non-U.S. Treasuries/Government Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	144,000	162,000
Non-U.S. Plans | Level 1 | Non-U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	34,000	58,000
Non-U.S. Plans | Level 1 | Non-U.S. Asset-Backed Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 1 | Non-U.S. Other Fixed Income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,000	2,000
Non-U.S. Plans | Level 1 | Insurance Contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 1 | Derivative Financial Instruments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 1 | Absolute Return Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,000	4,000
Non-U.S. Plans | Level 1 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 1 | Property
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	4,000	5,000
Non-U.S. Plans | Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	429,000	692,000
Non-U.S. Plans | Level 2 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9,000	36,000
Non-U.S. Plans | Level 2 | U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Non-U.S. Plans | Level 2 | Non-U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | Non-U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | Non-U.S. Small Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | Emerging Markets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | Non-U.S. Treasuries/Government Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | Non-U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	75,000	137,000
Non-U.S. Plans | Level 2 | Non-U.S. Asset-Backed Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	46,000	51,000
Non-U.S. Plans | Level 2 | Non-U.S. Other Fixed Income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 2 | Insurance Contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	177,000	265,000
Non-U.S. Plans | Level 2 | Derivative Financial Instruments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	56,000	91,000
Non-U.S. Plans | Level 2 | Absolute Return Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2,000	110,000
Non-U.S. Plans | Level 2 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	64,000	2,000
Non-U.S. Plans | Level 2 | Property
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	84,000	82,000
Non-U.S. Plans | Level 3 | Cash
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Non-U.S. Plans | Level 3 | Non-U.S. Large Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Non-U.S. Mid Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Non-U.S. Small Cap
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Emerging Markets
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Non-U.S. Treasuries/Government Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Non-U.S. Corporate Bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Non-U.S. Asset-Backed Securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Non-U.S. Other Fixed Income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Insurance Contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Derivative Financial Instruments
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Absolute Return Funds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Non-U.S. Plans | Level 3 | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3,000	10,000
Non-U.S. Plans | Level 3 | Property
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 81,000	$ 72,000

Employee Benefits - Reconciliat

Employee Benefits - Reconciliation of Level 3 Non-U.S. Plan Assets Held (Detail) - Pension Plan - Non-U.S. Plans $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	$ 1,320
Fair value of plan assets at end of year	920
Property
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	77
Fair value of plan assets at end of year	85
Other
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	12
Fair value of plan assets at end of year	67
Fair Value, Inputs, Level 1, 2 and 3
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,320
Fair value of plan assets at end of year	920
Level 3
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	82
Actual return on plan assets	(3)
Purchases, sales and settlements	5
Fair value of plan assets at end of year	84
Level 3 | Property
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	72
Actual return on plan assets	(2)
Purchases, sales and settlements	11
Fair value of plan assets at end of year	81
Level 3 | Other
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	10
Actual return on plan assets	(1)
Purchases, sales and settlements	(6)
Fair value of plan assets at end of year	$ 3

Employee Benefits - Weighted Av

Employee Benefits - Weighted Average Assumptions Used to Determine Postretirement Benefit Expense and Obligation (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Liability
Defined Benefit Plan Disclosure [Line Items]
Discount rate	5.40%	2.90%
Current medical cost trend rate	6.50%	6.75%
Ultimate medical cost trend rate	4.75%	4.75%
Expense
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.90%	2.60%
Current medical cost trend rate	6.75%	7%
Ultimate medical cost trend rate	4.75%	4.75%

Employee Benefits - Sensitivity

Employee Benefits - Sensitivity of Disclosures to Changes in Selected Assumptions (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
25 BP decrease in discount rate, change in ABO	$ 1
25 BP decrease in discount rate, change in pension expense	0
U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
25 BP decrease in discount rate, change in ABO	12
25 BP decrease in discount rate, change in ABO	11
25 BP decrease in discount rate, change in pension expense	0
25 BP decrease in long-term rate of return, change in pension expense	1
Non-U.S. Plans | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
25 BP decrease in discount rate, change in ABO	38
25 BP decrease in discount rate, change in ABO	37
25 BP decrease in discount rate, change in pension expense	5
25 BP decrease in long-term rate of return, change in pension expense	$ 3

Financial Instruments - Carryin

Financial Instruments - Carrying Amount and Estimated Fair Value of Financial Instruments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other current liabilities
Commercial Paper	$ 187	$ 324
Payments for (Proceeds from) Hedge, Investing Activities	0	0	$ 14
Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	483	711
Credit facilities and bank overdrafts	106	7
Derivative assets(3)	20	0
Derivative liabilities(3)	56	7
Commercial Paper	187	324
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	483	711
Credit facilities and bank overdrafts	106	7
Derivative assets(3)	20	0
Derivative liabilities(3)	56	7
Commercial Paper	187	324
Senior Notes - 2023 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes		300
Senior Notes, Current	300
Senior Notes - 2023 [Member] | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes		308
Senior Notes, Current	298
Senior Notes, Euro Notes, 2024 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	532	565
Senior Notes, Euro Notes, 2024 [Member] | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	519	585
Senior Notes, Euro Notes, 2026 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	845	900
Senior Notes, Euro Notes, 2026 [Member] | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	774	960
Senior Notes - 2028 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	398	397
Senior Notes - 2028 [Member] | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	380	452
Senior notes - 2047 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	495	494
Senior notes - 2047 [Member] | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	390	585
Senior Notes - 2048 [Member] | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	787	786
Senior Notes - 2048 [Member] | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	685	1,026
Senior Notes, Due Two Thousand Twenty Five | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	1,000	1,001
Senior Notes, Due Two Thousand Twenty Five | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	884	968
Senior Notes, Due Two Thousand Twenty Seven | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	1,215	1,218
Senior Notes, Due Two Thousand Twenty Seven | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	1,006	1,180
Senior Notes, Due Two Thousand Thirty | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	1,510	1,511
Senior Notes, Due Two Thousand Thirty | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	1,188	1,466
Senior Notes, Due Two Thousand Forty | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	774	775
Senior Notes, Due Two Thousand Forty | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	535	762
Senior Notes, Due Two Thousand Fifty | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	1,571	1,572
Senior Notes, Due Two Thousand Fifty | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	1,021	1,556
2024 Term Loan | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	625	625
2024 Term Loan | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	625	625
2026 Term Loan | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	625	625
2026 Term Loan | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes	625	625
Senior Notes, Due Two Thousand Twenty Two | Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes, Current	0	300
Senior Notes, Due Two Thousand Twenty Two | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior Notes, Current	$ 0	$ 300

Financial Instruments - Derivat

Financial Instruments - Derivative Instruments Notional Amount Outstanding (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Forward Currency Contracts
Schedule Of Information By Major Category Of Credit Derivatives Contracts [Line Items]
Derivative instruments outstanding	$ (92)	$ (46)
Currency Swap
Schedule Of Information By Major Category Of Credit Derivatives Contracts [Line Items]
Derivative instruments outstanding	(1,400)	(300)
Commodity Contract
Schedule Of Information By Major Category Of Credit Derivatives Contracts [Line Items]
Derivative instruments outstanding	$ (1)	$ (10)

Financial Instruments - Deriv_2

Financial Instruments - Derivative Instruments Measured at Fair Value (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	$ 20
Total Fair Value, Derivative Liabilities		$ 7
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other current liabilities
Foreign Currency Contracts [Member]
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	$ 1
Total Fair Value, Derivative Liabilities		2
Currency Swap
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	19
Total Fair Value, Derivative Liabilities	56	5
Fair Value of Derivatives Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	19
Total Fair Value, Derivative Liabilities		5
Fair Value of Derivatives Designated as Hedging Instrument [Member] | Foreign Currency Contracts [Member]
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	0
Total Fair Value, Derivative Liabilities		0
Fair Value of Derivatives Designated as Hedging Instrument [Member] | Currency Swap
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	19
Total Fair Value, Derivative Liabilities	56	5
Fair Value of Derivatives Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	1
Total Fair Value, Derivative Liabilities		2
Fair Value of Derivatives Not Designated as Hedging Instrument | Foreign Currency Contracts [Member]
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	1
Total Fair Value, Derivative Liabilities		2
Fair Value of Derivatives Not Designated as Hedging Instrument | Currency Swap
Derivatives, Fair Value [Line Items]
Total Fair Value, Derivative Assets	0
Total Fair Value, Derivative Liabilities	$ 0	$ 0

Financial Instruments - Deriv_3

Financial Instruments - Derivative Instruments Which Were Not Designated as Hedging Instruments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (expense), net	Other income (expense), net
Foreign Currency Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain or (loss) on derivative	$ 7	$ 6

Financial Instruments - Deriv_4

Financial Instruments - Derivative Instruments Designated as Cash Flow and Net Investment Hedging Instruments (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	$ 0	$ (7)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	54	$ 132
Total Fair Value, Derivative Assets	$ 20
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of goods sold	Cost of goods sold
Payments for (Proceeds from) Hedge, Investing Activities	$ 0	$ 0	$ (14)
Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	19
Fair Value of Derivatives Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	1
Interest Rate Swap | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	0	1
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	0	1
Senior Notes Maturing 2021 through 2026 [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	43	72
Foreign Currency Contracts | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	0	(6)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	0	7
Senior Notes, Euro Notes, 2024 [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	27	38
Cross Currency Swaps [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	(16)	$ 14
Foreign Currency Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	1
Foreign Currency Contracts [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	0
Foreign Currency Contracts [Member] | Fair Value of Derivatives Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	1
Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	19
Currency Swap | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	19
Currency Swap | Fair Value of Derivatives Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Total Fair Value, Derivative Assets	$ 0

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) € in Millions, $ in Millions		3 Months Ended			12 Months Ended
	May 18, 2017 USD ($)	Sep. 30, 2022 USD ($) swap	Mar. 31, 2016 USD ($) Agreement	Mar. 31, 2016 EUR (€) Agreement	Dec. 31, 2022 USD ($) swap	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Derivatives, Fair Value [Line Items]
Total fair value, derivative assets					$ 20
Proceeds from unwinding of derivative instruments					173	$ 0	$ 0
Payments for (Proceeds from) Hedge, Investing Activities					0	0	$ (14)
Derivative Liability, Fair Value, Gross Liability						7
Forward Currency Contracts
Derivatives, Fair Value [Line Items]
Derivative instruments outstanding					92	46
Currency Swap
Derivatives, Fair Value [Line Items]
Derivative instruments outstanding					1,400	300
Total fair value, derivative assets					19
Derivative Liability, Fair Value, Gross Liability					56	5
Interest Rate Swap
Derivatives, Fair Value [Line Items]
Loss incurred on termination of interest rate swaps			$ 3	€ 3
Gain on deal contingent derivatives	$ 5
Number of interest rate derivatives held | Agreement			2	2
2022 Cross Currency Swaps | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Derivative instruments outstanding		$ 1,400
Fair Value of Derivatives Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total fair value, derivative assets					1
Derivative Liability, Fair Value, Gross Liability						2
Fair Value of Derivatives Not Designated as Hedging Instrument | Currency Swap
Derivatives, Fair Value [Line Items]
Total fair value, derivative assets					0
Derivative Liability, Fair Value, Gross Liability					0	0
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total fair value, derivative assets					19
Derivative Liability, Fair Value, Gross Liability						5
Designated as Hedging Instrument | Currency Swap
Derivatives, Fair Value [Line Items]
Total fair value, derivative assets					19
Derivative Liability, Fair Value, Gross Liability					$ 56	$ 5
Designated as Hedging Instrument | 2019 Cross Currency Swaps
Derivatives, Fair Value [Line Items]
Interest Income (Expense), Net		$ 11
Number of Foreign Currency Derivatives Held | swap		14
Proceeds from unwinding of derivative instruments		$ 183
Designated as Hedging Instrument | 2022 Cross Currency Swaps
Derivatives, Fair Value [Line Items]
Number of Foreign Currency Derivatives Held | swap		12			12
Derivative Assets (Liabilities), at Fair Value, Net					$ 37

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss, net of tax	$ 21,082
Accumulated other comprehensive loss, net of tax	17,684	$ 21,082
Foreign Currency Translation Adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss, net of tax	(1,133)	(285)	$ (373)
OCI before reclassifications	(904)	(848)	88
Amounts reclassified from AOCI	0	0	0
Net current period other comprehensive income (loss)	(904)	(848)	88
Accumulated other comprehensive loss, net of tax	(2,037)	(1,133)	(285)
(Losses) Gains on Derivatives Qualifying as Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss, net of tax	1	(7)	2
OCI before reclassifications	0	1	(5)
Amounts reclassified from AOCI	0	7	(4)
Net current period other comprehensive income (loss)	0	8	(9)
Accumulated other comprehensive loss, net of tax	1	1	(7)
Pension and Postretirement Liability Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss, net of tax	(291)	(406)	(346)
OCI before reclassifications	148	97	(74)
Amounts reclassified from AOCI	10	18	14
Net current period other comprehensive income (loss)	158	115	(60)
Accumulated other comprehensive loss, net of tax	(133)	(291)	(406)
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive loss, net of tax	(1,423)	(698)	(717)
OCI before reclassifications	(756)	(750)	9
Amounts reclassified from AOCI	10	25	10
Net current period other comprehensive income (loss)	(746)	(725)	19
Accumulated other comprehensive loss, net of tax	$ (2,169)	$ (1,423)	$ (698)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Loss) - Reclassifications of Accumulated Other Comprehensive Income to Consolidated Statement of Comprehensive Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of goods sold	$ 8,289	$ 7,921	$ 2,998
Interest expense	(336)	(289)	(132)
Tax	(239)	(75)	(74)
(Losses) Gains on Derivatives Qualifying as Hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Tax	0	1	(1)
(Losses) Gains on Derivatives Qualifying as Hedges | Foreign Currency Contracts [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of goods sold	0	(7)	6
(Losses) Gains on Derivatives Qualifying as Hedges | Interest Rate Swap
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense	0	(1)	(1)
(Losses) Gains on Derivatives Qualifying as Hedges | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total	0	(7)	4
(Losses) gains on pension and postretirement liability adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Tax	(4)	4	(9)
(Losses) gains on pension and postretirement liability adjustments | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total	(10)	(18)	(14)
Prior service cost
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
(Losses) gains on pension and postretirement liability adjustments	7	7	7
Actuarial losses
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
(Losses) gains on pension and postretirement liability adjustments	(21)	(38)	(30)
Other items
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
(Losses) gains on pension and postretirement liability adjustments	$ 0	$ 17	$ 0

Concentrations Of Credit Risk -

Concentrations Of Credit Risk - Additional Information (Detail) - Customer Concentration Risk [Member] - customer	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Concentration Risk [Line Items]
Number of customers that accounted for more than 10% of consolidated net sales	0	0	0
All Foreign Countries [Member] | Sales [Member]
Concentration Risk [Line Items]
Concentration risk threshold	10%	10%	10%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)

3 Months Ended

12 Months Ended

Mar. 11, 2020

Oct. 29, 2019

Sep. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Dec. 31, 2017

Dec. 31, 2022

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2021

Jul. 28, 2021

Aug. 25, 2020

Commitments And Contingencies [Line Items]

Bank guarantees related to appeals on income tax and indirect tax cases

$ 14,000,000

Available lines of credit

1,859,000,000

Bank guarantees and pledged assets to pursue defenses related to other contingencies

22,000,000

Property, plant and equipment

4,203,000,000

$ 4,368,000,000

Bank Guarantees and Standby Letters of Credit, Amount Outstanding

116,000,000

Lines of Credit Facility, Current Borrowing Amount/Total Amount Drawn Down

297,000,000

Bank Guarantees, Commercial Guarantees, Letters Of Credit and Surety Bonds, Facility Amounts

434,000,000

Commercial Paper

187,000,000

324,000,000

Revolving Loan Facility [Member]

Commitments And Contingencies [Line Items]

Revolving credit facility

902,000,000

$ 1,000,000,000

Revolving Loan Facility [Member] | Citibank, N.A [Member]

Commitments And Contingencies [Line Items]

Revolving credit facility

2,000,000,000

$ 2,000,000,000

Chief Executive Officer [Member]

Commitments And Contingencies [Line Items]

Deferred Compensation Arrangement with Individual, Compensation Expense

$ 20,000,000

$ 20,000,000

Minimum

Commitments And Contingencies [Line Items]

Estimated maximum future costs of environmental liabilities for identified sites (less than $5 million)

0

Maximum

Commitments And Contingencies [Line Items]

Estimated maximum future costs of environmental liabilities for identified sites (less than $5 million)

46,000,000

Hangzhou, China [Member]

Commitments And Contingencies [Line Items]

Proceeds from Sale of Land Held-for-use

$ 4,000,000

Property, plant and equipment

59,000,000

CHINA

Commitments And Contingencies [Line Items]

Property, plant and equipment

258,000,000

$ 259,000,000

Manufacturing Facility [Member] | CHINA

Commitments And Contingencies [Line Items]

Property, plant and equipment

243,000,000

Pledged assets [Member]

Commitments And Contingencies [Line Items]

The amount of pledged assets, principally PP&E to cover income tax and indirect tax assessments

8,000,000

Pharma Solutions

Commitments And Contingencies [Line Items]

Current accrual

34,000,000

Malpractice Loss Contingency, Period Increase (Decrease)

19,000,000

BRAZIL | Foreign Tax Authority [Member]

Commitments And Contingencies [Line Items]

Proceeds from Income Tax Refunds

$ 4,000,000

$ 8,000,000

BRAZIL | Foreign Tax Authority [Member] | BRAZIL

Commitments And Contingencies [Line Items]

Proceeds from Income Tax Refunds

$ 3,000,000

Zhejiang Ingredients Plant [Member] | Zhejiang, China [Member]

Commitments And Contingencies [Line Items]

Gain Contingency, Relocation Payments Received

$ 13,000,000

$ 30,000,000

Gain Contingency, Expected Relocation Payments

$ 50,000,000

Guangzhou Flavors Plant [Member] | Guangzhou, China [Member]

Commitments And Contingencies [Line Items]

Property, plant and equipment

51,000,000

Guangzhou Fragrance Plant [Member] | Guangzhou, China [Member]

Commitments And Contingencies [Line Items]

Property, plant and equipment

7,000,000

Zhangjiagang Flavors Plant | Zhangjiagang, China

Commitments And Contingencies [Line Items]

Property, plant and equipment

$ 37,000,000

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance	$ 35
Sale of a subsidiary with redeemable non-controlling interests	7	$ 9	$ 4
Exercises of redeemable non-controlling interests	5
Exercises of redeemable non-controlling interests	2	2	1
Ending balance	30	35
Redeemable Noncontrolling Interest [Member]
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance	105	98	99
Sale of a subsidiary with redeemable non-controlling interests	4	6	3
Redemption value adjustment for the current period	5	2	(2)
Exercises of redeemable non-controlling interests	(49)		(12)
Exercises of redeemable non-controlling interests		(2)	(2)
Impact of foreign exchange translation	(6)	1	13
Measurement period adjustments			(1)
Ending balance	$ 59	$ 105	$ 98

Business Divestiture (Details)

Business Divestiture (Details) - USD ($) $ in Millions		12 Months Ended
	Jul. 01, 2022	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets held for sale		$ 1,200		$ 1,122
Equity Method Investments		10		$ 86
Microbial Control | Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Gross	$ 1,254
Transition Services Agreement, Fair Value	(36)
Disposal Group, Transaction Costs	(11)
Escrow Deposit	15
Post-closing adjustments	$ (3)
Transition Services Agreement, Term	19 months
Transition Services Agreement, Income, Reduction To Costs Not Included In Revenue		11
Disposal Group, Including Discontinued Operation, Consideration	$ 1,219
Cash Transferred to the Buyer on the Closing Balance Sheet	(49)
Employee Reimbursement Receivable	(1)
Proceeds From Divestiture Of Business, Net	$ 1,169
Assets held for sale			$ 263
Intangible Assets, Net (Including Goodwill)			867
Equity Method Investments			74
Other assets			80
Total assets held-for-sale			1,284
Accounts payable			41
Other liabilities			35
Total liabilities held-for-sale			76
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax		11
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation		$ 96
Disposal Group, Including Discontinued Operation, Net Assets			$ 1,208

Assets Held For Sale (Details)

Assets Held For Sale (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 52	$ 0	$ 0
Operating lease right-of-use assets	636	767
Disposal Group, Held-for-sale, Not Discontinued Operations | Savory Solutions and Fine and Specialty Ingredients
Assets
Cash and cash equivalents	52
Trade receivables, net	85
Inventories	157
Property, plant and equipment, net	92
Goodwill	348
Other intangible assets, net	428
Operating lease right-of-use assets	13
Other assets	25
Total assets held-for-sale	1,200
Liabilities
Accounts payable	56
Deferred tax liability	92
Other liabilities	64
Total liabilities held-for-sale	$ 212
Disposal Group, Held-for-sale, Not Discontinued Operations | Microbial Control
Assets
Trade receivables, net		63
Inventories		125
Property, plant and equipment, net		30
Goodwill		536
Other intangible assets, net		349
Operating lease right-of-use assets		5
Other assets		14
Total assets held-for-sale		1,122
Liabilities
Accounts payable		69
Deferred tax liability		24
Other liabilities		8
Total liabilities held-for-sale		$ 101

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for doubtful accounts [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 46	$ 21	$ 16
Additions (deductions) charged to costs and expenses	19	6	6
Acquisitions	0	0	0
Accounts written off	0	(1)	(1)
Translation adjustments	(12)	0	0
Other	0	20	0
Balance at end of period	53	46	21
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	232	257	204
Additions (deductions) charged to costs and expenses	51	(18)	35
Acquisitions	0	9	0
Accounts written off	0	0	0
Translation adjustments	(21)	(16)	18
Other	0	0	0
Balance at end of period	$ 262	$ 232	$ 257